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Multiple sclerosis (MS) is a debilitating disease in which the immune system aberrantly targets 
the central nervous system (CNS). There is compelling evidence that Epstein-Barr virus (EBV) 
is associated with MS development but the pathogenic mechanisms are unknown. The 
molecular mimicry hypothesis suggests the immune response to EBV, which normally would 
restrain the virus infection, mistakenly targets CNS components. This thesis characterised 
humoural and cellular responses to the virus in healthy controls (HC) and MS patients, 
increasing the range of EBV and CNS proteins investigated and seeking evidence of cross-
reactivity as predicted by the hypothesis.  
Compared to HC, patients had elevated EBNA1 and virus capsid antigen-specific antibody 
responses. EBNA3-specific antibody responses were also more frequently detected in patients, 
a previously undescribed observation. Both groups had similar frequencies of circulating T-
cells specific for autologous lymphoblastoid cell lines (LCL) or EBNA1, although minor 
differences in cytokine profile were detected.  
LCL-specific T-cell cultures established from both patients and HC exhibited cross-reactivity 
to CNS antigens. This result supports a role for molecular mimicry but also suggests that other 
unknown or more complex factors must influence MS development. While such T-cells are a 
necessary prerequisite for the molecular mimicry hypothesis, their presence in HC suggests 
other factors must influence MS development. Identification of these factors must be a priority 
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The immune system is a highly specialised and dynamic system of cells, tissues and organs 
which work together to protect against disease. It is critical in defending against pathogens and 
cancerous cells, however these mechanisms are not perfect and when dysregulated can damage 
tissues and cause disease. This system can be roughly divided into two main arms: the innate 
and the adaptive immune responses.  
 
1.1 Innate immunity 
 
The ability to guard against pathogenic invasion is a highly-conserved trait which can be traced 
back to the evolution of multicellular organisms, and it has evolved to protect hosts against a 
multitude of infections such as viruses, bacteria, fungi and helminths. The innate immune 
system is the oldest in evolutionary terms and forms the first line of defence against invading 
pathogens. Innate immune mechanisms form a somewhat non-specific protection and consist 
of a network of barriers and cells generally considered to have no element of memory, forming 
a rapid and non-specific responses against infection through a variety of mechanisms. 
The innate immune defence comprises three barriers to infection: physical barriers such as the 
skin, an impenetrable layer of keratinised cells which acts to prevent pathogen entry (Friedman, 
2006), epithelial surfaces which form a resilient barrier due to tight junctions connecting the 
cells (Citi and Cordenonsi, 1998), and internal epithelia sustain a flow of mucus over their 
surfaces via cilia or peristalsis which physically removes pathogens and debris from the body 
(Sheehan et al., 2006). Epithelial membranes also produce a wide variety of antimicrobial 
chemicals that protect from invasion, for example the upper gastrointestinal tract produces 
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hydrochloric acid as well as digestive enzymes, lysolipids and many other components which 
protect the body from ingested pathogens (Dann and Eckmann, 2007).  
The second barrier comprises complement proteins, a family of large, soluble molecules in the 
plasma that coat bacteria and other foreign particles in a process called opsonisation, enabling 
them to be taken up by phagocytic cells (Sarma and Ward, 2011).  
The third barrier is formed by a range of innate immune cells. These are produced in the bone 
marrow from pluripotent haematopoietic stem cells (HSCs), first differentiating into common 
myeloid progenitors (CMPs) which can then either differentiate into granulocytes (eosinophils, 
basophils, neutrophils and mast cells) or monocytes (dendritic cells and macrophages) 
(Cowland and Borregaard, 2016).  
Innate immune cells primarily act by recognising molecules that do not naturally occur under 
normal physiological conditions in the host organism. These can be derived from infectious 
agents, termed pathogen-associated molecular patterns (PAMPs), or molecules which are 
normally “hidden” from immune cells and are only accessible upon tissue damage, termed 
damage-associated molecular patterns (DAMPs). Recognition of PAMPs and DAMPs by 
innate immune cells is achieved via pathogen recognition receptors (PRRs) on their surface. 
Once PRRs are activated, a cascade is triggered in the cell which both induces production of 
inflammatory mediators and attracts other immune cells to the area (Thompson et al., 2011).  
Dendritic cells of the innate immune system perform a critical role, alerting and directing 
adaptive immune responses to incoming pathogens. 
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1.2 Adaptive immunity 
 
In addition to innate immunity, vertebrates have also evolved an adaptive immune system to 
provide a more sophisticated level of defence (Hirano et al., 2011). Adaptive immune 
mechanisms establish immunological memory upon first exposure to an antigen, resulting in 
an enhanced response to pathogens upon subsequent exposures. Evolution of adaptive immune 
cells to randomly recombine their pathogen receptor gene segments and produce a diverse 
receptor repertoire enables their recognition of an almost infinite number of epitopes (Laydon 
et al., 2015). However, this vast repertoire, whilst invaluable in guarding against pathogens, 
can also generate responses with reactivity to self-tissues, and as such systems to prevent 
autoreactivity have evolved alongside these defences.  
The ability to maintain a population of antigen-specific cells which can expand rapidly upon 
subsequent exposure to antigen is fundamental to forming a memory response, and enables 
protection from re-infection with previously encountered pathogens. Adaptive immunity in 
vertebrates can be broadly subdivided into two main categories: cellular which is 
predominantly arbitrated by T-cells, and humoural which is mostly mediated by antibodies 
produced by B-cells.  
 
1.2.1 Overview of B-cell biology 
 
T- and B-cells were first identified in the 1960s by Good, Peterson and Cooper when 
observations from chickens following removal of either the thymus or bursa of fabricus – the 
site of haematopoiesis in birds – caused animals to develop two very different forms of immune 
deficiency (Gitlin and Nussenzweig, 2015, Cooper et al., 1965). These observations were then 
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applied to immune insufficiencies in humans and eventually led to the discovery of the bone 
marrow as the site of human haematopoiesis 10 years later (Gitlin and Nussenzweig, 2015). 
Bone marrow resident haematopoietic stem cells (HSCs) first divide to give multipotent 
progenitors (MPP) which then go on to produce common lymphoid progenitors (CLP) which 
are the precursors to all lymphoid lineages, including immature B-cells.  
Naïve B-cells undergo somatic recombination of their immunoglobulin (Ig) genes in the bone 
marrow, generating receptor diversity and giving each cell a different antigen specificity. It is 
here that B-cells undergo rounds of selection to prevent autoreactive B-cells from leaving the 
bone marrow (Shlomchik, 2008). Maturation and proliferation of B-cells is dependent on the 
nature of the antigenic challenge, and can have direct downstream implications for the type of 
response generated. Immature B-cells migrate to the spleen and lymph nodes where, if they 
encounter their cognate antigen, they mature to become short-lived plasma cells and produce 
pentameric IgM antibodies with moderate affinity for their ligand (Melchers et al., 2000, 
Fagarasan and Honjo, 2000).  
B-cells can become activated in two main ways. The first is by antigen alone in a thymus-
independent manner; these antigens tend to be larger, often containing repeated structures in 
their surface which cross-link B-cell receptors (BCRs) on the B-cell surface, inducing 
activation and low affinity antibody production (Mond et al., 1995).  
Most antigens, however, require CD4+ T-cell help to induce an antibody response with high 
affinity. In this process BCRs first bind antigen and are internalised, delivering the foreign 
antigen to lysosomes where it is processed and re-expressed on the cell surface bound to major 
histocompatibility complex (MHC) class II molecules. TCRs on the CD4+ T-cell surface 
recognise specific peptides presented by MHC Class II molecules alongside co-stimulatory 
interactions. TCR engagement causes cytokine production in the T-cell and sends strong 
signals to the B-cell inducing activation and proliferation. BCR and co-receptor ligation 
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strongly amplifies the antibody response to antigen and is essential for creating both memory 
B-cell and long-lived plasma cell repertoires (Radbruch et al., 2006).  
Following activation, B-cells migrate to germinal centres in lymph nodes where they undergo 
a number of important changes through germinal centre reactions. Somatic hypermutation in 
the variable (V) regions of immunoglobulin genes introduces single point mutations in specific 
areas and leads to a process called affinity maturation. This process can change the receptor’s 
affinity for its antigen, and B-cells bearing receptors with an increased affinity for their cognate 
antigen survive, mutated B-cells with decreased affinity receptors die by neglect (Eisen, 2014). 
These selected, high affinity B-cells then undergo class switching of their immunoglobulin 
heavy chains before differentiating into either memory B-cells or into long-lived plasma cells. 
Memory B-cells reside in the periphery and can rapidly divide and differentiate into plasma 
cells upon re-exposure to antigen. Plasma cells produce large quantities of higher affinity 
antibodies, and these are capable of three main functions: opsonising bacterial or viral 
components to facilitate phagocytic uptake, neutralising soluble antigen and activation of the 
classical complement pathway (Forthal, 2014). 
 
1.2.2 T-cell receptor generation and structure 
 
Interminable variation in pathogens and their constant evolution provides an immense 
challenge for the immune system, which must be able to respond to every theoretical or real 
antigen it may encounter. Using a finite genome, T-cells have met this need by evolving a 
repertoire with an almost infinite number of specificities produced from one section of the 
genome termed the T-cell receptor gene locus. The locus is made up from a large number of 
contiguous segments of three types, named the variable (V), joining (J) and diversity (D) 
regions which are joined together in random genetic recombination events to form a T-cell 
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receptor (TCR) (Figure 1.2.1). These recombination events are similar to those used for 
rearrangement of immunoglobulin genes in B cells, and are directed by DNA recombinase and 
flanking regions upstream of the TCR locus leading to the insertion of non-germline 
nucleotides between segments to create greater diversity (Gellert, 2002). 
Figure 1.2.1 TCR rearrangement and expression. ab TCR are made up from two discrete chains, 
and are expressed from gene segments that are rearranged during somatic recombination events in 
the T-cell. These events are homologous to those that generate immunoglobulin chains in B-cells. 
Top The a chain Va segment is joined to a Ja segment to form the variable region of the TCRa chain. 
The VJa region is then joined to a Ca , forming the mRNA that encodes the functional TCRa chain. 
Bottom The b chain variable domain is formed by three different gene segments: Vb, Db and Jb. These 
segments are rearranged and form the functional variable b chain exon, before being spliced to the 
Cb region, forming a functional TCRb locus that is then transcribed and translated to form the TCRb 
chain. a and b chains bind each other soon after their synthesis to form a functional ab-TCR 
heterodimer. Adapted from Janeway’s Immunobiology 8th Edition. 
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Each ab T-cell has approximately 30,000 identical T-cell receptors on its surface, each made 
up from a single a and b chain joined by a disulphide bond, termed the a:b TCR (Figure 1.2.2).  
T-cells expressing a:b TCRs make up the majority of T-cells, however a subset express g:d 
TCRs which have different antigen recognition properties and are not thought to be MHC 
restricted (Brenner et al., 1986, Lew et al., 1986). These events create an enormous TCR 
repertoire with an equally large number of specificities. Each T-cell has its own, distinct T-cell 
receptor, making it genetically traceable and the association of the a and b chains on the cell 
surface provides an added layer of complexity. 
 
Figure 1.2.2 Similarities in a:b T-cell receptor and immunoglobulin structure. Left The Fab fragment of 
an antibody is made up from a heavy and a light chain, each containing a constant (C) and a variable (V) region 
which are linked by a disulphide bond. The variable regions make up the antigen-binding site of the antibody; 
each antibody molecule contains two of these sites. Right Like the Fab fragment, the T-cell receptor (TCR) is 
also a heterodimer linked by a disulphide bond, containing regions termed immunoglobulin-like C and 
immunoglobulin-like V domains with the V regions forming the antigen-binding site. T-cell receptor structure 
is formed from two homologous transmembrane glycoproteins chains which are termed a and b. Each domain 
has a carbohydrate side residue, and a disulphide bond in the stalk of each chain connects the two molecules. 
Transmembrane helices contain basically-charged residues with the cytoplasmic tail projecting into the cell and 
mediating cytoplasmic signalling. Figure adapted from Janeway’s Immunobiology 8th Edition.   
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TCR recombination produces almost inexhaustible variation in TCR structure, however not all 
of receptors produced will be immunologically effective, as some will not recognise self-MHC 
molecules or will have a high affinity for self-antigens and be autoreactive (discussed further 
in chapter 1.3). 
 
1.2.3 T-cell development and central tolerance 
 
As with B-cells, T-cells are named after the organ in which they mature – the thymus. Soon 
after their production, lymphoid progenitors migrate from the bone marrow to the thymus after 
which they can be referred to as “thymocytes”. The thymus is a primary lymphoid organ in the 
upper chest, and has an essential role in the adaptive immune system as the site of all major 
stages in T-cell development.  
T-cell progenitors first enter the thymus from the blood via venules and localise to the cortico-
medullary junction, where they interact with thymic stroma via Notch1 and begin their 
commitment to T-cell lineage (Radtke et al., 2013). At this stage cells are termed “double-
negative” as they still lack expression of CD3 and the two main subtype markers CD4 and 
CD8. As double-negative thymocytes migrate through the cortex to the subcapsular region they 
undergo T-cell receptor gene recombination, first rearranging the b chain locus (Nitta et al., 
2008). Following b chain recombination, double negative thymocytes begin to proliferate and 
become “double-positive”, expressing both CD4 and CD8 receptors. Double-positive 
thymocytes make up the majority of T-cells in the thymus, and following the rapid division 
phase their expansion slows down. They reduce in size and they begin the rearrangement of 
their a chain locus, which continues until a productive chain which pairs efficiently with the b 
chain already expressed on the surface is produced (Petrie et al., 1993). Once double-positive 
thymocytes have a functional TCR expressed on their cell surface, they continue their 
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migration back through the cortex towards the medulla where they undergo rounds of positive 
selection by interacting with medullary epithelia. 
Rounds of positive selection occur in the thymus to ensure that only thymocytes with a TCR 
that can engage peptide:MHC complexes are maintained. T-cells with no binding or too high 
affinity for peptide:MHC complexes displayed by medullary epithelial cells do not survive 
long-term. Negative selection ensures that immature T-cells with a TCR that strongly 
recognises self-peptide:MHC on specialised antigen presenting cells (APCs) in the thymus die 
by apoptosis.  This ensures ineffective or autoreactive T-cells are removed from the T-cell 
repertoire before they exit the thymus or mature. Binding with moderate affinity of a TCR to 
self-MHC:peptide complexes causes T-cells to receive survival signals and these cells go on to 
lose expression of either CD4 or CD8 to become single positive CD4 or CD8 naïve T-cells.  
A subset of cells with TCRs that bind to self-peptide:MHC with high avidity – but not high 
enough to initiate cell death – survive, turning on the expression of the transcription factor 
FoxP3 and receiving signals to become natural T regulatory cells (Treg), characterised by CD4 
and CD25 expression (Li and Zheng, 2015). Through this, positive selection has a role in 
influencing expression of cell surface receptor expression, as most thymocytes with TCRs that 
recognise peptides bound to MHC class I molecules will differentiate into CD8-expressing 
immature T-cells; likewise, most cells that recognise MHC class II become CD4+ T “helper” 
cells.  
Specialised stromal cells called medullary thymic epithelial cells (mTEC) express the 
transcription factor AIRE (autoimmune regulator) which interacts with transcriptional 
machinery and increases protein transcript length from the promoter. AIRE elongates 
transcripts which would otherwise have terminated at an earlier point, and through this 
mechanism mTECs are able to express proteins that would normally be found in peripheral 
tissues (Zumer et al., 2013). Peptides from AIRE-synthesised proteins are presented on MHC 
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molecules, and interaction of a TCR with peripheral self-peptide:MHC complexes causes 
apoptosis in the bound T-cell. This process occurs alongside positive selection in the thymic 
cortex and medulla and prevents self-reactive immature thymocytes from exiting the thymus 
and maturing into potentially autoreactive T-cells.  
Once T-cells have undergone rounds of positive and negative selection they end their migration 
through to the cortico-medullary region via acquisition of the CCR7 receptor, exiting into the 
blood to be carried to peripheral lymphoid tissues as naïve T-cells (Forster et al., 2008). Once 
in the circulation, these cells first home to secondary lymphoid organs using receptors such as 
L-selectin (CD62 ligand) and CCR7 to bind proteins on the high endothelial venule (HEV) 
which enables them to pass into lymph nodes (Forster et al., 2008). CCR7 is also expressed on 
peripheral dendritic cells (pDC) and these cells traffic to the lymph nodes where they present 
processed antigens to naïve T-cells via MHC class I and II molecules in the T-cell zones of the 
lymph node (Itano and Jenkins, 2003).  
 
1.2.4 MHC and antigen presentation 
 
MHC class I and II molecules have distinct structures but share many similarities in function, 
and both present peptide fragments to be recognised by TCRs on the surface of T-cells.  
MHC class I molecules are expressed on all nucleated cells and are formed from the MHC 
heavy chain and b2 microglubulin (b2m) making a heterodimer. Two extracellular domains in 
the heterodimer form the peptide binding groove, creating a closed pocket into which peptides 
of approximately 8-11 amino acids in length can bind (Garrett et al., 1989). HLA class I 
molecules have three main types, termed A, B and C, with the chains being highly 
polymorphic; heterozygous individuals can express up to 6 different alleles, allowing a wide 
range of peptides to be presented (Lund et al., 2004). Peptides presented by MHC class I 
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molecules are mostly endogenous to the cell, and MHC class I:peptide complexes are engaged 
by T cells expressing the CD8 co-receptor.  
MHC class II molecules are only expressed on antigen presenting cells (APC) and structurally 
resemble MHC class I but are formed from two homologous, transmembrane glycoprotein 
chains, termed the a and b chains. The tops of both chains form the peptide binding groove 
which, unlike MHC class I, is not a closed space, meaning that the length of peptides able to 
bind into the groove is not constrained and peptides of varying length (usually between 12 and 
22 amino acids) are able to bind MHC class II molecules. The overhanging amino acids from 
these interactions are termed the peptide flanking region and these domains have been shown 
to affect TCR interactions with peptide:MHC class II (Moudgil et al., 1998). Analogous to 
class I, MHC class II are highly polymorphic, allowing extensive variation in the peptides 
displayed on the molecules, which are mostly exogenous and derived from proteins taken up 
by the cell. MHC class II molecules present peptides to helper T-cells which express CD4 as 
the TCR co-receptor.  
As previously discussed, T-cell function is reliant on their capacity to recognise infected cells 
or those that have internalised foreign proteins. Generally surface MHC class I and II molecules 
present internally processed peptide fragments for recognition by CD8+ and CD4+ T-cells 
respectively.  
Classically MHC class I molecules present peptides derived from endogenous proteins, whilst 
MHC class II proteins present fragments of proteins that have been phagocytosed by APCs – 
exogenous antigens. However, MHC class II proteins have also been shown to present 
endogenous peptides on the surface (Rammensee et al., 1999), and likewise, MHC class I 
proteins are also known to be able to present exogenous peptides to CD8+ T-cells (Huang et 
al., 2005). CD4+ T-cells have also been shown to exhibit direct cytotoxic activity as well as 
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their classical role providing immunological help to CD8+ T-cells and B-cells, affording 
another way in which the immune system can directly recognise and remove infected cells. 
 
1.2.5 T-cell responses 
 
Naïve T-cells migrate through the blood and secondary lymphoid tissues, sampling 
peptide:MHC complexes displayed on the surface of DCs that have migrated from peripheral 
tissues. Naïve T-cells not able to stably bind to the peptide:MHC complex via their TCR are 
quickly released from the interaction and go on to interact with other DCs displaying alternative 
peptides until they either bind with high affinity or migrate back into the circulation. If a T-cell 
engages a peptide:MHC complex able to bind strongly to its TCR it also needs to receive co-
stimulatory signals to become activated: binding of CD28 on T-cells to CD80 (B7.1) ligand 
expressed on DCs induces expression of IL-2 , up-regulation of high affinity IL-2 receptor (IL-
2R) and clonal expansion of the T-cell (Lin and Leonard, 1997).  
This stimulation of naïve T-cells also triggers their differentiation into effector phenotypes. 
Differentiation allows T-cells to carry out their function upon subsequent exposure to cognate 
antigen without the need for co-stimulatory signals; differentiated T-cells are primed for 
response and are able to dock onto MHC:peptide complexes on target cells and carry out their 
function without needing co-stimulation (Lanzavecchia and Sallusto, 2001, van Stipdonk et al., 
2001, Kaech and Ahmed, 2001).  
There are two main groups of T-cell defined by their effector phenotype and function, and 
classified into subsets by the expression of CD4 and CD8 markers. Differentiated CD8+ T-
cells are cytotoxic lymphocytes (CTLs), exhibiting direct killing activity on target cells after 
docking their TCR with a cognate peptide:MHC complex and forming an immunological 
synapse. The immunological synapse is enriched for TCR and co-stimulatory molecules, and 
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target cells are killed through release of perforin and granzymes (Cullen and Martin, 2008). 
Naïve CD4+ T-cells become “helper” cells and have a number of different effector subsets 
each with subtly distinct roles in directing adaptive immune responses. 
CD4+ T-cells differentiate into effector cells upon antigen encounter, and it was previously 
accepted that they can be broadly divided into two main groups based on their cytokine 
secretion. TH1 CD4+ T-cells produce IFNg and IL-2 and differentiate following priming by a 
DC in the presence of IL-12 (Nizzoli et al., 2013); TH1 cells provide help to cytotoxic cells 
such as macrophages and CD8+ T-cells and produce stimulatory cytokines (eg. IL-2) to aid 
killing of intracellular pathogens such as viruses and bacteria (Mosmann and Coffman, 1989).  
TH2 cells are harnessed to target extracellular bacteria and helminths, and are primed by DCs 
in the presence of IL-4 to produce IL-4, IL-5 and IL-13, also providing help for B-cells 
(Mosmann et al., 2005, Geginat et al., 2014).  
However, it is now clear that there are several more subsets, including TH17 cells which are 
marked by their production of IL-17 and IL-22 and perform essential roles in inflammatory 
responses to extracellular pathogens by recruiting innate cells such as macrophages and 
neutrophils (Veldhoen et al., 2006). Follicular helper T-cells (TFH) are characterised by 
expression of the transcription factor Bcl-6 and their production of IL-4 and IL-21. TFH cells 
have a range of effector functions, including the provision of help to follicular B-cells for their 
maturation and antibody production (Qi, 2016). A summary of CD4+ T-helper subsets with 
transcription factors controlling their differentiation, cytokines produced and effector function 
is shown in Figure 1.2.3.  
Classical reports of CD4+ T-cells describe them as helpers with no direct cytotoxic function, 
however this is no longer the case and CD4+ T-cells have been shown to be able to target 
virally-infected cells directly via recognition of MHC class II molecules up-regulated on the 
surface of infected cells (Debbabi et al., 2005). CD4+ T-cells now have a widely-recognised 
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role in antiviral defences and have been shown to help control infections such as measles and 
gammaherpes viruses as well as for many other viruses (Reich et al., 1992, Sparks-Thissen et 
al., 2004).  
 
Figure 1.2.3 CD4+ T-helper cells have adapted to perform many different roles. Differentiation of CD4+ T-
cells into subsets occurs after recognition of cognate antigen, and is regulated by transcription factors and soluble 
cytokines in the local environment which determine effector lineage. Whilst CD4+ T-cells are classically divided 
into subgroups via their markers and function they are also plastic and are able to adapt their function to the 
pathogen encountered in vivo. Classically TH1 cells are primarily thought to be responsible for clearance of viral 
pathogens but it is now apparent that multiple subsets are involved. Cytolytic CD4+ T-cells have been shown to 
be able to directly kill virus-infected cells in vitro. TFH cells have a key role in priming B-cells to produce 
neutralising antibodies and also those specific for viral proteins. TH17 cells are defined by their production of IL-
17 and their function is primarily pro-inflammatory, recruiting neutrophils and macrophages to infected tissues. 
TH17 cells have also been implicated in chronic inflammation and autoimmunity. Following re-stimulation 
memory CD4+ T-cells are able to rapidly produce effector cytokines and provide helper functions to other immune 
cell subsets. Adapted from Swain et al.(Swain et al., 2012). 
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1.3 Peripheral immune tolerance and T-cell anergy 
 
Peripheral tolerance acts to maintain a balance between protective T-cell responses which clear 
infection and self-recognition, preventing damage to tissues by removing autoreactive TCRs 
from the repertoire. However, mechanisms of tolerance deleting self-reactive T-cells from the 
repertoire are not perfect and some autoreactive cells can survive, and this is evident from the 
development of autoimmune diseases.  
As previously described, TCRs recognise peptides expressed by MHC class I or II molecules, 
and all nucleated cells in peripheral tissues express HLA class I; HLA class II molecules are 
mainly expressed on APCs and on activated cells. APCs, such as dendritic cells (DCs), migrate 
to peripheral lymphoid tissues to present exogenously derived peptides on HLA class II to T-
cells and B-cells.  
As previously described, to amount a T-cell response co-stimulatory molecules are needed in 
addition to TCR interaction with peptide:MHC complexes. Under normal, uninfected 
conditions, peripheral tissues and DCs do not express these co-stimulatory molecules which 
are needed to efficiently activate T-cells engaging their TCR. Interaction of a cognate TCR 
with peptide:MHC complexes without co-stimulation results in the T-cell being rendered 
anergic, a state in which a T-cell becomes unresponsive to stimulation. Anergic T-cells are 
unable to respond to their cognate antigen upon subsequent exposure, even in the presence of 
co-stimulatory signals.  
The two-checkpoint model for efficient T-cell activation requires two separate signals for the 
cell to become activated. However, anergy is only one possible outcome of T-cells receiving 
antigen-specific signals without co-stimulation, and they may also undergo apoptosis or 
differentiate into induced CD25+ regulatory T-cells. This feature, in addition to central 
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tolerance, provides another layer of protection against autoimmunity by removing or silencing 




1.4 Multiple sclerosis 
 
Multiple sclerosis is a chronic, debilitating condition of the central nervous system (CNS), 
characterised by inflammation which causes damage to the brain and spinal cord over time. 
Clinical presentation is extremely heterogeneous, with symptoms depending largely on the area 
of the CNS where inflammatory lesions have formed. Over time, damage to the CNS can 
become more severe and progress to secondary progressive multiple sclerosis (SPMS) which 
is characterised by increased neurological dysfunction and fewer definite periods of clinical 
remission. Average age of diagnosis for the relapsing-remitting form of MS (RRMS) is 20-40 
years, and, after trauma, MS remains the second most common cause of neurological disability 
in young adults in the UK affecting approximately 130,000 people (Mackenzie et al., 2014).  
The first clinical episode in patients is termed clinically isolated syndrome (CIS), and a 
definitive diagnosis of conversion to MS is only made following the patient experiencing a 
second episode (Filippi et al., 2016). It is also possible for lesions to be detected in a patient’s 
CNS by magnetic resonance imaging (Koini et al.) without experiencing symptoms, and this is 
termed radiologically isolated syndrome (RIS). Approximately 85% cases of MS present with 
RRMS form of disease. A minority of cases present with a more insidious syndrome without 
periods of remission named primary progressive MS (PPMS). The majority of RRMS patients 
go on to develop SPMS after a variable number of years. SPMS patients still undergo relapses 
and these are characterised by continual accumulation of disability with pathology showing 
persistent microglial activation and demyelination. 
Despite extensive research, very little is known regarding MS disease pathogenesis and 
progression, and as worldwide prevalence of MS increases it is more important than ever that 
we are able to understand and develop treatments to slow or prevent progression of disease.
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1.4.1 History of multiple sclerosis 
 
Numerous reports of neurological conditions with symptoms consistent with modern 
observations of MS are apparent throughout history, with the earliest dating back to the 
fourteenth century (Murray, 2009). However, it was only in the mid-nineteenth century that 
observations from many physicians throughout Europe were brought together by a French 
neurologist named Jean-Martin Charcot and subsequently published in a series of books and 
lectures describing symptoms and post-mortem observations, naming the condition “sclérose 
en plaques” (Murray, 2009).  
The late 1800s marked a surge of interest in MS, and for the first time epidemiological aspects 
of disease distribution were considered and published by Sir Byron Bramwell, who reported 
an increased prevalence of MS at higher latitudes (Murray, 2009). Genetic contribution towards 
disease development also began to be investigated, however these avenues required much 
larger study cohorts and in-depth analysis of heredity was not possible until the 1970s and 
1980s.  
In the 20th century several epidemics of MS broke out in different European locations, most 
notably in the Faroe Islands, which had previously not had any diagnosed cases between 1900 
and 1943 (Kurtzke, 2013). After the Islands’ 5-year occupation by British forces during the 
Second World War, many MS cases emerged and for several decades researchers have 
speculated whether an infectious agent was introduced to the islands at this time and caused 
the epidemic. However, this hypothesis is not widely accepted and much speculation still 
surrounds the cause of this sudden rise in disease incidence around this time (Kurtzke and 
Heltberg, 2001, Poser et al., 1988).  
 The modern view of MS is that of an autoimmune-mediated disease affecting the CNS which 
is brought about in some genetically pre-disposed individuals by a series of unknown 
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environmental triggers. Our understanding and attitudes to MS have changed with the advent 
of MRI to image the brain in high definition and availability of immunomodulatory treatments 
which can ameliorate disease, and these will continue to change as our knowledge of disease 
becomes more comprehensive.  
 
1.4.2 Diagnosis and prognosis 
 
Onset of RRMS can be insidious, with many individuals only experiencing mild symptoms 
years before they seek medical help, by which time the disease may no longer be in the early 
stages. Classic symptoms of RRMS begin as mild neurological deficits and it is common for 
patients to experience sensory occlusion, such as vision disturbances or changes to touch, 
hearing, taste and smell. These symptoms are caused by specific parts of the brain becoming 
inflamed and impeding neuronal function in that precise area. A neurological episode is defined 
as lasting for 24 hours or more, but the attacks can last for up to several weeks (Figure 1.4.1).  
Patients are assessed using the revised McDonald Criteria (Filippi et al., 2016) which uses 
neurological evaluation, presence of brain and spinal cord lesions over time as pictured by 
MRI, and presence of oligoclonal bands (OCB) in cerebrospinal fluid (CSF) to confirm MS 
diagnosis. OCB are bands of immunoglobulins which indicate antibody production, they can 
be found in sera or CSF and are used in diagnosis of MS as their presence in CSF is indicative 
of an intrathecal immune response. OCB are also present in other diseases, such as infections, 
and observed on their own are not diagnostically conclusive for MS. 
Amongst RRMS cases there is a stark gender bias towards females reported in many developed 
countries across the world including Canada, Australia, the United States of America (Larsen 
et al.) and Japan (Orton et al., 2006, Wallin et al., 2004, Barnett et al., 2003, Houzen et al., 
2003), with the ratio of women developing MS relative to men being calculated as high as 
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~3.2:1 (Orton et al., 2006). It is not clear what is driving this increase but it is apparent that this 
trend is only becoming stronger. A study of Canadian patients showed the ratio of male:female 
patients to be increasing each year, further supporting findings that prevalence of MS is 
increasing in women (Orton et al., 2006). 
 
Figure 1.4.1 Disease progression of relapsing-remitting multiple sclerosis is heterogeneous. RRMS disease 
course is characterised by a first clinical episode which resolves and generally leaves no long-term disability. 
Subclinical episodes may occur with brain lesion formation but with no obvious neurological dysfunction. 
Remission is interspersed with periods of relapse, becoming more severe over time with eventual accumulation 
of disability as neuronal injury becomes greater. Approximately 80% of RRMS patients eventually develop the 
secondary progressive form of disease (SPMS) which is characterised by gradual loss of brain volume and 
atrophy. 10% of patient present with the primary progressive (PPMS) form, which is disease that accumulates 
without apparent remission from symptoms (blue line in graph). Figure adapted from Dendrou et al. (Dendrou 
et al., 2015).  
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1.4.3 Clinically isolated syndrome and early disease 
 
85% of people who develop MS present with a single neurological disturbance named clinically 
isolated syndrome (CIS), caused by a single or multiple lesions in cerebral white matter 
(Maurer et al.). Symptoms vary greatly between patients, and a review of CIS presentation 
reported that 46% of patients had spinal cord symptoms, 10% had disease affecting the 
brainstem, 21% with optic neuritis and 23% with multiple areas affected (Miller et al., 2005). 
Presenting symptoms were not predictive of conversion rate to MS but number of lesions and 
volume correlated moderately with progression and future disease severity (Brex et al., 2002). 
Early disease is thought to be pathologically different to late disease, and the exact triggers for 
immune infiltration into the CNS are unclear; it is also not known whether the pathogenic T-
cells attacking myelin are activated in the periphery or within the CNS itself. Early disease is 
characterised by immune infiltration into the brain parenchyma via direct entry from meningeal 
blood vessels, subarachnoid space or via the CSF and the choroid plexus. Immune cells, 
including innate and adaptive cells, accumulate in the perivascular space surrounding 
parenchymal tissue where they mediate damage either via cell contact-dependent mechanisms 
or through secretion of inflammatory mediators. T-cells, B-cells, DCs and macrophages may 
be involved in these processes, with CNS-resident microglia and astrocytes becoming activated 
in an environment that promotes inflammation and demyelination. Early in disease the damage 
is often reversible in the sense that there are no lasting clinical symptoms. However, damage 
can accumulate with ongoing inflammatory processes leading to late stage disease and 
permanent disability.  
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1.4.4 Late disease and neurodegeneration 
 
Late stage disease is marked by lower immune cell infiltrate from the circulation, and it has 
been speculated that this may be due to exhaustion of adaptive immune cells due to chronic 
antigen exposure over time. However, astrocyte secretion of chemokines such as GM-CSF and 
CCL2 can promote immune cell infiltration of the CNS perpetuating the inflammatory 
environment and preventing resolution of inflammation (Mayo et al., 2014).  
Lingering inflammation in brain tissues promotes loss of axons that accumulate and 
compromise tissue function. Neuroaxonal damage interrupts the extremely metabolically 
demanding transport of cellular components, such as mitochondria, down axons. Disruption to 
energy transport in neurones leads to metabolic stress and further damage to the cell, 
compromising function.  
In SPMS tertiary lymphoid structures form in meningeal spaces. These structures consist of 
aggregates of immune cells that form in different sites under conditions of chronic 
inflammation, and are made up from a mixture of T-cells, B-cells, plasma cells and follicular 
DCs. Aggregates form inflammatory loci in the meninges and contribute towards long-term 
cortical injury; formation of these structures has also been observed for other conditions such 
as infectious diseases and those involving chronic brain inflammation (Howell et al., 2011).  
Lesion formation is a very complex process and is still not fully understood in MS due to early 
inflammatory events often being subclinical and therefore impossible to sample and the 
inability to biopsy brain tissue. Post-mortem samples, whilst informative, only give an end 
stage picture of disease and provide very little insight into early MS pathogenesis. Observations 
from the CSF during inflammatory events may provide more answers regarding initial disease 
processes in the MS brain. 
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1.4.5 Immunology of MS 
 
The initial triggers of CNS attack in early MS are not known, and it is thought that a complex 
interplay between genetic predisposition and environmental factors are responsible for the first 
inflammatory events which progress into clinical disease. However, difficulties in obtaining 
samples from early MS mean that only immunological processes in later disease have been 
investigated in humans, and it is only based on these finding that potential mechanisms for 
disease initiation have been developed.  
Without a clear picture of the exact triggers, it is not known whether initial immunological 
events driving MS disease are derived from the periphery or from inside the CNS itself. In the 
externally-primed model, T-cells are thought to become activated in peripheral tissues and 
migrate to the CNS alongside other immune cells such as B-cells and macrophages. It is not 
known how these cells may become activated to target neuronal tissue, and potential 
mechanisms include molecular mimicry, bystander activation or co-expression of TCRs on 
individual T-cells with different specificities (Olson et al., 2001, Ji et al., 2010). The second 
model suggests that primary events are initiated in the CNS, with influx of immune cells from 
the periphery as a secondary phenomenon. These initial intrinsic triggers are so far unknown, 
but suggested mechanisms include potential viral infections of the CNS or from primary 
neurodegenerative mechanisms similar to those observed in Alzheimer’s or Parkinson’s 
disease (Heneka et al., 2014). 
The blood-brain barrier (BBB) and anatomical separation of the CNS from the lymphatic 
system provides a certain level of protection for the brain and spinal cord by limiting entry of 
leukocytes, and for many years the CNS was considered an immune privileged site. However, 
recent studies have shown that this is not the case, and immune surveillance by memory T-cells 
has been observed in healthy neuronal tissues; the discovery of CNS lymphatic vessels in mice 
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has further challenged this view (Ransohoff and Engelhardt, 2012, Shechter et al., 2013, 
Louveau et al., 2015). Natural surveillance of CNS tissues by adaptive immune cells therefore 
indicates the potential for a T-cell to become activated in the CNS without the need for 
permeabilisation of the BBB, triggering an inflammatory event with further recruitment of 
immune cells. 
T-cells in MS brain lesions are detectable in early disease but despite this their autoantigenic 
targets are still not known. Autoreactive targets are thought to be derived from myelin antigens 
and predominantly influenced by HLA type of patients, with disease progression leading to 
epitope spreading and greater variation between patient responses. CD4+ T-cells specific for 
CNS antigens have been detected in peripheral blood of MS patients but no consensus has been 
reached regarding their frequency, avidity or role in disease due to their additional detection in 
healthy individuals (Bielekova et al., 2004, Hellings et al., 2001). Lack of a candidate 
autoantigen in MS reflects the heterogeneity between patients and warrants the further 
investigation of this area to assess contribution of CNS-specific T-cells in disease initiation and 
progression.  
Much of what is known about MS immunopathology comes from observations in the murine 
model of disease, experimental autoimmune encephalomyelitis (EAE), and from 
administration of disease modifying therapies to patients. In EAE models, disease is induced 
by adoptive transfer of autoreactive CD4+ T-cells which are reactivated in the CNS by antigens 
presented by DCs. Activated autoreactive CD4+ T-cells produce pro-inflammatory cytokines 
which recruit innate cells (such as monocytes and macrophages) to the CNS and activation of 
naïve T-cells, leading to epitope spreading and perpetuation of the inflammatory environment 
(McMahon et al., 2005). 
CD4+ T-cells are thought to be key orchestrators in MS development, and TH1 and TH17 cells 
are implicated by various studies as the predominant pathogenic subsets in patients (Frisullo et 
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al., 2008, Tzartos et al., 2008). Disease modifying therapies have therefore aimed to target TH1 
and TH17 subsets with the aim of skewing them towards a TH2 (and potentially less pathogenic) 
phenotype, and this is thought to be how several licenced drugs are able to ameliorate MS 
disease: glatiramer acetate (Miller et al., 1998), dimethyl fumarate (Zoghi et al., 2011) and 
IFNb (Kozovska et al., 1999). However, a role for TH1 and TH17 cells in MS is not completely 
clear, and a failed clinical trial in RRMS of ustekinumab, which targets the p40 shared subunit 
of IL-12 and IL-23, sheds doubts on their involvement (Segal et al., 2008). IL-12 and IL-23 are 
involved in the differentiation of TH1 and TH17 cells respectively and blockade of these 
pathways was hypothesised to prevent generation of these pathogenic subsets. 
CD8+ T-cells, though thought to have a lesser role in disease initiation, are present in MS brain 
lesions at higher numbers than CD4+ T-cells and their numbers have been found to correlate 
with axonal damage (Frischer et al., 2009). EAE models have also shown CD8+ T-cells specific 
for myelin antigens become activated by epitope spreading via cross-presentation of antigens 
by DCs (Ji et al., 2013). Studies of human active brain lesions have shown a quarter of CD8+ 
T-cells to be IL-17 producing mucosa-associated invariant T-cells (MAIT-cells) (Willing et al., 
2014), and prolonged depletion of these cells following haematopoietic stem cell transplant 
(HSCT) indicates their potential role in MS pathogenesis (Abrahamsson et al., 2013). More 
research is needed to elucidate the exact contribution of CD8+ T-cells towards disease 
development and progression.  
Treg cells have been implicated in many autoimmune diseases, and alterations in this key subset 
have been shown to contribute to breakdown of immune tolerance. The role of Treg cells 
(CD4+FoxP3+) in CNS-mediated autoimmunity are not fully understood, and studies have 
varied in their reports of decreased frequency or function of Treg cells in MS patients compared 
to controls (Venken et al., 2008, Feger et al., 2007, Fletcher et al., 2009). Other studies suggest 
that, rather than impairment of frequency or function, it is pathogenic T-cells themselves that 
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are resistant to suppressive mechanisms. Impairment of the signal transducer and activator of 
transcription 3 (STAT3) signalling pathway via IL-6 and granzyme B (GzmB) has been shown 
to contribute towards resistance of MS patient derived effector T-cells to Treg suppression in 
vitro (Schneider et al., 2013, Bhela et al., 2015).  
Arguments against a role for Treg cell dysregulation in MS come from observations from a 
primary immunodeficiency affecting function of regulatory CD4+ T-cells. Patients with IPEX 
syndrome (immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) 
suffer from a severe, rare genetic disease caused by mutations in the transcription factor FoxP3 
resulting in the inability to generate Treg cells. Patients with this deficiency however do not 
develop CNS-directed autoimmunity, indicating that dysregulation of these cells are not solely 
responsible for autoimmune attack on the brain and spinal cord seen in MS (Bennett et al., 
2001).  
Therapeutic efficacy of B-cell-depleting monoclonal antibodies in MS, such as rituximab and 
ocrelizumab, in reducing relapse rates suggest that these cells contribute towards MS pathology 
(Hauser et al., 2008, Kappos et al., 2011). However, these immunomodulatory drugs 
specifically deplete CD20-positive cells, a marker which is not expressed on antibody-secreting 
plasma cell subsets. This therefore suggests that efficacy anti-CD20 therapies is due to other 
effector functions of mature B-cells, such as antigen presentation or promotion of inflammation 
via IL-6 secretion (Barr et al., 2012).  
Heterogeneity between patients and conflicting data in literature make it difficult to draw 
conclusions regarding immunological processes of MS, and much of what we know is derived 





Development of MS is thought to be complex and influenced by a combination of 
environmental factors in genetically predisposed individuals, and these factors are discussed in 




The genetic risk of developing MS has been previously estimated by studies of twins from 
British and Canadian cohorts which found a 5% chance of both dizygotic twins developing 
disease, but this increases to 25% in monozygotic twins (Willer et al., 2003, Mumford et al., 
1994). Studies of adopted children brought up in families with a history of MS show a similar 
risk of developing disease to the rest of the population but also show that biological relatives 
remain at increased risk, indicating a role for genetic factors in MS development (Ebers et al., 
1995, Dyment et al., 2006). 
The search for genes associated with MS revealed links to the MHC locus in the 1970s, with 
the HLA-DR15 haplotype being found to confer increased risk (Compston et al., 1976, 
Terasaki et al., 1976); this search has since been narrowed down to a single nucleotide 
polymorphism (SNP) (International Multiple Sclerosis Genetics et al., 2007). Subsequent 
investigations searching for MS risk alleles have been less fruitful, and HLA-DR15 remains 
the genetic factor conferring highest risk. Other reports have found further variants in the MHC 
locus which affect susceptibility, with the MHC class I allele HLA-A2 and HLA-C5 found to 
be negatively associated with MS (Yeo et al., 2007, Link et al., 2010). A recent study of 
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Goodpasture disease, an autoimmune condition driven by autoreactive HLA-DR15-restricted 
CD4+ T-cells, showed HLA-DR1 to be dominantly protective and to shape the immune 
repertoire by skewing autoreactive T-cell responses towards a TREG phenotype (Ooi et al., 
2017). Similar mechanisms of immune repertoire skewing by protective alleles may exist in 
MS but these have so far not been investigated. 
In addition to variants of the MHC locus affecting risk, genome wide association studies 
(GWAS) have identified other associated gene polymorphisms, with most having roles in 
immune regulation and function.  
The IL-2 receptor a (IL-2Ra) chain is part of the IL-2 receptor (IL-2R) which forms a complex 
with IL-2b and IL-2Rg chains to form the high affinity IL-2R complex. Components of the 
high affinity IL-2R are up-regulated to the cell surface upon T-cell stimulation and act to 
perpetuate the immune response and aid T-cell proliferation (Minami et al., 1993). SNPs in the 
IL-2Ra gene have been associated with an increase in susceptibility to MS (Wang et al., 2011b) 
(Cavanillas et al., 2010).  
Polymorphisms in other receptor genes have been associated with MS. The cytokine receptor 
for IL-7 (IL-7R) is expressed on T- and B-cells and polymorphisms have also been shown to 
confer increased risk of developing MS (Gregory et al., 2007). SNPs in the TNFa gene have 
been linked to MS, alongside other immune conditions such as TNF receptor-associated 
periodic syndrome (Caminero et al., 2011).   
Polymorphisms in alleles which encode for co-stimulatory molecules and their ligands have 
also been associated with MS, including CD28, CD80, CD86 and CTLA-4, with the SNPs also 
found to influence age of disease onset (Wagner et al., 2015). Despite influencing age of disease 
onset, the effects of polymorphisms in these loci on risk were more modest when compared 
with those of the MHC gene locus. 
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Approximately 10-15% of MS cases are thought to have a predominantly hereditary 
component, and a recent Canadian study identified a variant in the receptor NR1H3 (nuclear 
receptor subfamily 1 group H member 3) which confers a 70% chance of individuals 
developing disease (Wang et al., 2016). The study documented two families with multiple 
members initially diagnosed with RRMS that rapidly developed into progressive disease with 
significant morbidity. Such studies investigating functional significance of SNPs in genes 
linked to MS could give an insight into some of the mechanisms underlying development, as 
there is currently no universally accepted model of pathogenesis.  
Epigenetics have increasingly been recognised for the role they play in MS, and several studies 
have investigated the environmental and hereditary impact of gene modifications on disease 
development. One of the most striking effects of epigenetic modification impacts the MHC 
gene locus, with reports that the HLA-DR15 haplotype is carried by more women than men 
and daughters being more likely to inherit the allele from their mother than from their father 
(Chao et al., 2010).  
Researchers have investigated effects of epigenetic changes to the enzyme peptidylarginine 
deiminase (PAD2) on brain lesion pathology, and higher levels of citrullinated myelin basic 
protein (MBP) were found to be the result of epigenetic changes to the PAD2 gene promoter 
causing increased expression of the PAD2 enzyme in MS patient brains (Mastronardi et al., 
2007).  
MicroRNA (miRNA) have also been implicated in MS pathogenesis, with altered expression 
of miRNAs between active and dormant lesions of RRMS patients indicating a role for 
epigenetic regulation of CD47 in MS brain lesions (Junker et al., 2009). Differentially 
expressed miRNAs in TH17 cells from MS patients have been shown to influence pathogenic 
T-cell differentiation (Du et al., 2009).  
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Despite the excitement surrounding them, epigenetics may only have a modest influence on 
disease development, and one study showed that different concordance rates between identical 
twins were not attributable to epigenetic changes (Baranzini et al., 2010). Genetics account for 
~30% of susceptibility to MS, but there is a greater role for environmental factors in 





Recent meta-analyses have established many factors that are involved in the complex interplay 
of MS disease initiation. Many of these factors involve lifestyle choices, as shown by large 
multicentric studies of healthy people which include those who go on to develop MS over time.   
For many years, it has been apparent that MS incidence increases with distance from the 
equator, with the highest number of people with MS residing in countries with relatively little 
sunlight. These observations have been backed up by analysis of serum vitamin D levels, and 
a study of 7 million people using the US military serum repository found that increased serum 
25-hydroxyvitamin D in Caucasians had a protective effect and lowered risk of developing MS 
(Munger et al., 2006). Other studies have corroborated these findings (Duan et al., 2014, 
Pakpoor and Ramagopalan, 2015), and low vitamin D levels and reduced sunlight exposure are 
considered to be key risk factors in MS pathogenesis. Migration studies of individuals have 
also supported a role for sunlight exposure, with early reports of US military veterans from 
Northern states experiencing a lower incidence of MS after being deployed South (Kurtzke et 
al., 1985). Studies of adopted children have also shown MS risk to be conferred by where they 
spent the majority of their early years (Gale and Martyn, 1995).  
One of the highest risk factors for developing MS identified only in recent years is smoking, 
with reports showing that it can increase risk by ~50% and has an even more pronounced effect 
in young adults (Handel et al., 2011, Salzer et al., 2013). It is not clear exactly what contribution 
smoking makes towards the development of MS, however it has been shown that nicotine 
increases permeabilisation of the blood-brain barrier in rats (Chen et al., 1995), which can 
potentially facilitate migration of pathogenic cells into the CNS. In addition to this it has also 
been shown that smoking increases citrullination of proteins by upregulation of the enzyme 
PAD2 in lung alveoli, which may in turn lead to synthesis of novel epitopes and autoimmunity 
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in some patients who are genetically susceptible (Makrygiannakis et al., 2008). As previously 
mentioned, the HLA DR15 haplotype is associated with increased risk of developing MS, 
however more recent studies investigating interaction of risk alleles with environmental factors 
have shown current smokers who possess the HLA DR15 allele to be 13.5 times more likely to 
develop disease, whereas non-smokers with the same genetic background only have an 
increased risk of 4.9-fold (Hedstrom et al., 2011). Smoking is now widely accepted to be a key 
risk factor for developing MS, although more research is needed to determine exactly what 
contribution smoking makes to disease development and progression.  
Global obesity rates have increased significantly in the last 30 years, with an estimated 10.8% 
of males worldwide being classified as obese and 14.9% of women (Collaboration, 2016). 
Coincidentally, incidence of MS in the western world has also steadily increased in the 20th 
century, particularly RRMS in women (Grytten et al., 2015, Alonso et al., 2007). The first 
comprehensive study to investigate a relationship between MS development and obesity was 
the Nurses’ Health Study in the USA which found women with a BMI of 30kg/m2 or more to 
have a 2.25-fold increased risk compared to those of “normal” weight (Munger et al., 2009). A 
large population study from Sweden also calculated that individuals with a BMI of 30kg/m2 or 
more had a two-fold increased odds ratio of developing MS, a finding which was significant in 
both men and women (Hedstrom et al., 2012). Other studies from Norway and Italy have also 
replicated this two-fold increased incidence of MS amongst overweight individuals (Wesnes 
et al., 2015).  
High socioeconomic status has been suggested as a risk factor for MS with the hypothesis of 
greater hygiene leading to later exposure of individuals to pathogens and skewed or altered 
immune responses. However, this idea is not widely accepted with conflicting and varied 
studies not reaching any commonly accepted conclusion (Goulden et al., 2015). Low 
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socioeconomic status is associated with poor lifestyle and, in Western countries, accompanies 
smoking and obesity in groups with lower standards of living.  
Infectious agents have also been implicated in MS development. The gram-negative bacterium 
Chlamydia pneumoniae (C. pneumoniae) was suggested as a potential trigger for disease after 
detection of bacterial DNA and antibodies in the CSF of MS patients (Sriram et al., 1999). 
However, after further analysis of intrathecal antibody production against C. pneumoniae levels 
were found to have no significant correlation with disease severity or duration, MRI disease 
activity or presence of OCB, and a potential link between MS and the bacterium is no longer 
considered (Krametter et al., 2001, Tsai and Gilden, 2001).  
Human herpesvirus 6 (HHV-6) is a b herpesvirus which has been more frequently found in 
blood and CSF of MS patients than healthy controls, and virus reactivation has been put 
forward as a contributing factor in disease development. However, results from DNA and 
antibody analysis were mixed, with the virus reactivation detected only in a proportion of MS 
patients (Liedtke et al., 1995, Goldberg et al., 1999, Alvarez-Lafuente et al., 2002, Nielsen et 
al., 1997). It was concluded that HHV-6 DNA was only detected in a small proportion of MS 
patients and was also present in patients with other neurological diseases. 
Human endogenous retroviruses have also been implicated in MS pathogenesis, and several 
studies have investigated a relationship between reactivation and disease development. 
However, the majority of studies found evidence of viral transcription in both healthy controls 
and patients; one report found transcripts of several endogenous retroviruses in the peripheral 
blood mononuclear cells (PBMC) of MS patients and controls (Rasmussen et al., 1997), and 
Hackett et al. reported no findings of retrovirus in serum, CSF or PBMC of MS patients 
(Hackett et al., 1996). 
The most compelling evidence for an infectious role in MS disease development lies with EBV. 
Research in this area is discussed further in chapter 1.5.2.
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1.5 Epstein-Barr virus 
 
EBV is a gammaherpes virus containing a double-stranded DNA genome of ~192kbp, and 
formally known as human herpesvirus 4 (HHV4). It was first isolated over 50 years ago from 
a Burkitt’s lymphoma sample by Anthony Epstein and Yvonne Barr, and became the first 
cancer-causing virus discovered to infect humans (Epstein, 2015). EBV DNA is enclosed in an 
icosahedral capsid, surrounded by a tegument layer rich in viral proteins and finally an outer 
layer derived from the plasma membrane of the host cell during virus budding (Brown and 
Newcomb, 2011).  
EBV infects B-cells establishing a latent infection which cannot be fully cleared by the body’s 
own defences. Latency is a state in which the virus down-regulates viral gene expression in 
order to avoid detection by immune cells and establish long-term infection of a cell. Most 
children are first exposed to the virus in infancy or early childhood, with most individuals 
becoming asymptomatic carriers. 
EBV is listed as a group 1 carcinogen by the World Health Organisation due to its ability to 
transform B-cells, and it is a listed cause of a growing number of cancers, including Burkitt’s 
lymphoma, Hodgkin’s lymphoma, nasopharyngeal carcinoma and gastric carcinoma amongst 
others.  
EBV is now increasingly recognised for its role in multiple sclerosis; associations with other 
autoimmune diseases (eg. rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)) 
have been put forward but are less well associated.  
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1.5.1 Life Cycle and primary infection 
 
EBV is transmitted orally and first establishes a lytic infection of epithelial cells and local B-
cells of the oropharynx. Large amounts of virus are shed in the throat, and newly infected B-
cells migrate to local lymphoid tissue where they establish a growth-transforming infection of 
B-cells and enter a phase of gene expression termed latency III. Some EBV-infected B-cells 
Figure 1.5.1 Epstein-Barr virus life cycle and establishment of latency in the immunocompetent host. 
EBV is transmitted orally, infecting B-cells and squamous epithelia of the oropharynx with some infected B-
cells going on to down-regulate gene expression to avoid immune cell surveillance. Infected B-cells are targeted 
during primary infection (IM) by NK cells, CD4+ T-cells and large expansions of lytic protein-specific CD8+ 
T-cells; expansions shrink in the months following IM to leave low but stable levels of EBV-specific cells in 
the blood of carriers. Blue arrows indicate transfer of infectious virions, black arrows signal transfer or 
transformation of infected cells, wide grey arrows indicate targets of cellular immune responses. Abbreviations: 
Ag, antigen; EBV, Epstein-Barr virus; GC, germinal center; IM, infectious mononucleosis; Lat 0, Latency 0; 
Lat III, Latency III; NK, natural killer. Adapted from Taylor et al.  (Taylor et al., 2015). 
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further down-regulating antigen expression to a latency 0 programme, or antigen-negative 
state, to avoid immune detection.  
Latency 0 is maintained long-term in transformed memory B-cells and is characterised by 
expression of only viral micro RNA (miRNA) and EBV-encoded small RNAs (EBERs), 
allowing the virus to avoid detection by host CD4+ and CD8+ T-cells. Infected B-cells with 
latency I phenotype express only EBERs, viral miRNA and EBNA1. Newly infected B-cells 
and those transformed in vitro are characterised by a latency III phenotype and express EBNA 
1, 2, 3A, 3B and 3C, LMP1, LMP2A and B proteins and miRNA and EBERs (Rowe et al., 
1992, Rowe et al., 2014), making them more easily recognisable by host T-cells. In vivo, newly 
infected B-cells with latency III phenotype rapidly downregulate their latent antigen expression 
to a latency 0 program to avoid detection by the immune system.  
Latently-infected B-cells occasionally become reactivated to produce infectious virions via 
mechanisms that are unclear but may be initiated by signals in the cellular environment or by 
differentiation into plasma cells, causing low-level foci of replication and virus production into 
the oropharynx. Levels of virus production are controlled by immune cells as lytic cells express 
viral proteins and are rapidly targeted and killed by T-cells and other effectors (Figure 1.5.1). 
Infected B-cells expressing a latency III program of gene expression are also rapidly killed by 
immune cells due to viral latent proteins being strong immunogenic targets. 
Once acquired, EBV persists as a lifelong latent infection in the memory B-cell pool with 
restricted viral antigen expression. Latent infection transforms B-cells so that they are able to 
pass on EBV DNA in episomal form to both daughter cells upon cellular division via EBNA1 
(Yates et al., 1985). EBV latency programmes describe the viral antigens expressed in infected 
B-cells, and this is dependent on many factors including the duration of infection or underlying 
disease.  
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B-cells transformed with EBV in vitro establish immortalised cell lines termed lymphoblastoid 
cell lines (LCLs) and are an important tool used to analyse T-cell responses to the virus. LCLs 
in culture typically have a latency III phenotype and reactivate into lytic cycle at low levels via 
mechanisms that are unclear. Induction into lytic cycle is triggered by expression of the 
transactivator protein BZLF1 and knock down of this protein maintains LCLs that are unable 
to reactivate into lytic cycle and produce virus (Sinclair, 2013, Murata, 2014). Persistence of 
latently infected B-cells in hosts maintains virus-specific CD4+ and CD8+ T-cell responses 
throughout life and these can be detected in the blood of virus carriers. 
Infectious mononucleosis (IM) is the primary symptomatic infection with EBV, causing 
significant morbidity in most patients and characterised by four key symptoms which can last 
up to 6-weeks in duration: sore throat, cervical lymphadenopathy, fever and fatigue (Luzuriaga 
and Sullivan, 2010). However, the majority of virus conversions are asymptomatic and go 
unstudied, and most children whose exposure to the virus occurs early do not develop IM; 
incidence of symptomatic infection increases with age at first exposure (Balfour et al., 2013).  
Symptoms of IM are thought to be caused by large expansions of immune cells observed in the 
blood of patients, and these expansions include immune cell subsets such as NK cells (CD3-
CD56+), CD4+ T-cells (CD3+CD4+) and CD8+ T-cells (CD3+CD8+).  
The role for NK cells in IM remains unclear, but evidence from humanised mouse models of 
EBV infection have identified a population of early differentiated NK cells that expand and 
target virus-infected cells in the blood, appearing before expansions of CD8+ T-cells (Chijioke 
et al., 2013). Circulating numbers of this early, undifferentiated subset of NK cells have also 
been found by another study to reduce in number with age, indicating their potential role in 
protecting against EBV infection and IM in children (Azzi et al., 2014).  
CD4+ T-cell responses during IM are significantly expanded but at much lower levels than 
seen in the CD8+ T-cell compartment, and with a greater proportion of responses directed 
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against latent proteins of EBV. CD4+ T-cell responses to the latent protein EBNA1 however 
have been showed to be delayed, and only become detectable 3-6 months following primary 
infection for reasons that are unclear; EBNA1-specific antibody responses also reflect this 
pattern (Long et al., 2013). Circulating EBV-specific CD4+ T-cell numbers have been shown 
to correlate with viral load over time in IM, and CD4+ T-cell expansions shrink to those of 
normal, low levels typical of long-term virus carriers following disease resolution (Long et al., 
2013, Precopio et al., 2003). CD4+ T-cell responses to EBV proteins are maintained throughout 
life by the persistence of EBV-infected B-cells, and responses to a variety of antigens can 
readily be detected in the blood of virus carriers. A summary of CD4+ T-cell responses to EBV 
proteins can be found in Figure 1.5.2. 
The expansion of CD8+ T-cell responses to EBV in IM is dramatic, with some lytic epitope-
specific responses constituting up to 50% of peripheral CD8+ T-cells (Abbott et al., 2013). The 
majority of expanded CD8+ T-cells in IM are directed against lytic antigens; latent antigen 
specificities have been estimated to represent ~5% of the CD8+ T-cell pool during IM (Hislop 
et al., 2005). These responses, as for CD4+ T-cells, shrink over time to levels found in healthy 
virus carriers and continue to control reactivation of infected B-cells into lytic cycle throughout 
life. EBV-specific CD8+ T-cell responses are maintained following seroconversion throughout 
life; size and antigen specificity of responses are largely dependent on the HLA type of the 




Figure 1.5.2 CD4+ and CD8+ T-cell responses to EBV latent and lytic proteins. Summary of known CD4+ 
(bottom) and CD8+ (top) T-cell responses to EBV proteins: 2 immediate early (IE), 14 early (E), 13 late (L) 
and to 8 latent proteins. Results from comparative studies of CD4- or CD8-depleted PBMC from >30 Caucasian 
donors screened against peptide pools spanning the sequence of each EBV protein using IFNg ELISpot assays. 
Height and depth of arrows indicate mean size of response in CD8+ and CD4+ T-cells respectively relative to 
other proteins. Arrow shading indicates how common responses are amongst subjects in cohorts, with dark red 
indicating frequent responses and colourless arrows representing rare responses. CD8+ scale is larger than that 
of CD4+ responses and reflects the generally 10-20-fold difference in size between these subsets. E, early; 
EBNA, EBV nuclear antigen; EBV, Epstein-Barr virus; IE, immediate early; L, late; LMP, latent membrane 
protein; n.t., not tested. Figure adapted from Taylor et al. (Taylor et al., 2015).  
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1.5.2 Epstein-Barr virus and multiple sclerosis 
 
EBV has long been known to be associated with autoimmune diseases, the most convincing 
evidence supporting an association with MS (Ascherio and Munger, 2010). MS is very rare in 
individuals not infected with the virus; almost 100% of MS patients are seropositive for EBV 
compared with ~90% of healthy, age-matched controls (Pakpoor et al., 2013). These findings 
are mirrored in paediatric cohorts where children with MS show significantly increased EBV 
infection rates compared to healthy controls (Pohl et al., 2006, Alotaibi et al., 2004, Banwell 
et al., 2007). Long-term study of seronegative individuals in one particular cohort showed no 
cases of MS development before acquisition of the virus (Levin et al., 2010), further supporting 
EBV’s role as a causal factor.  
In addition to EBV carriage increasing risk of MS, results from serology have shown a 
correlation with antibody IgG titres directed against the latent protein EBNA1 and EBNA 
complex with MS risk. EBNA complex consists of several viral proteins that associate to form 
a functional unit in the virus lifecycle, and includes EBNA1, EBNA2, EBNA3 proteins and 
EBNA leader protein (EBNA-LP). Results from the US military serum repository analysing 
large numbers of subjects have shown elevated anti-EBNA1 antibodies to increase risk of MS 
by 8-fold, and inflated anti-EBNA complex IgG to increase risk 36-fold compared to those 
with lower levels (Munger et al., 2011, Levin et al., 2005).  
Studies investigating antibody responses to EBV antigens are numerous and have used several 
different MS patient cohorts, and it is widely accepted that elevated anti-EBNA1 IgG and anti-
EBNA complex IgG titres are a feature of multiple sclerosis and have potential use as 
diagnostic markers (Ascherio et al., 2001, Sundstrom et al., 2004, Levin et al., 2005, DeLorenze 
et al., 2006). However, it is not clear whether these elevated antibody responses to EBV 
antigens in MS patients are involved in development of disease or are an effect of MS disease 
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itself, and without an accepted mechanism of how EBV contributes towards development it is 
difficult to draw conclusions. 
Correlation of anti-EBNA antibody responses with increased risk has also been shown to be 
independent of risk conferred by the HLA-DR15 allele (De Jager et al., 2008), the strongest 
genetic predictor of MS, indicating that elevated EBNA1 IgG are not driven by this haplotype 
and suggesting that the two contributing factors influence development of MS separately.  
Two studies investigating a relationship between EBV serology and disease activity in patients 
have been carried out with different results. Farrell et al. found the number of gadolinium-
enhancing lesions and disability scores to be positively correlated with EBNA1 IgG titres but 
not with virus capsid antigen (VCA) IgG titres (Farrell et al., 2009). Zivadinov et al. showed 
that anti-VCA IgG titres were linked to loss of brain volume in a cohort of 50 MS patients over 
a 3-year period (Zivadinov et al., 2009). VCA is a complex made up from BALF4 (gp125) and 
p160 (Pearson, 1988), and antibody responses to VCA have been reported to be elevated in MS 
patient sera and CSF compared to controls (Castellazzi et al., 2010, Zivadinov et al., 2009). 
The majority of one cohort’s EBNA1 antibody responses were mapped to the glycine-alanine 
repeat, suggesting that this region has high immunogenicity (Ruprecht et al., 2014). Further 
mapping of antibody responses from paediatric cohorts to specific regions of the EBNA1 
protein have revealed a broader specificity of responses with antibodies reacting to many 
regions (Lunemann et al., 2008a); this effect that has also been observed in CD4+ T-cell 
responses to EBNA1 of adult MS patients (Lunemann et al., 2006).  
As well as extensive studies on EBNA1 and EBNA complex serology, other antibody 
responses to EBV proteins have been investigated in the context of MS, with early reports from 
the 1980s observing an elevation in anti-capsid antigen IgG titres among patients (Larsen et 
al., 1985, Sumaya et al., 1985). More recently, elevated IgG titres have also been found in 
patients against certain lytic protein antigens; Lindsey et al. found a broad increase in titres 
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with reactivity to EBV early antigens, but neutralising antibody responses to the virus capsid 
antigen gp350 were unchanged between MS patients and controls (Lindsey et al., 2010). A 
modest increase in IgG responses to the immediate early BZLF1 protein has been shown in one 
cohort (Massa et al., 2007), and a more in depth analysis by Dooley et al. screened MS patient 
sera for reactivity to 28 EBV latent and lytic proteins, with only three exhibiting an elevated 
titre compared to healthy seropositive controls. EBNA1 showed the strongest association, with 
BFRF3 – a major structural protein – and BRRF2 also showing increased responses compared 
to controls (Dooley et al., 2016).  
Serology from the CSF is more difficult to analyse, and diagnosis often uses the presence of 
OCB which are present in 95% of MS patients. However, OCB are also present for other 
diseases affecting the CNS such as infections and their analysis is semi-quantitative, making 
them subject to interpretation. No consensus has been reached on the antigen specificity of 
OCB in MS patient CSF, with conflicting results from different research groups. A study using 
epitope mapping and a brain-tissue derived cDNA library mapped the two most frequent 
responses in MS OCB to EBNA1 and BRRF2 proteins of EBV (Cepok et al., 2005), and these 
findings agree with those previously found in a different cohort suggesting that CSF levels of 
anti-EBNA1 IgG are elevated in patients (Bray et al., 1992). In contrast a study from the 
Netherlands showed there to be no evidence of intrathecal anti-EBNA1 IgG synthesis in their 
cohort (Jafari et al., 2010).  
Conflicting data regarding EBV serology in MS make it difficult to draw conclusions regarding 
the role of antibodies in disease development. However, differences between patient cohorts 
and variation in technique and sensitivity of experimental techniques may all contribute to this 
variation, and more standardised research is needed regarding EBV-specific antibody 
responses to address this. EBV infection rates and serology strongly implicate a role for EBV 
 43 
in the development of MS, but despite this mounting aetiological and serological evidence no 
consensus has been reached regarding how this might occur.  
 
1.5.3 T-cell responses to EBV in MS 
 
Cellular responses to EBV have been extensively studied in MS patients, with the aim of 
correlating these with the serology of patients. There have been conflicting reports on whether 
cellular immunity to EBV is unchanged, increased or decreased in MS patient blood, and with 
an unclear picture surrounding virus-specific T-cell responses it is difficult to unravel EBV’s 
contribution to disease development. However, elevated risk of developing MS following IM 
suggests a role for perturbation of immune responses to EBV in the disease process. As 
previously described, the EBV-specific T-cell compartment expands and becomes 
dysregulated during IM, and it is possible that T-cell events during this process contribute 
towards MS pathogenesis after disease convalescence. 
Ex vivo T-cell responses to LCLs can be measured for cytokine production allowing frequency 
and phenotype of circulating cells specific for EBV antigens to be measured accurately. Early 
studies in the 1980s observed a reduced cytotoxicity of MS patient lymphocyte cultures as 
measured by their inability to control outgrowth of LCLs in vitro, suggesting an impaired 
control of viral replication in patient cells (Fraser et al., 1979, Craig et al., 1983). More recent 
studies investigating T-cell responses to LCL found no difference in cytokine production by 
CD4+ or CD8+ subsets between patients and controls. Lindsay et al. observed a reduced 
proliferative capacity in patient T-cells but these effects did not reach significance (Lindsey 
and Hatfield, 2010). However, patients in the study were on IFNb or glatiramer acetate therapy 
which may confound results, and whilst these treatments do not have a direct 
immunosuppressive effect on T-cells they do have immunomodulatory properties (Dhib-Jalbut 
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and Marks, 2010, Racke et al., 2010). Cepok et al. also investigated T responses to EBV latent 
proteins in MS patients and found CD4+ responses to be unchanged between groups but an 
elevation in CD8+ T-cell responses (Cepok et al., 2005); studies from a Danish patient cohort 
showed increased T-cell responses to two MHC class I-restricted epitopes from EBNA3A and 
LMP2 proteins from EBV (Hollsberg et al., 2003).  
Investigation of EBV-specific T-cell responses in the CSF is of key interest as this is closest to 
the tissue affected in MS. Several groups have reported a reduced T-cell response to LCL and 
have consistently shown circulating CD8+ T-cell responses to be decreased in MS patients 
(Pender et al., 2009, Pender et al., 2017, Jilek et al., 2012). However, other studies have shown 
CD8+ T-cell responses to be intrathecally enriched for EBV specificity, and some researchers 
argue that this suggests a lack of control of viral replication with infiltration of infected cells 
in the CNS (Jaquiery et al., 2010).  
Higher frequencies of autologous LCL-specific CD4+ and CD8+ T-cells were also detected in 
the CSF of MS donors by van Nierop et al., and CNS-derived CD8+ T-cells were further 
characterised to reveal oligoclonal expansions with specificity for EBV lytic proteins (van 
Nierop et al., 2016b).  
Interestingly an increased frequency of EBNA1-specific CD4+ T-cells in MS patient blood 
was reported by Lunemann et al., with responses also showing a broadened range of epitope 
specificities to the antigen with the majority of epitopes belonging to the C-terminal of the 
protein (Lunemann et al., 2006); these findings are interesting and tie in with widely accepted 
elevated EBNA1-specific IgG serology. 
Cellular responses to EBV are still widely debated in the MS field, hindering development of 
a consensus mechanism for the virus’s contribution to disease. However, five general theories 
exist which are described below. 
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1.5.4 Proposed mechanisms of EBV’s role in MS 
 
The first theory derives from data investigating post-mortem brain samples and suggests that 
immune cell attack on CNS-infiltrating EBV-transformed B lymphocytes causes bystander 
damage and inflammation to brain tissue. Serafini et al. described ectopic B-cell follicles 
formed in the meninges of post-mortem brains from SPMS samples, suggestive of specific 
CNS infiltration of EBV infected B-cells in MS as these structures were not found in the brains 
of patients with other neurological diseases (Magliozzi et al., 2007, Serafini et al., 2007, 
Serafini et al., 2017). Activation of innate immune mechanisms such as IFNa production by 
microglia and macrophages were also found in active MS lesions by Tzartos et al. and 
coincided in areas staining positive for EBERs (Tzartos et al., 2012). However, these results 
and theory of bystander activation in MS brain lesions are not accepted as consensus due to a 
lack of independent verification (Lassmann et al., 2011).  
The second theory, based on reports of increased viral load in MS patients detected by some 
studies, suggests dysregulation of T-cell responses to EBV contributes towards disease 
development by allowing EBV-infected B-cells to gain access to the CNS (Lunemann et al., 
2010). Viral load in PBMC is used as a crude measure of EBV reactivation in individuals, and 
those with a high copy number of virus genomes have generally either recently acquired the 
virus, are suffering from symptomatic primary infection (IM) or have ineffective control of 
virus replication. However, these reports of decreased EBV-specific T-cell responses are 
contradicted by other studies which found no difference compared to healthy controls (Cocuzza 
et al., 2014, Wagner et al., 2004, Lindsey et al., 2009, Santiago et al., 2010, Alvarez-Lafuente 
et al., 2006, Lucas et al., 2011).  
Other autoimmune diseases such as systemic lupus erythematosus have been shown to have an 
increased EBV load. However, this is thought to be an effect and not a cause of disease, and is 
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attributed to activation of B-cells due to underlying autoimmunity and exhaustion of CD8+ T-
cells, rather than a specific causal role for the virus in lupus pathogenesis (Moon et al., 2004, 
Larsen et al., 2011). 
The third theory suggests that EBV-transformation rescues B-cells that are specific for 
autoreactive epitopes, ensuring their survival from tolerance mechanisms. These self-reactive 
B-cells have been hypothesised to survive tolerance mechanisms by EBV-transformation, and 
are able migrate to the CNS of MS patients in an environment with impaired EBV-specific 
CD8+ T-cell responses. It could also be argued that intrathecal enrichment of EBV-specific 
CD8+ T-cell responses is due to infiltration of EBV-infected B-cells in the CNS (Jaquiery et 
al., 2010). Research showing a diminished cellular response to EBV has been published since 
the 1980s but despite this the theory is not accepted as consensus (Pender et al., 2009, Pender 
et al., 2017, Jilek et al., 2012, Craig et al., 1983, Craig et al., 1988).  
However, other research groups have found peripheral CD8+ T-cell responses to be unchanged 
or increased in frequency in MS patients (Lindsey and Hatfield, 2010, Jilek et al., 2008) and, 
combined with analysis of EBV-infected B-cell pools, provides no evidence for enrichment of 
autoantigen specificity (Tracy et al., 2012). Doubt has therefore been cast on EBV “rescue” of 
autoreactive B-cells a plausible mechanism for MS pathogenesis.  
The fourth theory surrounds mistaken self, and suggests that EBV infection and transformation 
of B-cells causes the up-regulation of self-antigens, which in turn become the target of 
autoreactive CD4+ T-cell responses in MS patients. Supporting this theory is the observation 
that virally-infected B lymphocytes upregulate expression of aB-crystallin (CRYAB) in vitro 
(van Sechel et al., 1999). Further studies have gone onto confirm expression of CRYAB in 
active brain lesions of MS patients and as a target of T-cell responses (van Noort et al., 1995, 
van Noort et al., 2010, Bajramovic et al., 1997). CRYAB has been identified as the target of 
pathogenic CD4+ T-cell responses secreting TH1-type cytokines (Chou et al., 2004). 
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However, reports of the effect of free CRYAB peptide on T-cell responses in MS have 
suggested a role for the protein in tolerisation of autoreactive responses, and a clinical trial 
administering “sub-immunogenic” amounts of intravenous CRYAB protein to RRMS patients 
have reported beneficial results after 9 months of therapy (van Noort et al., 2015). Experimental 
autoimmune encephalomyelitis (EAE) models also produced similar results of tolerisation 
when CRYAB administered to animals with a pre-established T-cell response to the 
autoantigen (Verbeek et al., 2007). Quach et al. reported CRYAB peptide to have a repressive 
effect on pathogenic CD4+ T-cell cytokine production in vitro (Quach et al., 2013), and this 
may be due to free peptide antigen inducing anergy in autoreactive T-cells. Further studies are 
needed to establish the effect of CRYAB epitope processing and presentation on MHC 
molecules.  
As well as CRYAB, studies have shown other self-antigens to be up-regulated in B-cells upon 
EBV infection and these proteins have drawn interest from researchers in several different 
fields including autoimmunity and EBV-driven cancer. Long et al. showed that LCL-reactive 
CD4+ T-cells could not be mapped by specificity to any known EBV antigens, suggesting that 
they were specific for self-antigens up-regulated by EBV-transformation. The identified non-
EBV antigen restricted CD4+ T-cells were also able to kill LCLs in vitro (Long et al., 2009). 
Despite lack of characterisation, previous studies have also shown CD4+ T-cells in LCL-
stimulated polyclonal T-cell lines that have no known reactivity to EBV epitopes to have 
cytotoxicity against LCLs (Haque et al., 2002, Comoli et al., 2002), further supporting the 
presence of CD4+ T-cell responses generated against a host of self-proteins up-regulated upon 
EBV infection and transformation of B-cells. 
The fifth theory suggests that molecular mimicry between virus and neuronal antigens is 
responsible for the CNS tissue damage observed in MS patients, and is discussed in detail in 
the following section. 
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1.5.5 Molecular mimicry in EBV-induced T-cell responses 
 
The theories described above do not fully explain important epidemiological and clinical 
observations reported in recent studies of MS patients, which need to be taken into account 
when constructing a mechanism linking EBV to MS.  
There are several arguments against the hypothesis that MS arises from uncontrolled EBV 
infection, the first being that MS is not a reported complication of patients undergoing 
immunosuppressive therapy after post-transplant lymphoproliferative disease (PTLD), and 
other conditions such as chronic active EBV or X-linked lymphoproliferative disease patients 
do not experience neurological symptoms or MS-like disease. Immunosuppression is in fact 
used to treat MS and, were uncontrolled infection the cause of MS, such therapy would 
exacerbate symptoms.  
It is also apparent that MS symptoms take at least months or even years to develop following 
acquisition of EBV, findings demonstrated by Levin et al. (Levin et al., 2010) and supported 
indirectly by a lack of MS cases in individuals who have recently experienced IM (Yea et al., 
2013). If uncontrolled infection were the cause of MS then at least a proportion of patients 
suffering from symptomatic primary infection would develop neurological symptoms upon 
acquiring the virus. In addition to this, studies of EBV load in serum or PBMC of MS patients 
have only reported a modest increase (Wagner et al., 2004, Buljevac et al., 2005, Lindsey et 
al., 2009), a contrast to the high viral loads observed during IM and viral reactivation in patients 
with PTLD (Gartner et al., 2002).  
Natalizumab is a monoclonal antibody that prevents migration of T-cells into the CNS by 
blocking a4b1 integrin and has been shown to be an effective immunomodulatory therapy for 
MS (Polman et al., 2006). Prevention of T-cell entry into the CNS would therefore exacerbate 
disease if uncontrolled EBV infection was one of the contributing factors of MS development. 
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Observations from the clinical efficacy of rituximab, a monoclonal anti-CD20 antibody, have 
also shown the role of B cells in MS to be more complex than just production of antibodies. 
Plasma cells are responsible for antibody production but no longer express the marker CD20, 
and are therefore are not directly depleted by rituximab therapy. Rituximab has been shown to 
reduce relapse rates in MS patients within a few weeks of treatment initiation and before 
antibody titres are reduced, suggesting that B-cells may contribute towards MS pathogenesis 
in other ways, such as antigen presentation or cytokine production (Hauser et al., 2008, von 
Budingen et al., 2011, Lisak et al., 2012). This clinical observation also implies that production 
of autoreactive antibodies is not the sole contribution of B-cells to MS development, and 
suggests that clinical efficacy of rituximab would be less rapid if rescue of autoreactive B-cells 
was one of the major mechanisms driving MS disease. 
Elevated EBV antibody titres have also been strongly linked to risk of developing MS in young 
adults, such as those specific for EBNA complex and EBNA1 (Ascherio et al., 2001), and is 
an effect that has been confirmed by several independent studies (Sundstrom et al., 2004, Levin 
et al., 2005, DeLorenze et al., 2006, Munger et al., 2011). Elevated antibody titres are not 
immediately present in initial infection but take several months to become elevated, consistent 
with the delayed onset of MS after primary infection (Levin et al., 2010) and also delayed 
development EBNA1-specific antibody and CD4+ T-cell responses (Long et al., 2013). This 
delayed onset of MS symptoms following EBV infection and the strong genetic association 
with HLA-DR15 is suggestive of disease that is driven by the immune response to EBV, rather 
than uncontrolled viral replication.  
Considering all of these arguments, we therefore sought to investigate an alternative 
mechanism linking EBV with MS development which is (so far) not strongly contradicted by 
clinical and epidemiological studies. 
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The most reasoned theory currently explaining EBV’s role in MS development is molecular 
mimicry. Here, infection with EBV induces T-cell responses – most likely CD4+ – which 
recognise both EBV and CNS epitopes displayed by MHC molecules. Strong evidence for 
elevated anti-EBNA1 IgG in MS patient sera, coupled with work by Lunemann et al. describing 
an increased and broadened CD4+ T-cell response to the protein (Lunemann et al., 2006), has 
made EBNA1 the focus of most investigations into cross-reactivity of EBV-specific T-cell 
responses.  
Lunemann et al. found a population of expanded TH1 CD4+ T-cells with mixed central memory 
and effector memory phenotype in MS patients which were further characterised and revealed 
to have higher reactivity to a pool of myelin peptides and co-produce IFNg and IL-2. CNS 
proteins included in the pool were myelin basic protein (MBP), proteolipid protein (PLP), 
myelin oligodendrocyte glycoprotein (MOG), and 2’,3’-cyclic nucleotide 3’-
phosphodiesterase (CNP) (Lunemann et al., 2008b). Increased polyfunctionality of this cross-
reactive, EBNA1-specific CD4+ T-cell population suggests chronic antigen stimulation like 
that seen in controlled, latent viral infections.  
Less work has been completed at the single cell level, however there are several examples of 
EBV antigen-specific CD4+ T-cells which also display reactivity to a specific myelin epitope. 
BALF5 is an EBV protein with DNA polymerase activity, and CD4+ T-cells specific for this 
protein have been shown by two research groups to cross-react with an epitope found in the 
neuronal antigen MBP. Lang et al. structurally modelled a TCR from an MS patient with 
reactivity to both MBP (85-99) and BALF5 (627-641), restricted by HLA-DR15 (HLA-
DRB1*15:01) and HLA-DR51 (HLA-DRB5*01:01) respectively (Lang et al., 2002). This 
finding, coupled with the epitope restriction to the allele conferring highest risk for MS, 
supports a role for EBV inducing degenerate responses that are able to react with structurally 
similar peptide:MHC complexes from EBV and the CNS. Further work by Holmoy et al. found 
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BALF5/MBP-specific CD4+ T-cells to be specifically enriched in the CSF of a MS patient 
compared to a matched blood sample, indicating tissue specific homing of the cross-reactive 
T-cell to the CNS (Holmoy et al., 2004). 
Despite evidence of cross-reactivity between EBV and neuronal epitopes from these studies no 
new examples of this phenomenon have been published in several years, and further 
investigation is warranted regarding this mechanism in the context of MS. 
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1.6 Scope of thesis 
 
EBV’s contribution to the development of MS is critical, as demonstrated by epidemiological 
and serological evidence. It is therefore of key clinical importance that we understand the 
immune mechanisms involved in disease pathogenesis in order to develop better therapies for 
MS. This thesis explores the broad immune responses to EBV in healthy controls, individuals 
with a recent history of IM and MS patients, investigating viral load, antibody responses, CD4+ 
and CD8+ T-cell responses to latently-infected B-cells. Cross-reactivity of cellular responses 
to EBV were investigated using a panel of novel modified Vaccinia Ankara (MVA) viruses 




2.1 Tissue Culture 
 
2.1.1 Tissue culture media and reagents 
 
RPMI-1640 – Roswell Park Memorial Institute-1640 medium supplemented with 2mM L-
glutamine (Sigma) 
DMEM – Dulbecco’s Modified Eagle’s medium (Sigma) 
IMDM – Iscove’s Modified Dulbecco’s medium (Gibco) 
B-cell blast media – IMDM, 10% HuS, IL-4 (100IU/mL), 5.5x10-7 cyclosporin A, 1% 
penicillin-streptomycin solution (Gibco), 2mM L-glutamine 
T-cell media – RPMI 8% FCS, 1% HuS, 30% MLA-144 supernatant (filtered), IL-2 50IU/mL 
Opti-MEM (Gibco) 
Foetal calf serum (FCS) (Gibco) 
Human serum (HuS) (Corning) derived from male, AB+ donors, virus and mycoplasma 
tested 
Express Trypsin (Gibco) 
Penicillin-Streptomycin 100x stock (Gibco) 500IU/mL penicillin and 5000µg/mL 
streptomycin 
L-glutamine (Gibco) 100x stock (200mM) 
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Phosphate buffered saline (PBS) made up in house using 10xPBS tablet (Oxoid) per litre of 
distilled water (KCl 2.68mM, KH2PO4 1.47mM, NaCl 136.89mM, Na2HPO4 8.10mM), 
sterilised by autoclaving (20mins at 121°C)  
MACS buffer – 0.5%, BSA, 2mM EDTA in distilled water and sterilised by autoclaving 
(20mins at 121°C) 
Paraformaldehyde (PFA) (Sigma) 
Saponin extract from quillaja bark (Sigma) 
IL-2 – Recombinant interleukin-2 (Peprotech) stock made up in 1% BSA PBS at 105IU/mL 
IL-4 – Recombinant interleukin-4 (Peprotech) stock made up in 1% BSA PBS at 105IU/mL 
IL-7 – Recombinant interleukin-7 (Peprotech) stock made up in 1% BSA PBS at 105IU/mL 
MLA-144 – Monkey Leukocyte Antigen-144 cell line supernatant, filtered, grown in-house 
and originally obtained from the ATCC 
Lymphoprep (Cedar Wood) 
Dimethyl sulphoxide (DMSO) (Sigma) 
Staphylococcal enterotoxin B (Sargsyan et al.) 
TNFa processing inhibitor (TAPI-0) (Enzo Life Sciences) 
 
2.1.2 Peptides and peptide pools 
 
Peptides were synthesised by Alta Biosciences and dissolved in DMSO to obtain a 
concentration of 5mg/mL and stored at -20°C. Overlapping peptide pools were obtained from 
JPT (PepMixes) and consisted of 15mers overlapping by 11 amino acids. Pools were 
reconstituted in DMSO at 250µg/mL and stored at -20°C. 
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2.1.3 PBMC isolation from whole blood and plasma collection 
 
Peripheral blood was collected from donors into 9mL vacuum tubes containing Lithium 
heparin (Grenier Bio One) and diluted 1:1 with warm RPMI. 35mL blood/RPMI was then 
layered onto 15mL lymphoprep in 50mL falcon tubes and centrifuged for 30 minutes at 900G 
with brake off. Lymphocyte layer was aspirated off and the cells washed with RPMI twice. 
Cells were either used immediately or frozen down (Chapter 2.1.6). Plasma was harvested from 
above the lymphocyte layer as a 1:1 mix of plasma:RPMI and frozen down immediately for 
later use.  
 
2.1.4 Generation of B-cell blast cultures from whole PBMC 
 
L-CD40L cells (ATCC) were cultured in DMEM supplemented with 8% FCS to ~90% 
confluency before being trypsinised (0.00625% (w/v) Trypsin in EDTA), washed and 
irradiated (100 Grays) before being seeded into 6-well tissue culture plates and incubated for 
6 hours at 37°C at 5% CO2 to allow adhesion to plates. Donors’ PBMCs were re-suspended in 
B-cell blast medium at a concentration of 1.7x105 cells/mL. Supernatant was aspirated off 
irradiated L-CD40L cells and the re-suspended PBMCs were added dropwise onto the feeder 
layer (~5x106 cells/well). At 3 day intervals expanding B-cell blasts were layered onto fresh L-
CD40L monolayer in fresh medium.  At day 14 expanded B-cell blast populations were ready 
for use in further experiments or frozen in freezing medium and subsequently thawed at a later 




2.1.5 Generation of lymphoblastoid cell lines 
 
Wild type LCL 
5x106 PBMC were re-suspended in 5mL of filtered B95.8 cell line supernatant and incubated 
overnight at 37°C, 5% CO2. The following day cells were washed and re-suspended in RPMI-
1640 supplemented with 10% FCS and 1µg/mL cyclosporin A and put into one well of a 24-
well plate; cells were monitored for B-cell transformation over 2 weeks. Cells were then bulked 
up until they could be maintained in a T25 tissue culture flask in RPMI-1640 8% FCS. 
BZLF1 KO LCL 
293 cells containing the BZLF1 KO construct were a gift from Henri-Jacques Delecluse and 
have been described previously (Feederle et al., 2000). Method was as described above for 
B95.8 LCL generation using supernatant from the 293-BZLF1 KO cells harvested after 




Cells to be frozen in liquid nitrogen were centrifuged and re-suspended in freezing medium 
(RPMI-1640, 40% FCS, 10% DMSO) and transferred to cryovials (Nunc). “Mr Frosty” 
containers were used to gradually cool specimens by 1 degree per minute to -80°C before 





2.1.7 Thawing of cryopreserved cells 
 
Cryovials were placed into a 37°C water bath to thaw, washed twice with RPMI-1640 10% 
FCS before being re-suspended in appropriate media. Cells were then cultured in an incubator 
(37°C, 5% CO2). 
 
2.1.8 Mycoplasma testing 
 
All cell cultures were routinely tested for mycoplasma using a Mycoalert kit (Cambrex) 
according to the manufacturer’s protocol.  
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2.2 Generation of recombinant MVA virus panel 
 
2.2.1 Construction of plasmids with central nervous system protein inserts 
 
Plasmids containing CNS protein inserts under control of the bacteriophage T7 promoter were 
made prior to this project by Yolanda van Wijck (van Wijck, Y. (2011) Construction of 
recombinant MVAs encoding CNS proteins and testing the MVA-T7 system with EBNA1-
specific T-cells. MSc internship unpublished thesis. Vrije Universiteit, Amsterdam, The 
Netherlands and the University of Birmingham, UK.) and Marye Hogenboom (Hogenboom, 
M. (2012) Cloning of CNS proteins as cross-reactive targets for EBNA1-specofoc T-cells of 
MS patients. MSc internship unpublished thesis. Vrije Universiteit, Amsterdam, The 
Netherlands and the University of Birmingham, UK.). 
 
2.2.2 Recombination of MVA viruses with plasmids expressing CNS proteins 
 
BHK21 cells were cultured to ~90% confluency and infected with wild type MVA at a MOI of 
0.1 in PBS supplemented with 1% FCS; infected cells were incubated at 37°C, 5% CO2 for 90 
minutes, rocking every 30 minutes. Lipofectamine 2000TM was used to transfect recombinant 
plasmid DNA (protocol as Lipofectamine 2000TM guidelines) containing CNS protein 
sequences into wild type MVA-infected BHK21 cultures (protocol as Chapter 2.2.4) and 
incubated for 4 hours to generate recombinant virus. DMEM supplemented with 2.5% FCS 
was added and the cultures monitored for CPE for 48-72 hours. Once 90-100% CPE had been 
achieved the cells were harvested, freeze-thawed three times and sonicated. The virus 
preparations were then used to infect BHK21 cells at a MOI of 0.1 in 1%FCS PBS, and 
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infections were incubated for 4 hours at 37°C, 5% CO2, after which 2.5% FCS DMEM was 
added to the cultures. After 3 days GFP-positive recombinant plaques were picked with a 
pipette tip under a fluorescent microscope and used to inoculate 250µL PBS (1% FCS). The 
inoculated PBS was used to infect a further monolayer of 80-90% confluent BHK21 cells, and 
successive rounds of plaquing were carried out until WT (GFP-negative) plaques were no 
longer observed. The purified recombinant virus plaques were then amplified in BHK21 cells 
by infecting confluent cultures at larger increments, freeze thawing and sonicating the virus 
between each stage. The final amplification step in BHK21 cells was used to produce virus 
stock reagents, which were used throughout this project for all experiments. A list of 
recombinant MVA viruses is listed in Table 2.1.  
 
Table 2.1 List of generated recombinant MVA viruses 
Recombinant CNS MVA  Full name of recombinant protein inserts 
Empty vector pYWK 
CNP 2’,3’-cyclic nucleotide 3’ phosphodiesterase 
Contactin-2  
MAG Myelin associated glycoprotein  
MOG Myelin oligodendrocyte glycoprotein 
PLP Proteolipid protein 
MBP Myelin basic protein 
MBP V8 Myelin basic protein variant 8 
MOBP Myelin-associated oligodendrocyte basic protein 
CRYAB Alpha-B crystalline 
Claudin-11  
Tal-H Transaldolase-H 
EBNA1 Epstein-Barr virus nuclear antigen 1 
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2.2.3 Titration of MVA virus stock 
 
Virus stocks were prepared as described in Chapter 2.2.2. Prepared virus stock was serially 
diluted from 10-2 to 10-9 in PBS 1% FCS and 500µL each dilution used to infect at least 2 wells 
(6-well plate) of 80-90% confluent BHK21 cells before incubating at 37°C, 5% CO2 for 4 
hours, rocking plates every hour to ensure cultures do not dry out. After 4 hours virus 
preparation was aspirated off and 3mL of semi-solid virus overlay was added slowly to each 
well (DMEM 2.5% FCS, 2.5% carboxymethyl cellulose), and plates were incubated at 37°C, 
5% CO2 for 3 days. After 3 days, infected BHK21 cells were observed under a fluorescent 
microscope and the GFP-positive virus plaques counted. The lowest dilution at which GFP-
positive plaques could be observed was used to calculate titre for each MVA virus stock.  
 
2.2.4 MVA infection of cells for use in Western blotting and stimulation assays 
 
Cell lines were washed in 1% FCS media twice and re-suspended in residual volume. T7 
polymerase MVA and CNS MVA were added to cells at a MOI of 10 and 5 respectively, before 
incubating at 37°C, 5% CO2 for 4 hours, re-suspending cells every hour. For cellular 
stimulation assays, following incubation cells were washed twice with sterile 1% FCS medium 
and re-suspended in 8% media containing cells to be stimulated. For Western blots, infected 
cells were re-suspended in 2.5% FCS media and incubated for 24 hours at 37°, 5% CO2, after 
which cells were washed twice in PBS and cell pellets prepared as Chapter 2.4.1.  
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2.3 Cellular and immunological assays 
 
All tissues that required long-term culture were kept sterile with experiments performed in a 
microbiological safety cabinet (class II).  
 
2.3.1 Intracellular cytokine staining of PBMC 
 
PBMCs were washed in RPMI 8% FCS and re-suspended before being added to separate FACS 
tubes with various stimuli: Staphylococcal enterotoxin B (SEB) (0.2µg/mL), autologous wild 
type LCL (B95.8 LCL) (ratio 1:1), autologous BZLF1 KO LCL (ratio 1:1) or EBNA1 peptide 
mix (JPT) (1µg/mL). Brefeldin A (Sigma) (10µg/mL) was added after 1 hour and cells 
incubated overnight at 37°C, 5% CO2. No overnight toxicity was observed from incubating 
cells with the concentration of Brefeldin A indicated. The following morning samples were 
washed twice in cold PBS and re-suspended in residual liquid. Surface stain antibodies (Table 
2.2) were added and cells were mixed before incubating for 30 minutes on ice. Following 
incubation, cells were washed once with cold PBS and once with cold MACS buffer and re-
suspended in residual volume. 0.4% paraformaldehyde (Sigma) was added to samples before 
cells were incubated at room temperature (RT) in the dark for 30 minutes. Samples were then 
washed twice with cold MACS buffer and 0.5% saponin (Sigma) was added to samples and 
they were incubated in the dark at RT for 5-10 minutes. Intracellular antibodies (Table 2.2) 
were added and samples were incubated for 30 minutes in the dark at RT. Samples were then 





Table 2.2 List of antibodies used in ICS of PBMC 
Surface antibodies  
CD3 APC-Cy7 Cambridge Bioscience 
CD4 PE-Cy7 eBioscience 
CD8 PerCP-Cy5.5 eBioscience 
CD14 PECF594 BD Biosciences 
CD19 PECF594 BD Biosciences 
Viability Live/Dead Red Life technologies 
Intracellular antibodies  
IFNg FITC Cambridge Bioscience 
IL-2 PE Cambridge Bioscience 
IL-17 Pacific Blue Cambridge Bioscience 
GM-CSF APC Cambridge Bioscience 
 
 
2.3.2 Generation of polyclonal T-cell lines 
 
PBMC were recovered from freezing and washed twice in RPMI 2% HuS. PBMC were then 
re-suspended in RPMI 8% HuS supplemented with IL-7 (1ng/mL) containing irradiated 
autologous wild type LCL (40:1) or autologous B-cell blasts infected with MVA EBNA1 
(protocol as Chapter 2.2.4) (10:1). PBMCs were plated out at 2x106 cells/well in 24-well plates 
and incubated for 7 days at 37°C, 5% CO2. On day 7 cultures were re-stimulated with the same 
stimulus, re-suspended in T-cell medium at the same concentration and incubated at 37°C, 5% 
CO2. Polyclonal T-cell lines were incubated for a total of 2 weeks before T-cell cloning or 4 
weeks before screening by ICS against MVA CNS-infected B-cell blasts. 
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2.3.3 T-cell cloning techniques 
 
All T-cell cloning methods used polyclonal T-cell lines generated according to the protocol 
outlined in Chapter 2.3.2.  
Feeder cells were prepared by isolating PBMC from buffy coats (obtained from the Blood 
Transfusion Service, Birmingham, UK) from three separate donors by Ficol separation 
(Chapter 2.1.3). After separation, buffy coat cells were mixed together and rested overnight in 
RPMI 8% FCS containing phytohaemagglutinin (PHA) (10µg/mL). The following day buffy 
coat cells were washed five times in fresh medium, irradiated (40 Grays) and added to cultures 
as feeder cells. 
 
Limiting dilution only cloning 
Polyclonal T-cell lines (method Chapter 2.3.2) were re-suspended at differing concentrations 
of 3 cells/mL and 30 cells/mL in RPMI 8% HuS containing IL-7 (1ng/mL) with irradiated (40 
Grays) autologous wild type LCL (1x105/mL) and feeder cells (1x106/mL). Polyclonal T-cell 
suspensions were then plated out using 100µL/well in 96-well plates (U-bottom), which gave 
final concentrations of 0.3 and 3.0 polyclonal T-cells per well. Plates were incubated at 37°C, 
5% CO2 for 5 days, after which 100µL T-cell media was added to each well. Plates were 
incubated for a total of 2 weeks, after which expanded microcultures started to become visible 





IFNg capture and limiting dilution cloning 
IFNg capture was performed using the human IFNg secretion assay cell enrichment and 
detection kit (PE) from Miltenyi Biotech under sterile conditions. Autologous B-cell blasts 
were infected with selected MVA CNS viruses (protocol as Chapter 2.2.4) and incubated 
overnight in B-cell blast media at 37°C, 5% CO2. The following day, infected B-cell blasts 
were washed 3 times and irradiated (40 Grays) before re-suspending in RPMI media (no 
supplements) with prepared polyclonal T-cell lines (protocol as Chapter 2.3.2) (1:1) for 3 hours 
at 37°C, 5% CO2 re-suspending cells every hour. Following stimulation cells were washed 
twice in RPMI media, then once in cold MACS buffer after which the cell pellet was re-
suspended in 80µL cold MACS buffer and 20µL catch reagent was added per 1x107 cells, after 
which cells were incubated on ice for 5 minutes. 10mL warm RPMI media was then added per 
1x107 cells and tubes were incubated on a rotator at 37°C for 45 minutes. Cells were then 
washed with cold MACS buffer and the supernatant aspirated off, the pellet was then re-
suspended in 80µL cold MACS buffer. 20µL IFNg detection antibody (PE) was added per 
1x107 cells, vortexed and incubated on ice for 10 minutes. Cells were washed again in cold 
MACS buffer and the supernatant aspirated off. The cell pellet was then re-suspended in 80µL 
cold MACS buffer and 20µL PE microbeads were added, after which samples were vortexed 
samples incubated for 20 mins at 2-4°C. Samples were washed again with cold MACS buffer, 
the supernatant aspirated off and cells re-suspended in 0.5mL cold MACS buffer. MS columns 
(Miltenyi Biotech) were places into a magnetic separator and rinsed with 0.5mL cold MACS 
buffer, the effluent discarded. The now magnetically labelled cells were applied to the column 
and were allowed to pass through into a fresh tube by gravity flow. The column was washed a 
further 3 times with 0.5mL cold MACS buffer and the effluent collected as the negative fraction 
which was then discarded. The column was removed from the magnet and placed above a fresh 
tube. 1mL cold MACS buffer was then applied to the column to flush through the retained 
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cells, this was the positive fraction and contained the IFNg-producing activated T-cells. 
Limiting dilution cloning technique was then used to plate out positively selected cells as 
described above but, instead of infected B-cell blasts, anti-CD3 antibody (OKT3 30ng/mL) 
(eBioscience) was added to T-cell media to provide non-specific stimulus. Plates were 
incubated at 37°C, 5% CO2 for 5 days, after which 100µL T-cell media was added to each well. 
Microcultures were observed after two weeks and screened for antigen specificity. 
 
TNFa capture and FACS cloning 
Autologous B-cell blasts were infected with selected MVA CNS viruses (protocol as Chapter 
2.2.4) and incubated at 37°C, 5% CO2 overnight in B-cell blast medium. The following day 
infected B-cell blasts were washed 3 times, irradiated and re-suspended in RPMI 8% HuS 
containing IL-7 (1ng/mL) with prepared polyclonal T-cell lines (protocol as 2.3.2) at a ratio of 
1:1. TAPI-0 (1µg/mL) and TNFa APC antibody (eBioscience) was added to stimulations and 
samples were incubated at 37°C, 5% CO2 for 4 hours, re-suspending every hour to prevent 
clumping and aid stimulations. Surface staining of samples was performed under sterile 
conditions as and is described in Chapter 2.3.4. 96-well U-bottom plates were prepared for 
sorting and each well contained 100µL RPMI 8% HuS containing IL-7 (1ng/mL) with feeder 
cells (1x106/mL) and OKT3 (30ng/mL). After surface staining, cells were re-suspended in cold 
RPMI and run on a FACS Aria II machine (BD Biosciences). Single, live, CD19-, CD3+, 
TNFa+ cells were sorted into prepared 96-well U-bottom plates at 1 cell per well. Plates were 
incubated at 37°C, 5% CO2 for 5 days, after which 100µL T-cell media was added to each well. 
After 2 weeks incubation microcultures were observed and screened for specificity.  
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2.3.4 TNFa capture staining and single cell sorting 
 
Cells were stimulated with selected targets for 4 hours in the presence of TAPI-0 (1µg/mL) 
and TNFa APC antibody (eBioscience) and incubated at 37°C, 5% CO2, re-suspending cells 
every hour. Samples were then washed twice in cold, sterile PBS before addition of surface 
stain antibodies (Table 2.3) and samples incubated on ice for 30 minutes. Cells were then 
washed once in cold PBS and once in MACS buffer, before re-suspending in cold RPMI (for 
cells run on cell sorter, see Chapter 2.3.3) or MACS (for cells run on flow cytometer). All 
samples were kept on ice and run immediately on a LSR II (BD Biosciences) flow cytometer.  
 
Table 2.3 List of antibodies used in TNFa capture staining  
Surface antibodies  
CD3 FITC BioLegend 
CD19 PECF594 BD Biosciences 
Viability Live/Dead Aqua Life Technologies 
TNFa APC (added prior to stimulation) eBioscience 
 
2.3.5 IFN-γ ELISA 
 
T-cell activation was measured by IFNγ production in an IFNγ enzyme-linked immunosorbent 
assay (ELISA). 1x104 T-cells per well were incubated with target cells (5x104/well) or peptide 
(1µg/mL) and incubated overnight at 37°C, 5% CO2 in RPMI 8% FCS. Supernatant was 
harvested the following day and IFNγ measured using the IFNγ ELISA kit as per the 
manufacturer’s instructions. IFNγ antibody (clone 2G1, 1.01mg/mL, Thermofisher Scientific) 
diluted 1:7500 in ELISA coating buffer (carbonate-bicarbonate buffer 100mM) was used to 
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coat Nunc-Immuno MicroWellTM 96-well plates with MaxiSorpTM surface (50µL/well). Plates 
were incubated overnight at 4°C. The following day the antibody solution was flicked off, 
100µL blocking buffer (PBS, 0.05% Tween-20, 10% BSA) was added to each well and plates 
were incubated for 1 hour at room temperature. Plates were then washed five times with wash 
buffer (PBS, 0.05% Tween-20) and then 50µL cell supernatant was harvested and added to the 
Nunc plates. Recombinant IFNγ (Peprotech) was used to make a standard curve by doubling 
serial dilutions from 20,000pg/mL down to 78.125pg/mL in RPMI 8% FCS; 50µL each dilution 
was added in triplicate to plates with plain media used as a negative control. Plates with 
supernatant and standards added were incubated for a minimum of 3 hours at room temperature. 
After incubation plates were washed 5 times with wash buffer and 50µL/well biotinylated IFNγ 
monoclonal antibody (clone B133.5, 0.5mg/mL, Thermofisher Scientific) diluted at 1:7500 in 
blocking buffer was added and plates incubated for 2 hours at room temperature. Following 
this, plates were washed five times in wash buffer and 50µL streptavidin-peroxidase 
(ExtrAvidin®-peroxidase, Sigma) diluted 1:5000 in blocking buffer was added to each well 
and the plates incubated for a further hour at RT. Plates were washed eight times in wash buffer 
and 50µL peroxidase substrate (3,3’,5,5’-tetramethylbenzidine (TMB) solution, Tebu-Bio 
Laboratories) was added, the plates were then incubated at in the dark at RT for 20-30 minutes. 
The reaction was stopped with 50µL hydrochloric acid (1M HCl), after significant colour 
change to a blue solution in the top standards had occurred, resulting in a yellow solution. 
Plates were then read on an iMarkTM Microplate Absorbance Reader at dual wavelengths of 





2.3.6 Detection of antibodies in human plasma 
 
Blood collected from patients was separated using Ficol gradient separation (see protocol 2.1.3) 
and the plasma-RPMI fraction aspirated off and kept separately for further analysis of antibody 
responses by ELISA. 
 
EBNA1-specific IgG 
Levels of EBNA1 IgG in donor plasma were detected using the DiamedixTM 




EBV IgG positive and negative cell lines – P3HR1 and Bjab respectively – were re-suspended 
in PBS at a concentration of 107/mL. 10µL of re-suspended cell lines were pipetted onto holes 
of microscope slides (SM011) and air dried in a warm room at 37°C. Slides were then fixed in 
cold acetone for 10 minutes, dried and stored at -20°C.  
On day of staining, microscope slides were defrosted and blocked in PBS 10% HINGS for one 
hour at RT. Donor plasma was diluted down to 1:10, 1:20 and 1:40 in PBS 10% HINGS 
solution and 20µL of diluted serum was pipetted onto dried microscope slides before 
incubating for 1 hour at 37°C in a moist chamber. Slides were washed twice for 10 minutes in 
PBS using a magnetic stirrer, and the excess moisture wiped off around each hole. FITC-
conjugated human IgG antibody (Sigma) was diluted 1:50 in PBS 10% HINGS and 20µL 
pipetted onto each hole of slides. Slides were incubated for 1 hour at 37°C in a moist chamber. 
Slides were washed twice for 10 minutes in PBS with magnetic stirring. Slides were mounted 
using DABCO mounting fluid and examined under a UV microscope. 
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CMV-specific IgG 
Diluted mock lysate (1:4000) and virus-infected cell lysate (1:4000) was coated onto Nunc 
MaxiSorpTM plates and incubated overnight at 2°C. 100µL plasma samples (1:600 dilution) 
and appropriate standards (a mixture of 3 CMV-positive plasma samples) were added to the 
wells and the plate was incubated at RT for 1 hour, after which the plate was washed 3 times. 
100µL anti-human IgG-HRP (horseradish peroxidase) secondary antibody was then added to 
the plate before incubating for 1 hour. The plate was washed 3 times and TMB (3, 3′, 5, 5′-
tetramethylbenzidine) substrate was added. The plate was incubated in the dark at RT for 10 
minutes before addition of 100µL 1M HCl to each well. Absorbance was read on a plate reader 
at 450 nm. To determine plasma CMV IgG titres, mock values were first subtracted from lysate 
values. The data were then analysed using GraphPad Prism (GraphPad Software, San Diego, 
CA, USA) and CMV IgG titres were calculated with reference to the standard curve. Values 
greater than 10 were considered to be seropositive. All samples were tested in triplicate and 
final titres were calculated as the average of these values. 
 
Tetanus IgG detection 
Plasma tetanus-specific IgG were measured by the staff at the Clinical Immunology Service, 
University of Birmingham using a Roche HITACHI Cobas®6000, with Roche IgG reagent kits 
as per the manufacturer’s instructions. Plasma anti-tetanus IgG was measured using a 
previously described multiplexed bead based assay (Whitelegg et al., 2012). The definitions of 
protective antibody concentrations used have been previously characterised and published and 
are used as standards in the laboratory (Plotkin, 2001). 
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2.4 Western blotting 
 
2.4.1 Preparation of type 1 and 2 EBV and EBNA3 protein cell lysates 
 
The cord blood cell line C2 was infected with type 1 (OBA) and type 2 EBV (BL16) recovered 
from cell lines as described in the following publications (Rowe et al., 1989, Yao et al., 1996). 
For EBNA3A, B and C protein cell lysates, the EBV-negative cell line BJAB was infected with 
previously made MVA viruses containing EBNA3 genes separately (Long et al., 2009). BJAB 
cells were exposed to MVA viruses for 1 hour at a MOI of 10, before culturing in RPMI 2.5% 
FCS for 24 hours. After 24 hours cell lysates were prepared (method in Chapter 2.4.2). 
 
2.4.2 Cell lysates 
 
106 cells for each sample were washed in PBS and centrifuged. Pellets were then re-suspended 
100µL urea buffer (9M) and the samples sonicated for 30 seconds at 40% intensity (probe 
sonicator). Samples were then spun at 8500g for 20 minutes and the supernatant transferred to 
a fresh tube. Lysates were then either used immediately (Chapter 2.4.2 and 2.4.3) or frozen at 






2.4.3 Protein preparation for SDS-PAGE 
 
β-mercaptoethanol was added to 2X Laemmli buffer (Bio-Rad) at a ratio of 1:20 in a fume 
hood, and the mixture was then used to dilute cell lysates. Diluted samples were then heated to 
100°C for 5 minutes to denature proteins.  
 
2.4.4 BCA protein determination assay 
 
The bicinchoninic acid assay (BCA) was used to determine protein concentration of all cell 
lysates. Cell lysates (from Chapter 2.4.2) were diluted 1:5 in urea buffer (9M). Standards using 
bovine serum albumin (BSA) were diluted to a working range of 2ml/mL down to 
0.125mg/mL, and 10µL diluted cell lysates and BSA standards were added in triplicate to a 96-
well flat-bottomed plate. Working reagent was prepared by mixing reagents A and B (50:1) 
(Thermofisher Scientific) and adding 200µL to each well of the 96-well plate. The plate was 
incubated at 37°C for 30 minutes. After the plate had returned to RT, absorbance was read at 




Commercially pre-made resolving gels of 4-15% acrylamide (Bio-Rad) were used to separate 
proteins in a Mini-PROTEAN® Tetra electrophoresis cell by SDS polyacrylamide gel 
electrophoresis (SDS-PAGE). Pre-cast gels were placed into the tank and submerged in running 
buffer (25mM Tris, 0.19M glycine, 0.1% SDS, pH8.3). 15µL of protein preparations were 
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loaded into each well with one lane Precision Plus ProteinTM Dual Colour Standard (Bio-Rad). 
Gels were then run at 140V for ~1 hour.  
 
2.4.6 Protein transfer 
 
Resolved proteins were then transferred to PVDF membranes using the Trans-Blot® TurboTM 
Transfer System according to manufacturer’s instructions.  
 
2.4.7 Staining of PVDF membranes 
 
Presence of protein transfer to membranes was determined by Ponceau staining PVDF 
membranes for 30 seconds and subsequent washing with distilled water. Membranes were then 
blocked for a minimum of one hour at RT in 5% skimmed milk powder in PBS-Tween solution. 
Patient plasma was diluted 1:1000 in 5% skimmed milk powder PBS-Tween solution before 
being used to probe membranes by incubating them in the solutions overnight at 4°C with 
rocking. Membranes were washed a minimum of 5 times in PBS-Tween to remove primary 
antibody. Secondary anti-human IgG antibody conjugated with peroxidase (anti-human IgG 
Fc-specific peroxidase antibody produced in goats (Sigma)) was used to probe the membranes 
at a 1:2000 dilution in 5% skimmed milk powder in PBS-Tween solution for 1.5 hours at RT 
with rocking. Membranes were washed 5 times in PBS-Tween for one hour. Bound antibodies 
from donor sera were detected using ECL Western blotting detection reagent (Amersham) by 
chemiluminescence as per manufacturer’s protocol.  
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2.5 Molecular techniques  
 
2.5.1 Quantitative polymerase chain reaction for EBV genome load 
 
DNA was extracted from ~1x106 PBMC using the Qiagen DNeasy commercial kit following 
the manufacturer’s protocol and eluted in a total volume of 100µL. The DNA concentration 
was determined by UV-spectrophotometry at 260nm using a Nanodrop spectrophotometer.  
Dilution of Namalwa Burkitt’s Lymphoma (BL), which contains two copies of integrated EBV 
genomes per cell, were used to make DNA standards with the DNA being isolated as described 
above. The sample was adjusted to a final concentration of 132ng/µL and is equivalent to 
40,000 EBV genome copies/µL; assuming that one cell contains 6.6pg DNA and each 
Namalwa BL cell contains two viral genomes. From this serial dilutions were made using PCR 
water. 
Primers to detect EBV POL (BALF5) and the human β-2microglobulin (B2m) gene were used 
to probe EBV genome and serve as an endogenous control respectively. Primers were re-
suspended at working stock concentrations of:- 
POL F and R primers  2µM 
POL probe   5µM 
B2m F primer   3µM 
B2m R primer   4µM 
B2m probe   5µM 
Test samples were run in triplicate. PCR master mix was prepared as followed for each well 
(total volume 25µL):- 
Taqman Universal 2 x master mix   12.5µL 
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POL F primer (2µM)     2.5µL 
POL R primer (2µM)    2.5µL 
POL probe (5µM)    1µL 
B2m F primer (3µM)    0.5µL 
B2m R primer (4µM)    0.5µL 
B2m probe (5µM)    0.5µL 
20µL master mix and 5µL sample DNA was pipetted into each well of a 96-well PCR plate. 
The plate was run in an ABI7500 PCR machine (Thermo Fisher Scientific) and the data 
analysed using 7500 system v1.4 software (Thermo Fisher Scientific). 
Table 2.4 Taqman primers and probes 
EBV POL (BALF5)  
Forward primer CTTTGGCGCGGATCCTC 
Reverse primer AGTCCTTCTTGGCTAGTCTGTTGAC 
POL probe (FAM)-CATCAAGAAGCTGCTGGCGGCC-(TAMRA) 
β2m  
Forward primer GGAATTGATTTGGGAGAGCATC 
Reverse primer CAGGTCCTGGCTCTACAATTTACTAA 
β2m probe  AGTGTGACTGGGCAGATCATCCACCTTC-(BHQ) 
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2.6 Software and data analysis 
 
2.6.1 Analysis of flow cytometric and combination gate data 
 
All flow cytometry data was analysed using Kaluza flow cytometric software (Beckman 
Coulter). T-cell subsets were defined as single lymphocytes that stained as LiveCD14-CD19-
CD3+ cells positive for either CD4 or CD8 markers. Tree plot analysis of cytokine production 
was used to determine percentage of T-cells in each combination gate set by the analysis 
software. Combination gate data was exported into the program Microsoft Excel and analysed 
using Funky Cells software. Background staining for analysis of ex vivo T-cell responses was 
set individually for each donor by the level of staining of each cytokine in the unstimulated 
control, and these values were deducted from all stimulated samples using Funky cells. 
Background staining for stimulations with MVA-infected B-cell blasts was set individually for 
each donor by subtracting level of staining in the MVA empty vector (pYWK)-infected B-cell 
blast control, allowing calculation of cytokines produced in response to CNS protein only. This 
normalisation of data allowed an unbiased comparison of cytokine staining for each donor and 
group. Funky cells also calculated the polyfunctionality index (PI) of each sample which was 
used as an arbitrary measure of the number of cytokines produced by cells in each stimulation 
(Larsen et al., 2012b). Combination gate data exported from Funky cells was analysed using 
SPICE (Simplified Presentation of Incredibly Complex Results, National Institute of Allergy 
and Infectious Diseases) software, which allows combination gates to be visualised in pie chart 
format with in depth multiple cytokine production analysis. Differences between data groups 
were calculated in SPICE using the Wilcoxon Signed Rank test and permutation test, P values 
below 0.05 were deemed to be significant. 
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2.6.2 Statistical analysis of data using GraphPad Prism software 
 
Statistical significance of data was calculated using GraphPad Prism software (USA). The 
D’Agostino-Pearson omnibus normality test was performed to determine if data followed a 
Gaussian (normal) distribution and, with most data sets reporting a non-normal distribution, 
non-parametric tests were performed to determine statistical significance.  
The Kruskall-Wallis test is a non-parametric test used for data sets with three or more 
categories that are not normally distributed. This test was used to compare variation in data 
from three cohort groups. The Mann-Whitney test is also a non-parametric test and was used 
to directly compare variation between two data sets.  
Correlation of antibody responses and T-cell responses were calculated using the Spearmen’s 
rank correlation coefficient (r) for non-normally distributed data. 
The Fisher’s exact test was used to compare categorical data, where data points were either 
positive or negative. 
P values below 0.05 were deemed to be significant for all statistical tests used.
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3 Cohort demographics 
 
Our project aims were to investigate antibody and T-cell responses to EBV in MS patients, 
healthy controls (HC) and individuals with a recent history of IM. We recruited MS patients 
attending routine neurology clinics under the criteria that they were not currently suffering 
disease exacerbation or receiving immunomodulatory therapy for their condition. No prior 
administration of disease modifying therapy was of particular importance as this could 
potentially have impacted results.  
Recruitment of healthy donors provided a control group with which to compare EBV-specific 
antibody and T-cell responses from MS patients. In addition to a control group, patients with a 
recent history of IM were recruited and their responses compared. As previously discussed, IM 
is a significant risk factor for the development of MS and we hoped to understand how these 
early EBV-specific responses after symptomatic infection compare to those of MS patients. 
 
3.1 Ethics statement 
 
All experiments were performed at the University of Birmingham in accordance with ethics 
approved by the West Midlands and Black Country NRES committee (ethics number 
11/WM/0067 for MS and healthy control donors; ethics number 07/Q2702/94 for post-IM 
donors). All donors provided written informed consent for the collection of blood samples and 
their subsequent analysis. 
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3.2 Donor recruitment 
 
All RRMS patients were recruited via the MS Research Clinic at the Queen Elizabeth Hospital, 
Birmingham and the Guest Hospital, Dudley, UK. Patients were diagnosed with RRMS and 
were currently not undergoing any immunomodulatory treatment at the time of blood donation. 
Blood was donated during routine follow-ups and patients were not currently undergoing any 
clinical relapse of disease.  
IM patients were recruited from the Queen Elizabeth Hospital, Birmingham or from local 
general practice surgeries following a positive heterophile antibody test for IM. Blood was 
donated approximately 4-6 months following resolution of symptoms.  
Healthy control (HC) donors were recruited from laboratory staff and postgraduate students at 
the University of Birmingham. All HC donors tested positive for VCA IgG staining by 
immunofluorescence, had no verbal history of IM and were age, gender and HLA-DR15 
serotype matched as far as possible to MS donors in the study. Cohort demographics are shown 
in table 3.1.  
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Table 3.1 Cohort demographics 
 Donor group No. of donors Female Gender (F:M) Age (years MEAN +/- SD) HLA-DRB1*15:01-positive History of IM (%) 
HC 33 23/33 2.3:1 35.67(+/-9.60) 15/33 (45.46%) 0/33 (0%) 
MS 31 26/31 5.2:1 36.32 (+/-9.50) 13/31 (41.94%) 8/31 (25.81%) 
IM 17 8/17 1:1.38 21.42 (+/-3.60) 6/17 (35.29%) 11/11 (100%) 
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Table 3.2 Individual patient demographics and HLA type 
	     HLA type 
Donor Group Gender Age IM* A B DR DQ 
MS1 MS F 33 No 1 2 7 27 13 103 52a   6 7 
MS2 MS F 23 No 2 24 48 52 15 15(02) 51   6   
MS3 MS F 49 No 2 3 15 35 1 103     5   
MS4 MS F 39 No 2 11 7 40 4 15 51 53 6 8 
MS5 MS F 37 Yes 2 3 7 57 7 15 51   6 9 
MS6 MS F 45 No 2   15 27 13 103 52b   6 7 
MS7 MS M 45 Yes 1 3 8 39 8 17 52a   2 4 
MS8 MS F 60 No 1 2 8   4 17 52a 53 2 8 
MS9 MS M 30 Yes 11 29 15 35 12 16 51 52b 5 7 
MS10 MS F 27 No 1 3 7 8 15 51     6   
MS11 MS F 47 Yes 2   15 35 1 4 53   5 8 
MS12 MS F 21 No                     
MS13 MS F 41 No 1   8 57 15 17 51 52a 2 6 
MS14 MS F 27 Yes 3   7   15   51   6   
MS15 MS F 32 No 2 24 7 53 7 15 51 53 2 6 
MS16 MS F 53 No 1   8 37 4 14 52b 53 5 8 
MS17 MS F 37 Yes 1 3 8 51 17   52a   2   
MS18 MS F 23 No 1   7 8 15 17 51 52a 2 6 
MS19 MS F 36 No 11 24 8 18 11 17 52a 52b 6 7 
MS20 MS F 31 No 3 24 8 35(08) 15 17 51 52a 2 6 
MS25 MS M 48 No 3 24 7 8 13 17 52a 52c 2 6 
MS26 MS F 37 No 1 2 15 39 4 8 53   4 8 
MS27 MS F 36 Yes 2 3 27 40 15   51   6   
MS28 MS M 44 No 3 74 15 45 12 15 51 52b 6 7 
MS29 MS F 38 No 1 2 8 44(02) 4 17 52a 53 2 8 
MS30 MS F 40 No 1 3 7 8 15 17 51 52a 2 6 
MS31 MS F 30 No 2   13 27 7 103 53   2 7 
MS32 MS F 27 No 11 24 35 35(02) 1 17 52b   2 5 
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MS33 MS F 41 No 2 26 14 15 4 7 53   2 7 
MS34 MS M 25 No 2 2(05) 7 50 4 15 51 53 6 7 
MS35 MS F 24 Yes 2 31 13 40 7 8 53   2 4 
HC1 HC F 33 No 2 3 7   15   51   6   
HC2 HC M 42 No 2   22 40 7 16 51 53 2 5 
HC3 HC M 30 No 2 2(s) 40(s)   11 15 51 52b 6 7 
HC4 HC F 42 No 2 11 35 44 1 4 53   1 7 
HC5 HC F 30 No 26   44(02) 58 14 16 51 52b 5(02) 5(03) 
HC6 HC F 28 No 2 11 35 58 4 13 52c 53 6 7 
HC7 HC M 42 No 3 23 7 44(02) 4 15 51 53 6 7 
HC8 HC M 25 No 24 29 7 44 4 15 51 53 6 7 
HC9 HC F 46 No 2   40 41 8 103     4 5 
HC10 HC F 35 No 1   7 57 12 103 52   5 7 
HC11 HC F 34 No 1 24 8 18 17 7 52a 53 2   
HC12 HC F 31 No 2 26 15 27 7 8 53       
HC13 HC F 37 No 2 32 44   7 15 51 53 1 2 
HC14 HC F 49 No 29 30 7 45 4 15 51 53 6 7 
HC15 HC F 25 No 24 32 14 44 7 12 52b 53 2 7 
HC16 HC F 60 No 1 2 8 60 3 15 51 52a 2 6 
HC17 HC M 28 No 2   8 40 17   52a   2   
HC18 HC F 48 No 1 2 44(02)   11 15 51 52b 6 7 
HC19 HC F 34 No 1 2 44 57 4 7 53   7 9 
HC20 HC F 25 No 1 24 8 15 13 17 52a 52c 2 6 
HC21 HC F - No 24 31 40 57 4 7 53   8 9 
HC22 HC F 53 No 2 11 8 44 13 17 52a 52c 2 6 
HC23 HC F 28 No 1 3 7 15 13 15 51 52b 6 6 
HC24 HC M 29 No 1 11 35 44(02) 13 103 52a   5 6 
HC25 HC F 37 No 1 3 7 2705 4 15 51 53 6 8 
HC26 HC M 24 No 3 23 15 58 15(03) 17 51 52b 2 6 
HC27 HC M 28 No 2 3 7 40 1 4 53   5 8 
HC28 HC M 53 No 2 24 39   8 15 51   4 6 
HC29 HC F 43 No 2 11 51 60 4   53   3   
HC30 HC M 26 No 2 68 44 55 1 15 51   5 6 
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HC31 HC F 22 No 2 11 15 51 4 15 51 53 6 8 
HC32 HC F 37 No 2 68 35 49 1 12 52b   5 7 
HC33 HC F 37 No 2   27   1 15 51   5 6 
IM111.2 IM M 18 Yes 1 3 8 39             
IM121.3 IM M 20 Yes 2 33 8 44             
IM225.2 IM F 20 Yes 2 3 7 27 15 17 52a 51 2 6 
IM226.2 IM F 19 Yes 2   40 50 7 13(02) 52c 53 2 6 
IM230.2 IM F 20 Yes 3 68 35 44 13 17 52a   2 6 
IM231.2 IM F 25 Yes 3 24 35 51 4 7 53   2 7 
IM238.2 IM F 18 Yes 1 24 18 35 1 15 51/N   5 6 
IM239.3 IM M 21 Yes 1 2 8 51 13 17 52a 52b 2 6 
IM240.3 IM F 20 Yes 2 11 18 44 1 17 52b   2 5 
IM243.2 IM M 20 Yes 1 23 8 44 7 15 51 53 2 6 
IM253.3 IM M 25 Yes 3 24 7 37/N 4 15 51 53 6 8 
IM257.3 IM F 21 Yes 1 68 40(02) 56 1 11 52b   5 7 
IM265.7 IM M 18 Yes 23 26 7 44 7 15 51 53 2 6 
IM267.5 IM F 20 Yes 26 31 27   4 13 52a 53 7   
IM269.3 IM M 27 Yes 3 11 15 35 1 8     4 5 
IM270.4 IM M 21 Yes 3 26 14 38 12 13 52b 52c 6 7 
IM279.6 IM M 33 Yes 2 24 7 52 4 15/N 51/N 53 6 7 
 
* Self-reported history of IM for HC and MS donors 
/N Null allele
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4 EBV viral load and antibody responses 
 
Epidemiological data strongly implicates EBV in MS pathogenesis due to the almost universal 
seroprevalence and elevated anti-EBNA1 IgG antibodies prior to disease onset in patients 
(Pakpoor et al., 2013, Munger et al., 2011, Ascherio et al., 2001). However, despite over 30 
years of research, little is known about the contribution of EBV towards MS development. Our 
aim for this part of the project was to investigate EBV viral load, EBNA1 and VCA IgG titres 
and other antibody responses to EBV which have not yet been characterised in our cohort.  
 
4.1 EBV viral load 
 
EBV resides latently in memory B-cells of the peripheral immune system, and viral genome 
load provides an indication of how many of these cells are infected and therefore the viral 
burden on an individual. Increased viral replication causes genome copy number to increase as 
more cells become infected, and this can be used as a measurement of EBV reactivation in 
patients. Several autoimmune diseases, such as systemic lupus erythematosus (SLE) and 
rheumatoid arthritis (RA) display an increased EBV viral load however this is still debated in 
MS, with reports of both unchanged and increased viral load in patients compared to healthy, 
EBV seropositive controls (Wagner et al., 2004, Cocuzza et al., 2014, Lunemann et al., 2010).  
Viral load was investigated in whole PBMC in our cohort by qPCR using primers specific for 
the BALF5 gene of EBV. EBV genome copy numbers in our cohorts were found to be 
unchanged between MS patients and HC, suggesting no increase in number of circulating B-
cells infected with EBV in MS patients (Figure 4.1.1). Post-IM donors displayed an elevated 







Figure 4.1.1 EBV load in PBMC. EBV genome load was determined from whole PBMC by q-PCR. No 
difference was seen between viral load of HC and MS donors. Post-IM donors had a significantly elevated 
EBV load compared to both HC and MS donors (HC:IM p<0.0001, MS:IM p<0.0001). Black line represents 
median of data set. Statistics calculated using the Mann-Whitney test (ns p>0.05, * p≤0.05, ** p≤0.01, *** 
p≤0.001, **** p≤0.0001).  
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4.2 EBV-specific antibody production 
 
4.2.1 EBNA1 and VCA IgG titres 
 
Plasma anti-EBNA1 IgG titres have been much investigated in MS literature, most notably 
using the US Military Serum Repository, and have shown antibody titres to be elevated in MS 
patients up to 5 years prior to disease onset (Munger et al., 2011). As anti-EBNA1 antibodies 
are known to be elevated and are a potential biomarker in MS, we investigated this in our cohort 
by ELISA to establish whether it was confirmed in our cohort.  
Healthy EBV-seropositive donors had significantly lower levels of EBNA1-specific IgG 
antibodies in their plasma compared to MS donors, who also showed a strong increase when 
compared with post-IM donors (Figure 4.2.1A). 
Antibodies specific for virus capsid antigen (VCA) have been studied previously with 
conflicting results, with reports of both elevated and unchanged VCA IgG titres in MS patients 
compared to seropositive controls (Farrell et al., 2009, Castellazzi et al., 2010). Semi-
quantitative immunofluorescence was used to investigate levels in cohorts and MS patients 
were shown to have increased plasma anti-VCA IgG compared to HC and post-IM donors 
(Figure 4.2.1B).  
VCA IgG titres were calculated using serial dilutions of donor plasma, however samples were 
not blinded for cohort group. This means that results may have been subject to human bias, and 
over-estimation of titres in a particular group might affect results. As donor titres were 
investigated at multiple dilutions and on different occasions we estimated any effect of bias to 




Figure 4.2.1 EBNA1 IgG and VCA IgG titres in peripheral blood. A. Semi-quantitative plasma anti-
EBNA1 IgG titre was determined by ELISA. MS donors had significantly higher titres that HC or post-
IM donors (HC:MS p=0.0106, MS:IM p=0.0014). B. VCA IgG titres from serum were investigated by 
immunofluorescence. MS donors had significantly increased serum anti-VCA IgG levels than HC and 
post-IM donors (HC:MS p=0.0097, MS:IM p=0.0073). Black line represents median of data set. All 
statistics performed using the Mann-Whitney test (ns p>0.05, * p≤0.05, ** p≤0.01).  
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4.2.2 Antibody responses to type 1 and 2 EBV 
 
Research into EBV strains infecting MS patients has sought to investigate why an almost 
ubiquitous virus contributes towards disease in some individuals, and one theory suggests that 
a specific strain (or strains) could be responsible for disease development. Some studies have 
implicated that certain polymorphisms in EBNA1, EBNA2 and other EBV proteins are 
overrepresented in MS patients compared to HC (Brennan et al., 2010, Mechelli et al., 2015). 
An increased frequency of co-infections with type 1 and 2 virus was found in MS patients in 
one Spanish cohort (Santon et al., 2011), which may have an impact on pathogenesis and T-
cell and antibody responses to the virus in vivo. 
Type 1 and 2 subtypes of EBV are distinct from each other mainly in the sequence of their 
EBNA2 and EBNA3C proteins, and we investigated antibody responses to each virus in patient 
plasma by Western blot (Figure 4.2.2). Western blots were performed using lysates of cord 
blood cell lines infected with type 1 and 2 viruses separately, allowing us to see differences in 
antibody binding and protein size between the two strains and generating an “EBNA print” 
Western blot of latent protein serology. Position of EBNA1, EBNA2 and EBNA3C protein 
bands were identified using monoclonal antibodies (Yao et al., 1996) and are indicated on the 
blot (Figure 4.2.2).  
EBNA print profiles of HC and MS donors were analysed and the frequencies of EBNA bands 
corresponding to each latent protein were compared between patient groups. Whilst this 
method was not quantitative, frequency of antibody responses could be detected and the 
intensity of bands are able to give an approximate indication of the amount of antibody present 
in donor plasma.  
There were no observable differences in frequency of antibody responses to EBNA1 or EBNA2 
proteins between HC and MS patients, and representative Western blots are shown in Figure 
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4.2.2. A band for an unknown small protein was observed in blots for some donors, however 
we were not able to identify which protein this belonged to using monoclonal antibodies. Table 
4.1 shows all responses identified in cohort groups in EBV type I and type II Western blots and 
also to EBNA3 proteins, and a summary of responses is shown in Table 4.2. 
Antibody responses to EBNA3 proteins showed the most notable difference. Plasma responses 
to EBNA3 were more frequently detected in MS patients with 72.41% (21/29) compared to 





Figure 4.2.2 Antibody responses directed towards latent antigens of type 1 or type 2 EBV. Cell 
lysates were made from the EBV negative cell line BJAB, and cord blood cells infected with either 
type 1 or type 2 EBV separately and blotted onto nitrocellulose membrane. All patient plasma was 
diluted 1:1000 and used to incubate membranes, generating an “EBNA print” of antibody responses 
for each donor. Bands representing type 1 and type 2 latent proteins are labelled on representative 
blots from three separate donors. No significant differences were seen between responses to EBV 
type 1 and type 2 viruses between MS and HC donors, however responses to EBNA3 proteins were 
more common amongst MS donors than healthy controls.  
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Table 4.1 Antibody responses to EBV type I and II proteins and to EBNA3 proteins detected by Western blot 
Donor 
C2 cells infected with type I or II EBV BJAB cells infected with MVA EBNA3A, B or C 
EBNA1 EBNA2 EBNA3s Unknown band EBNA3 
T1 T2 T1 T2 T1 T2 T1 T2 3A 3B 3C 
HC1 + + - - - - - - + - - 
HC2 + - - - - - - - - - - 
HC3 - - - - - - - - + - - 
HC4 + + - - - - + - - - - 
HC5 + + - - - - - - + - + 
HC6 + + + - + + + - + + + 
HC7 - - - - - - - - - - - 
HC8 - - - - - - - - - - - 
HC9 + + - - + - + - + - + 
HC10 + + + - + - + - + - + 
HC11 + + - - - - + - - - - 
HC12 + + - - - - - - + + + 
HC13 + + + - - - - - - - - 
HC14 + + + - - - - - - - - 
HC15 - - - - - - - - - - - 
HC16 + + - - - - - - + + + 
HC17 + + - - - - - - - - - 
HC18 + + + - + - + - + + + 
HC19 + + + + - - - - + + + 
HC20 + + + - + - + - - - + 
HC21 + - + - + - - - + + - 
HC22 + + - - - - - - - - - 
HC23 + + - - + + + - + - + 
HC25 + + + - + - - - + + + 
HC27 - - - - - - - - + + + 
HC28 + + + - + - - - + - + 
HC29 + + + + + + + - + + + 
HC30 - - - - - - - - - - - 
HC31 + + - - - - - - - - - 
HC32 + + + - - - - - + - + 
HC33 + + + - + + - - + + - 
MS1 + + - - - - - - + - - 
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MS2 + + - - - - - - + + - 
MS3 + + + - + + - - + + - 
MS4 + + + - + - - - + + + 
MS5 + + + - + + + - + + + 
MS6 + + + - + + + - + + + 
MS7 + + - - - - + - - - - 
MS8 + + + - + - + - + - + 
MS9 + + - - + - - - - + + 
MS10 + + - - - - - - + - - 
MS11 + + + + + + + - + + + 
MS13 + + - - + - + - + + + 
MS14 + + - - - - - - + + - 
MS15 + + + - + + - - + + + 
MS17 + + + - + + + - + + + 
MS18 - - - - - - - - + + + 
MS19 + + + - + + + - + + + 
MS20 + + + - + + + - + + + 
MS25 + + + - + - + - - - + 
MS26 + + + + + - + - + + + 
MS27 + + + + + + - - + + - 
MS28 + + + + + + + - + + + 
MS29 + + + + + + + - + + - 
MS30 + + + + + + + - + + + 
MS31 + + + - + + + + + + + 
MS32 + + + - + - + - + + + 
MS33 + + + - - - - - - - - 
MS34 + + - - + - - - + - - 
MS35 + + + - - + - - + + + 
IM225.2 + + + - + + + - + + + 
IM226.2 - - + - + - + - + + - 
IM238.3 + + - - - - - - + - - 
IM239.3 + + + - + - - - + + + 
IM240.3 + + - - - - - - + + - 
IM243.2 - - - - - - - - + + - 
IM253.3 + + + - + + - - + + + 
IM257.3 + + - - - - - - + - - 
IM265.7 + + - - - - - - + + - 
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IM267.5 + + + - - - - - + - - 
IM269.3 + + + - + + + - + + + 
IM270.4 + + - - - - - - + - - 
IM272.2 + + - - - - - - - - - 
IM275.3 + + - - + + - - + - - 
IM279.6 + + + - + + - - + + + 
 
 
Table 4.2 Summary of antibody responses to EBV type I and II proteins and EBNA3 proteins detected by Western blot 
Donor Group 
C2 cells infected with type I or II EBV 
EBNA1 EBNA2 EBNA3s Unknown band 
T1 T2 T1 T2 T1 T2 T1 T2 
HC 25/31 (80.65%) 23/31 (74.19%) 13/31 (41.94%) 2/31 (6.45%) 11/31 (35.48%) 4/31 (12.90%) 9/31 (29.03%) 0/31 (0%) 
MS 28/29 (96.55%) 28/29 (96.55%) 20/29 (68.97%) 6/29 (20.69%) 21/29 (72.41%) 14/29 (48.28%) 16/29 (55.17%) 1/29 (3.45%) 
IM 13/15 (86.67%) 13/15 (86.67%) 7/15 (46.67%) 0/15 (0%) 7/15 (46.67%) 5/15 (33.33%) 3/15 (20%) 0/15 (0%) 
         
         
Donor Group 
BJAB cells infected with MVA EBNA3A, B or C      
EBNA3      
3A 3B 3C      
HC 18/31 (58.07%) 10/31 (32.26%) 15/31 (48.39%)      
MS 25/29 (86.21%) 22/29 (75.86%) 20/29 (68.97%)      
IM 14/15 (93.33%) 9/15 (60%) 5/15 (33.33%)      
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To identify which EBNA3 protein was differentially recognised, cell lysates were made from 
the EBV-negative cell line Raji after infection with MVAs expressing EBNA3A, 3B and 3C 
separately and the protein preparations then used to perform Western blots with patient sera 
(Figure 4.2.3A). The presence of bands of the correct size for each of the EBNA3A, 3B and 
3C lysates indicated an antibody response to the proteins in donors, and example Western blots 
are shown in Figure 4.2.3A. Where there were clear bands each donor was marked as having a 
response, more faint bands were only considered a response if there was no background 
staining on the blot. For example, HC15 was scored as having no responses to all EBNA3 
proteins and MS6 was scored as having a response to all 3 proteins, but MS29 only had 
antibody responses to EBNA3A and B (Figure 4.2.3). 
EBNA3 antibody responses were more frequent amongst MS patients than HC, an effect that 
was strongest for EBNA3B (EBNA3A HC:MS p=0.0220, EBNA3B HC:MS p=0.0009, 
EBNA3C HC:MS P=0.1239) (Figure 4.2.3B). Responses to EBNA3C in MS patients were 
also significantly more frequent than in post-IM donors (MS:IM p=0.0303) (Figure 4.2.3B). 
Post-IM donor EBNA3A IgG responses were significantly higher than those of HC (HC:IM 
p=0.0180). 
In addition to EBNA3A responses being more frequent in MS patients than healthy donors, 
bands formed by antibody responses in Western blots appeared to be larger and darker than 
those seen for responses in HC (Figure 4.2.3A). Whilst Western blots are only semi-
quantitative, they do give an idea of the concentration of antibody when the same amount and 
concentration of cell lysate is applied to membranes between experiments. However, this 
observation would need to be measured using a quantitative method for these results to be 
verified. 
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Figure 4.2.3 Antibody responses directed against EBNA3 proteins. A. 
Protein preparations were made from uninfected BJAB-cells and cells 
separately infected with MVAs containing EBNA3A, EBNA3B and 
EBNA3C proteins. Example blots are shown from HC, MS and post-IM 
donors. B. Percentage of donors with an IgG antibody response to each of 
the EBNA3 proteins. MS and post-IM donors were significantly more likely 
to have an EBNA3A response than healthy controls (HC:MS p=0.0220, 
HC:IM p=0.0180). MS donors were significantly more likely to have an 
EBNA3B response than HC (HC:MS p=0.0009). Responses in MS patients 
to EBNA3C were more frequent than in post-IM donors (MS:IM p=0.0303). 
All statistics were calculated using Fisher’s exact test (ns p>0.05, * p≤0.05, 
** p≤0.01, *** p≤0.001). 
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4.3 CMV and tetanus toxoid antibody responses 
 
Whilst EBV is thought to have a key role in MS development, other pathogens have been 
implicated in the disease process. Previous studies have investigated a role for CMV in MS 
and have reported that early infections with CMV are more common in MS patients (Djelilovic-
Vranic and Alajbegovic, 2012). This suggests that CMV might have a role in disease 
development or progression, and evidence for this comes from reports that CMV also increases 
frequency of disease exacerbations in RRMS (Rainey-Barger et al., 2013, Buljevac et al., 
2002). 
Using a lysate of CMV-infected cells, an ELISA was performed on donors’ plasma to 
determine both serostatus and CMV antibody titre of those who were positive for CMV-
specific IgG. Frequency of CMV carriage was highest in post-IM donors, followed by MS and 
healthy controls respectively. There was an observable trend towards increased CMV infection 
in post-IM and MS donors, however when analysed using the Fisher’s exact test of categorical 
data this observed difference did not reach significance (HC:MS p=0.0716, MS:IM p=0.7507, 
HC:IM p=0.0615) (Figure 4.3.1A). CMV IgG titre was compared between positive donors, 
and the highest titre was seen amongst MS patients, however this only reached significance 
when compared to post-IM donors (MS:IM p=0.0261) (Figure 4.3.1B); MS patient titres need 
to be compared with a greater number of HC positive for CMV in order to establish if this 
effect is real.  
Tetanus toxoid-specific antibody responses were investigated in collaboration with the Clinical 
Immunology department at the University of Birmingham. Analysing tetanus toxoid responses 
allowed us to investigate whether elevations observed in antibody responses amongst MS 
patients were isolated to EBV or whether this effect was extended to other pathogens. Tetanus 
toxoid was selected as a control due to routine vaccination programs in the UK including the 
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antigen, and therefore donors in our cohort are all likely to amount an antibody response against 
the protein.  
Anti-tetanus IgG was measured by ELISA and post-IM donors were found to have significantly 
higher titres than MS donors (Figure 4.3.2). No differences were observed in levels of anti-
tetanus IgG between HC and MS donors (Figure 4.3.2). 
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Figure 4.3.2 Plasma antibodies directed against tetanus toxoid in cohorts. Anti-tetanus toxoid IgG 
levels in plasma were analysed by multiplex bead assay, and levels between HC and MS donors were 
shown to be unchanged. However, post-IM donors had significantly elevated titres compared to MS 
patients (MS:IM p=0.0092), but this did not reach statistical significance when comparing HC to post-
IM donors. All statistics performed using the Mann-Whitney test (ns p>0.05, * p≤0.05, ** p≤0.01).  
Figure 4.3.1 Anti-CMV IgG plasma titres. A. Donors were tested for carriage of cytomegalovirus using an 
in-house anti-CMV IgG ELISA, and number of donors positive for each group were as follows: HC 4/30, MS 
10/29, post-IM 6/15. Frequency of CMV carriage was compared between groups using Fisher’s exact test, with 
no significance found between groups (HC:MS p=0.0716, MS:IM p=0.7507, HC:IM p=0.0615).  B. Levels of 
anti-CMV IgG from CMV-positive donors were compared using the Mann-Whitney test to determine 
significance (* p≤0.05). MS patients exhibited significantly higher titres than those of post-IM donors (MS:IM 
p=0.0261). HC and MS groups did not differ significantly (HC:MS p=0.0893). CMV IgG antibody titres are 




EBV viral load and serology in MS patients have been extensively researched over many years, 
establishing an epidemiological role for the virus in pathogenesis that is now widely accepted 
by researchers. However, despite this there are still many conflicting ideas regarding how EBV 
causes disease, advocating the need for more in-depth study of this area. 
The work in this chapter sought to address some of the questions remaining surrounding serum 
parameters in previous MS literature, comparing MS patients with healthy donors and those 
with a recent history of IM with an aim to establish if these are unchanged, decreased or 
increased in our cohort from the West Midlands, UK. Post-IM donors have an increased risk 
of developing MS, and we analysed antibody responses to EBV proteins in these donors 
because they have not previously been investigated alongside MS patient samples. Analysis of 
EBV antibody responses in MS patients are of key importance due to the potential to develop 
markers for diagnosis and progression, as well as to understand the underlying immune 
mechanisms driving disease. 
EBV viral load in circulating B-cells of long-term carriers is a broad measure of level of virus 
burden, and can be an indication of impaired immune control of infection and viral replication. 
EBV transformation of autoreactive B-cells and defective CD8+ T-cell control allowing their 
migration into the CNS is one potential mechanism put forward to explain EBV’s contribution 
to disease, and this chain of events could potentially lead to an increased viral load in MS 
patients. However, only a few studies to date have reported an increased viral load in MS 
patients, including Lunemann et al. (Lunemann et al., 2010). A previous publication by 
Lunemann et al. found an elevated viral load amongst MS patients but the study did not have 
sufficient participants to determine significance (Lunemann et al., 2006). Pender et al. also 
reported an elevated viral load which has been used to argue that lack of control of EBV 
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replication in B-cells is due to ineffective CD8+ T-cell control of the virus allowing infected 
B-cells to enter the CNS of MS patients causing disease (Pender et al., 2014a, Pender et al., 
2017). Evidence for an unchanged cellular viral load in MS patients when compared with 
healthy, seropositive donors is far more widespread and data from our cohort corroborates these 
findings (Figure 4.1.1) (Cocuzza et al., 2014, Alvarez-Lafuente et al., 2006, Lindsey et al., 
2009, Lucas et al., 2011, Santiago et al., 2010, Wagner et al., 2004).  
Plasma viral load is a measure of reactivation of latently-infected B-cells into lytic cycle 
producing free virus, however, as with cell-associated viral load, this has been shown to be 
unchanged in MS indicating no underlying chronic reactivation of EBV is driving disease in 
MS patients (Wagner et al., 2004), although Ramroodi et al. reported this to be elevated in one 
Iranian cohort (Ramroodi et al., 2013). However, plasma viral load is an unreliable measure of 
virus quantification as qPCR techniques are also able to detect fragments of viral DNA that are 
not part of infectious virus particles, and this measure is used as a biomarker in patients with 
nasopharyngeal carcinoma (Chan, 2014). For the purpose of our study we elected to test 
cellular DNA as it is a more consistent and reliable method of quantifying EBV load. 
Viral load has also been studied in the context of other autoimmune diseases such as systemic 
lupus erythematosus (SLE) and rheumatoid arthritis (RA), with findings from these diseases 
showing it is elevated in these patients (Moon et al., 2004). However, this is thought to be due 
to autoimmune activation of the B-cell compartment driving increase in EBV load, and not 
related to EBV itself driving autoimmune disease in these patients (Larsen et al., 2011). This 
elevation in SLE and RA viral load contrasts with most findings in MS patients of an unchanged 
viral load, and supports evidence that MS pathology is predominantly T-cell-driven. 
EBNA1 IgG antibody titres in MS patient serum are subject to less debate and are generally 
considered to be elevated in cohorts around the world (Ascherio et al., 2001, Sundstrom et al., 
2004, Levin et al., 2005, DeLorenze et al., 2006), driving interest in the EBNA1 protein and 
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making it a potential marker of MS risk and diagnosis. Elevated EBNA1 antibody responses 
focussed attention onto a potential role for degenerate EBNA1-specific T-cell responses in 
patients.  
Anti-EBNA1 IgG titres were analysed in our cohort by ELISA with MS patients shown to have 
significantly higher levels than HC and post-IM (Figure 4.2.1A). These results are concordant 
with published reports, showing our study cohort to have similar EBNA1 serology to those 
studied in many different countries and supporting potential use of humoural responses to this 
protein in calculating risk of developing MS. The commercial ELISA kit used to analyse 
EBNA1 IgG responses in our cohort is specific for the C-terminus of the protein. Other studies 
have shown the glycine-alanine (GA) repeat region to be the most immunogenic, and it has 
been shown to be the dominant region to which antibody responses are generated in IM 
(Rumpold et al., 1987). Autoantibodies in IM were also shown by Rhodes et al. to have 
specificity for the GA repeat region of EBNA1 (Rhodes et al., 1987). The EBNA1 GA repeat 
region has been shown to limit its own transcription and translation by reducing the number of 
cis-linked sequences to CD8+ T-cells (Apcher et al., 2009, Apcher et al., 2010, Tellam et al., 
2012, Murat et al., 2014), but despite this T-cell responses to the protein can be detected in IM 
and healthy virus carriers (Blake et al., 2000). Analysis of antibodies to both the C-terminal 
and the GA repeat region of EBNA1 is needed in the same cohort to determine if these regions 
are similarly recognised in MS patients and IM donors.  
The clinical significance of elevated antibody responses against EBNA1 in MS patients is not 
known, and debate surrounds what is driving the EBNA1-specific antibody and CD4+ T-cell 
responses which develop 3-6 months post infection (Long et al., 2013). It is unclear whether 
CD4+ T-cell responses are driving EBNA1 antibody responses to become elevated via 
providing ‘help’ to B-cells, or whether atypical EBNA1-specific CD4+ T-cells follow IgG 
responses in their emergence. EBNA1 is an interesting protein in that, unlike other EBNA 
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proteins, it is not shed from the cell or into the cytoplasm from the nucleus, meaning that 
autophagosome processing and presentation of the protein on MHC class II molecules on the 
surface of infected cells is restricted to very low levels (Leung et al., 2010). Due to this known 
restriction of antigenic source it is not clear how antibody and CD4+ T-cell responses are 
primed, and other studies identifying methods of intercellular antigen transfer are not able to 
fully explain this phenomenon (Taylor et al., 2006). More research is needed in this area to 
understand why these responses are elevated in patients compared to long-term healthy virus 
carriers, and identifying this pathway might help elucidate what contribution EBNA1 CD4+ T-
cell and antibody responses are making to MS disease (Lunemann et al., 2006). Clues to their 
role come from observations that EBNA1 IgG antibodies correlate with disease activity as 
measured by MRI (Kvistad et al., 2014). 
Investigations into the specificity of oligoclonal bands in CSF of patients has led to findings 
supporting intrathecal anti-EBNA1 IgG in MS (Pfuhl et al., 2015), and in several studies 
evidence was found for anti-EBNA1 IgG intrathecal production in a proportion of patients but 
at levels too low to support a key role in disease pathogenesis (Pohl et al., 2010, Castellazzi et 
al., 2014). Studies of cross-reactivity in EBNA1-specific antibody responses has revealed 
immunoglobulins able to recognise both EBNA1 and myelin basic protein (MBP) peptides 
(Mameli et al., 2014) and human heterogeneous ribonucleoprotein L (HNRNPL) (Lindsey et 
al., 2016), indicating that autoreactive EBNA1 IgG might directly contribute towards CNS 
damage in the early stages of MS and help to perpetuate inflammatory immune mechanisms in 
the CNS.  It is likely that antibody responses detected in CSF are also synthesised in this 
compartment due to their inability to cross the blood brain barrier, therefore it is also apparent 
that the detected antibodies must be produced by B cells that have become activated within the 
CNS itself. However, intrathecal antibody responses have a limited clinical role in direct 
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damage of the CNS due to the controlled access of circulating immunoglobulins to the brain 
parenchyma (Pardridge, 2012).  
VCA-specific antibodies are less well studied than those with reactivity to EBNA1, but are 
used routinely in the diagnosis of acute IM, with presence of low affinity anti-VCA IgM 
demonstrative of recent primary infection before a switch to IgG indicating longer term virus 
carriage.  Kinetics of antibody responses to VCA are also very different from those of EBNA1; 
VCA IgG tend to be synthesised very quickly after primary infection and at high levels, 
gradually decreasing to a moderate level which is stable over time (Taylor et al., 2015). VCA 
antibody responses in multiple sclerosis are less well studied; our project investigated titres and 
found them increased (Figure 4.2.1B), consistent with previous reports finding anti-VCA IgG 
in MS patient sera and CSF to be increased (Castellazzi et al., 2010, Castellazzi et al., 2014, 
Simon et al., 2012). More research into viral capsid antigen humoural responses is needed to 
establish the contribution of these elevated VCA-specific antibody levels to disease, or to 
elucidate whether these elevated responses are secondary to MS disease itself. 
Theories of an EBV strain specific to MS have been investigated for many years, with evidence 
from MS “epidemics” such as in the Faroe Islands lending credence to such hypotheses. 
However, after many sequencing studies, researchers have failed so far to identify a specific 
virus strain as the cause of MS (Lay et al., 2012), with single nucleotide polymorphisms in 
viral DNA also failing to explain why some individuals develop MS and others do not (Lindsey 
et al., 2008, Brennan et al., 2010). However, Santon et al. published an increased frequency of 
co-infection of patients with MS with type 1 and 2 strains of EBV (Santon et al., 2011), an 
effect that has so far not been observed by any other groups.  
Patients within our cohort frequently showed antibody responses to proteins from type 1 EBV 
in our “EBNA print” analysis, with many also showing reactivity to the type 2 antigens but this 
may be due to sequence homology between proteins from different strains, as differences in 
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sequence mainly occur in the EBNA2 and EBNA3C loci (Rowe et al., 1989, Farrell, 2015). 
Sequencing would need to be performed on samples from our cohort to determine for certain 
whether co-infections are more common in MS patients, but no observable differences could 
be seen between groups to type 1 and type 2 EBV for Western blot analysis (Figure 4.2.2).  
Antibody responses to EBNA3 protein have not so far been investigated in the context of MS, 
and following on from increased frequency of responses to the locus in “EBNA print” analysis 
we sought to characterise the differential responses to EBNA3A, EBNA3B and EBNA3C 
separately. To different extents, antibody responses to all three EBNA3 proteins were found to 
be more frequent amongst MS patients compared to healthy virus carriers (Figure 4.2.3). 
However, Western blots are only semi-quantitative and further analysis would be needed by 
ELISA or machine-measured chemiluminescence to verify these results. Prevalence of 
EBNA3B-specific antibody responses in MS patients was significantly elevated compared to 
controls, but again this would need to be confirmed by quantitative experiments. 
The clinical significance of elevated EBNA3-specific antibody responses in MS is not known. 
Kinetics of latent antigen-specific T-cell responses following IM are generally lower than those 
for lytic proteins, however latent protein-specific CD8+ T-cells have been shown to make up 
to 5% of total CD8+ compartment in MS (Hislop et al., 2005). EBNA3A-specific CD8+ T-cell 
responses have been shown by one group to be elevated in MS patients during disease 
remission disease and lower during exacerbations, a contrast to the pattern observed for lytic 
protein T-cell responses in the same cohort (Angelini et al., 2013). CD4+ responses to 
EBNA3A in MS have so far not been studied but it is known to be a reasonably common EBV 
immune target in healthy virus carriers (Taylor et al., 2015).  
Compared to EBNA3-specific T-cell responses relatively little investigation has been carried 
out into antibody responses to the proteins. Elevated EBNA3A, B and C antibody responses 
observed in MS patients from our cohort may indicate why increased EBNA complex IgG were 
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observed in MS cohorts, as these proteins are found in the complex (Munger et al., 2011). More 
research is needed in this area to study the kinetics of antibody responses to EBNA3 proteins 
to understand whether CD4+ T-cell responses follow those seen for antibodies, as is seen with 
EBNA1-specific immune responses, or vice versa (Long et al., 2013). 
CMV is a b-herpesvirus which is less ubiquitous in the Western population, infection rates 
increase with age and approximately 80% of the over 65s population in the UK carry the virus 
(Vyse et al., 2009). CMV has been linked to MS but to a lesser extent than EBV; proposed 
mechanisms of the virus’s involvement in disease are similar to those for EBV, however there 
is less epidemiological and serological evidence for an association of the two (Vanheusden et 
al., 2015). CMV has been shown to be able to cross the blood-brain barrier and MS plaques 
have been found to be positive for the virus (Olival et al., 2013, Smyk et al., 2014, Djelilovic-
Vranic and Alajbegovic, 2012), with further evidence suggesting that CMV can contribute 
towards demyelination in immunocompromised patients  (t Hart et al., 2009, Cermelli and 
Jacobson, 2000). Serological studies are fewer but it has been reported that CMV DNA and 
virus-specific IgG titres were higher in MS patients compared to HC (Sanadgol et al., 2011), 
and that MS patients at diagnosis are 86% more likely to have an early CMV infection, 
indicating that the virus may contribute towards disease development (Djelilovic-Vranic and 
Alajbegovic, 2012).  
 Our findings that MS patients have a higher frequency of CMV infection than HC fit with the 
literature and support a contribution of the virus towards development (Figure 4.3.1A). 
However, rates of CMV infection in MS patients did not reach significance when compared 
with healthy donors, but this may be due to the small number of HC with CMV in our cohort 
reducing the statistical power of the data (Figure 4.3.1A). Only a third of MS patients in our 
cohort were CMV positive, suggesting that it is not the sole cause, but multiple virus co-
infections may contribute towards disease progression, as evidenced by previous studies 
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(Horakova et al., 2013, Wunsch et al., 2016). Prevalence of CMV infection has been shown to 
increase with age, but the mean age of healthy donors and MS patients in our study was 35.65 
and 36.32 years respectively, indicating that this increased frequency of CMV infection in MS 
patients cannot be attributed to this (Table 3.1). Increased co-infection with EBV and CMV in 
our cohort corroborates findings from previous studies (Djelilovic-Vranic and Alajbegovic, 
2012, Horakova et al., 2013, Wunsch et al., 2016), and indicates that dual infection with both 
viruses may contribute towards disease development and progression, and more research is 
needed to establish the contribution of immune responses to CMV in MS. 
CMV-positive individuals were separately compared for CMV IgG titres, with MS patients 
appearing to have higher levels, but again this did not reach significance and is possibly due to 
the small number of CMV-positive HC in the cohort (Figure 4.3.1B).  It is also likely that, due 
to similarities between EBV and CMV as herpesviruses, there might be some structural cross-
reactivity of responses to viral antigens confounding results and further investigation is needed 
to establish CMV’s direct contribution to disease (Grangeot-Keros and Cointe, 2001). 
One interesting observation from our cohort was the high frequency of CMV infections in post-
IM donors, despite the younger demographic of this group. 40.0% of post-IM donors in the 
cohort had anti-CMV IgG levels higher than background when tested in our study, a frequency 
that was higher than that observed in MS patients (34.48%) (Figure 4.3.1A). Post-IM donors 
were recruited after they received a positive heterophile test at diagnosis, and IgM antibodies 
detected by this test have been shown to cross-react with EBV antigens (Lang et al., 2001). 
Our analysis was conducted on plasma collected from individuals 4-6 months after onset of 
symptoms, by which time IgM antibodies have started to decline but low levels of cross-
reactive antibodies may still be present in the blood (Taylor et al., 2015). However, all IM 
donors in our study were subsequently tested for VCA IgG responses which have been shown 
to not cross-react with antibodies directed against CMV, indicating that their IM was caused 
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by primary infection with EBV. Higher prevalence of early CMV infection in people who go 
on to develop EBV-driven IM has not been previously shown, and more research is warranted 
in a larger donor cohort to investigate these findings and their potential contribution to MS 
development.  
Tetanus toxoid antibodies are almost ubiquitous in the UK population due to extensive 
vaccination programmes of all children, and thus we used these as a control marker of IgG 
antibody responses, finding them to be unchanged between healthy control donors and MS 
patients in our study (Figure 4.3.2). Post-IM donors were shown to have significantly higher 
titres of tetanus toxoid-specific antibodies when compared with MS patients, and this may be 
due to continued, low level dysregulation of the B-cell compartment following primary 
infection with EBV.  
Statistics performed in our study used the Mann-Whitney test, a non-parametric test used to 
directly compare distribution of two groups of data. However, whilst this is sufficient for two 
groups, more appropriate statistical analysis of three data sets could be achieved using the 
Bonferroni correction (or similar). This would enable calculation of more accurate p values 
and provide a more robust evaluation of variation between cohort groups in future analysis.  
Our study has confirmed previous studies’ findings of elevated EBNA1 and VCA-specific IgG 
responses amongst MS patients, lending support to the hypothesis that EBV immune responses 
are dysregulated in patients and may contribute towards disease development.  Lack of elevated 
viral load in patients compared to HC also suggests that there is no lack of control of viral 
replication, and this may indicate that it is EBV immune responses themselves driving disease 
rather than deficiency in anti-viral immunity. Increased frequency of CMV infections in MS 
patients reflects findings in previous reports stating that the virus can contribute towards 
disease exacerbations and progression. No increase in tetanus toxoid antibody responses in MS 
patients shows that elevations are specific to EBV. Taken together, these findings support a 
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role for EBV in MS development but further investigation of T-cell responses to EBV is needed 
to understand how this occurs.
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5 Ex vivo EBV-specific T-cell responses in peripheral blood 
 
T-cell responses to EBV in MS patients remain the subject of much speculation, and despite 
extensive research no consensus has been reached on whether they are altered in frequency or 
phenotype in patient peripheral blood. To address this question, we analysed CD4+ and CD8+ 
T-cell responses to EBV antigens in PBMCs from RRMS patients (MS), healthy EBV 
seropositive controls (HC) and patients with a recent history of IM, and analysed in depth the 
frequency, phenotype and polyfunctionality of these cells.  
The antigens were selected carefully to allow detailed analysis of circulating EBV-antigen 
specific T-cells. B95.8 virus was originally isolated from an elderly patient with IM and is used 
in many laboratories as a type I EBV reference strain  and is referred to in this thesis as wild 
type LCL (Skare et al., 1982, Baer et al., 1984). This virus was used to establish lymphoblastoid 
cell lines (LCLs) from each donor, and a minority of LCLs established with B95.8 virus 
spontaneously undergo lytic cycle, thus stimulating both latent and lytic antigen-specific T 
cells. A variant of B95.8 that lacks the transactivator protein BZLF1 required to initiate lytic 
cycle expresses only latent antigens (Feederle et al., 2000). Both viruses were used to establish 
LCLs from each donor allowing the total EBV and latent-specific EBV T-cell responses to be 
measured.  
Given the interest in EBNA1 in MS patients, an EBNA1 peptide mix was used to examine T-
cell responses to this antigen specifically, and we analysed ex vivo T-cell responses to the 
protein using a commercially sourced overlapping peptide mix. 
Staphylococcal enterotoxin B (SEB) was used as a non-specific, positive control stimulus for 
cytokine production as it binds to particular Vb chains of TCRs to activate T-cells (Rodstrom 
et al., 2014). Levels of SEB stimulation can vary a lot between donors due to different Vb chain 
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usage of an individual’s T-cell repertoire; SEB acts on specific TCR chains by cross-linking 
them with MHC molecules in a peptide-independent manner and producing a strong 
intracellular stimulus (Rodstrom et al., 2014). Due to restricted cell numbers some samples 
were not screened against SEB. 
All experiments were performed with cryopreserved, whole PBMC from each donor which 
were recovered and stimulated overnight with different antigen sources. The next day the cells 
underwent intracellular cytokine staining (ICS) and flow cytometry.  
 
5.1 Frequency of EBV-specific T-cell responses in peripheral blood 
 
Ex vivo stimulation of PBMCs with LCL and EBV antigens allows the accurate measurement 
of the number of circulating EBV-specific T-cells an individual has in their blood, enabling 
comprehensive analysis of the function and phenotype of these cells between donor groups. 
Intracellular cytokine staining (ICS) was used to determine cytokine production by T-cells and 
to accurately measure the number of cells responding to each stimulus, and the unstimulated 
control was used to set the cut-off for positive cytokine production for each individual donor. 
 
5.1.1 CD4+ T-cell responses 
 
Whole PBMC from each donor were isolated and stimulated overnight with SEB, autologous 
wild type LCL, autologous BZLF1 KO LCL or EBNA1 peptide mix. ICS was performed on 
cells to determine production of interferon-g (IFNg), interleukin-2 (IL-2), interleukin-17 (IL-
17) and granulocyte-macrophage colony-stimulating factor (GM-CSF) by CD4+ or CD8+ T-
cell subsets.  
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Figure 5.1.1 T-cell gating 
strategy for ex vivo PBMC 
stimulations. Example staining 
from MS11 PBMC stimulated 
with SEB (0.2µg/mL). Whole 
PBMC were stained for 
viability, CD14, CD19, CD3, 
CD4 and CD8. Cells were fixed 
with paraformaldehyde (4% in 
PBS) and permeabilised with 
saponin (0.5% in MACS buffer) 
before being stained 
intracellularly for IFNg, IL-2, 
IL-17 and GM-CSF. Singlets 
were gated using FSC-H versus 
FSC-A. FSC-A and SSC-A were 
then used to gate the lymphocyte 
population. T-cells were defined 
as Live/CD14-/CD19-/CD3+ 
cells with CD4+ and CD8+ 
populations gated on separately 
for cytokine production. Dashed 
line represents direction of 
gating strategy, unbroken line 
represents cytokine staining for 
CD4+ and CD8+ subsets. 
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Gating strategy for ex vivo T-cell analysis is shown in Figure 5.1.1. Example staining from 
MS11 is shown in Figure 5.1.2 for IFNg, IL-2, IL-17 and GM-CSF in unstimulated cells and 
those stimulated with SEB, autologous wild type LCL, BZLF1 KO LCL and EBNA1 peptide 
mix.  
Background staining for all four cytokines in our panel was minimal, and allowed the antigen-
specific and negative populations to be determined clearly in both CD4+ and CD8+ subsets 
(Figure 5.1.2 and 5.1.5).  
The greatest ex vivo T-cell response was predictably seen in the positive control samples 
stimulated with SEB, with response to the toxin varying greatly between individuals due to the 
differing levels of circulating T-cells with particular Vb chains. These observed differences 
between donors in T cell repertoire Vb chain usage is greatly influenced by previous antigenic 
exposure and also other factors such as age, gender and lifestyle. 
CD4+ T-cell responses to wild type and BZLF1 KO LCL were typically smaller than those 
seen for CD8+, and as with SEB size of response varied greatly between donors (Figure 5.1.3 
and 5.1.6). IFNg was generally the most frequent cytokine produced by donor T-cells in 
response to wild type and BZLF1 KO LCL, however a high proportion also produced IL-2 
following stimulation (Figure 5.1.3). A small amount of GM-CSF production was observed in 
response to EBV antigens, with the lowest cytokine response observed for IL-17 (Figure 5.1.3).  
Numbers of circulating CD4+ T-cells producing cytokine in response to the different stimuli 
in all donors are shown in Figure 5.1.3. 
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Figure 5.1.2 Ex vivo 
CD4+ T-cell responses to 
SEB and EBV antigens. 
PBMCs from an MS 
donor (MS11) were 
stimulated ex vivo with 
SEB, autologous wild type 
LCL, autologous BZLF1 
KO LCL and EBNA1 
peptides and their 
cytokine production 
measured by flow 
cytometry. Cells were 
gated as LiveCD14-
CD19-CD3+CD4+ T-
cells and then further 
gated for IFNg, IL-2, IL-
17 and GM-CSF. Values 
represent percentage of 
CD4+ T-cell population 
producing cytokine.  
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CD4+ T-cells from healthy donors and MS patients did not show any significant difference in 
cytokine response to SEB after overnight stimulation, with large variation in the size of 
response to SEB within the two groups (Figure 5.1.3A).  
CD4+ T-cells from MS donors did not show any significantly changed levels of IFNg, IL-2 or 
IL-17 production in response to autologous wild type LCL stimulation, however GM-CSF 
production was shown to be significantly higher in MS patient CD4+ T-cells compared to 
healthy donors (HC:MS p=0.0138, Mann-Whitney test) but not post-IM donors (Figure 
5.1.3B). 
IFNg, IL-2 and GM-CSF production was not significantly different between HC, MS or post-
IM donors after stimulation with autologous BZLF1 KO LCL (Figure5.1.3C), but IL-17 was 
produced at different levels between the groups in response to the latent LCL (p=0.0352, 
Kruskall-Wallis test). HC produced the highest amount of IL-17 but statistical comparison of 
HC and MS donor IL-17 responses using the Mann-Whitney test did not reach significance 
(Figure 5.1.1C). 
EBNA1 is a key protein of interest in MS pathogenesis due to the elevated anti-EBNA1 
antibody response in MS and post-IM patient blood (Long et al., 2013, Lunemann et al., 2006, 
Lunemann et al., 2008b). Analysis of CD4+ T-cell responses from our cohort to EBNA1 
peptide mix revealed no overall difference in production of cytokines in our panel after 
stimulation (Figure 5.1.3D).  
The median percentage of CD4+ T-cells producing IFNg and IL-2 (represented by the 
horizontal black lines) is similar for both cytokines following stimulation with wild type or 
BZLF1 KO LCL, and shows that these are the two main cytokines produced in response to 
LCL stimulation (Figure 5.1.3). IL-17 and GM-CSF were produced at lower levels than IFNg 
and IL-2 in response to LCL stimulation.  
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EBNA1 CD4+ T-cell responses were much lower than those for LCL, and cytokine production 
by responding cells was similar between all four cytokines, indicating a more varied functional 
response to the protein (Figure 5.1.3D).  
The strongest genetic link with MS is the MHC class II allele HLA-DR15, and we therefore 
wanted to address whether having the HLA-DR15 allele influenced levels of circulating T-cells 
with reactivity to EBV or their phenotype. Using the same experimental data, we compared 
only donors that were HLA-DR15+ and the results are shown in Figure 5.1.4.  
Pattern of cytokine production comparing HLA-DR15+ donors only did not alter the data 
significantly, however increases in the median of CD4+ T-cells responding to wild type LCL 
by producing IFNg and IL-2 indicate that the allele may have a modest effect on responses 
(Figure 5.1.4B); more HLA-DR15+ donors would need to be analysed to determine if these 
results are significant. GM-CSF production in response to B95.8 LCL remained significantly 
higher in MS patients compared to HC after removal of HLA-DR15 donors (HC:MS p=0.0454, 
Mann-Whitney test) (Figure 5.1.4B). However, variation in IL-17 production after following 
BZLF1 KO LCL stimulation was no longer significant after removal of donors that were not 
HLA-DR15+ (Figure 5.1.4C) and this may be due to the low number of donors in the IM group 
causing a lack of statistical power in the analysis.
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Figure 5.1.3 Ex vivo EBV-specific CD4+ T-cell responses. Whole PBMC were stimulated ex vivo and 
subjected to ICS. Responding CD4+ T-cells are presented as a percentage of the whole CD4+ T-cell 
population producing each cytokine in response to stimulation with: A. SEB B. wild type LCL C. BZLF1 KO 
LCL D. EBNA1 peptide mix. Colour of dots define patient group: blue=healthy control donors, red=RRMS 
patients and green=post-IM patients. Black bars represent median of data set (SEB stimulation: HC n=20, MS 
n=19, all other stimulations: HC n=29, MS n=29, post-IM n=7). Kruskal-Wallis test was used for comparison 




Figure 5.1.4 Ex vivo EBV-specific CD4+ T-cell responses in HLA-DR15+ donors. Whole PBMC from 
HLA-DR15+ donors were analysed separately to see if their responses were different in frequency or 
phenotype. Isolated cells were stimulated ex vivo and subjected to ICS. Responding CD4+ T-cells are 
presented as a percentage of the whole CD4+ T-cell population after stimulation with. A. SEB B. wild type 
LCL C. BZLF1 KO LCL and D. EBNA1 peptide mix. Colour of dots define patient group: blue=healthy 
control donors, red=RRMS patients and green=post-IM patients. Horizontal black line represents median of 
data set (SEB stimulation: HC n=8, MS n=9, all other stimulations: HC n=14, MS n=14, post-IM n=2). The 
Kruskal-Wallis test was used for comparisons of three groups and the Mann-Whitney test for comparison of 
two patient groups (ns p>0.05, * p≤0.05). 
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5.1.2 CD8+ T-cell responses 
 
Many studies have investigated CD8+ T-cell responses to EBV in MS but, as with many 
aspects of MS pathogenesis, there is currently no consensus reached on whether they are altered 
in patients. Conflicting reports of CD8+ T-cell immunity to the virus in peripheral blood 
highlight the need for more research in this area, and this was explored in our cohort. 
The same stimulation experiments were used for analysis of both CD4+ and CD8+ T-cell 
responses to EBV antigens. As previously described for CD4+ T-cells, whole PBMC were 
stimulated overnight with SEB, autologous wild type LCL, autologous BZLF1 KO LCL and 
EBNA1 peptide mix and their T-cells analysed to understand whether there are any significant 
differences between frequency and phenotype of CD8+ T-cell responding to EBV antigens.  
Example staining of CD8+ T-cell cytokine production in response to SEB, wild type LCL, 
BZLF1 KO LCL and EBNA1 are shown from a representative MS donor (MS11) in Figure 
5.1.5.  As with CD4+ T-cells, responses to SEB varied greatly between donors due to 
differences in TCR Vb chain usage in their repertoires. Minimal background staining was 
observed for IFNg, IL-2 and IL-17; GM-CSF staining showing some background but this effect 
was removed using Funky Cells software analysis.  
No significant differences were seen in the CD8+ T-cell SEB responses between HC or MS 
donors, despite there being a slight trend towards greater IL-2 and GM-CSF production in cells 
from MS patients (Figure 5.1.6A). 
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Figure 5.1.5 Ex vivo 
CD8+ T-cell responses to 
SEB and EBV antigens. 
Whole PBMC from one 
MS patient (MS11) was 
stimulated with SEB, 
autologous wild type 
LCL, autologous BZLF1 
KO LCL and EBNA1 
peptides separately and 
the intracellular cytokine 
responses analysed by 
flow cytometry. Cells 
were gated as LiveCD14-
CD19-CD3+CD8+ cells 
and then further gated for 
IFNg, IL-2, IL-17 and 
GM-CSF cytokine 
production. Values in top 
right corner of plots 
represents percentage of 
total gated CD8+ T-cells 
producing cytokine.  
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Lytic cycle proteins are major targets of EBV-specific CD8+ T-cell responses, and this is 
exaggerated during IM where CD8+ T-cells are massively expanded (Taylor et al., 2015). IM 
patients have elevated CD8+ T-cell responses directed against lytic antigens in their blood for 
several months following initial disease and this is evident in our cohort where up to 13% of 
post-IM donors’ circulating CD8+ T-cells are IFNg+ after ex vivo wild type LCL stimulation 
(Figure 5.1.6B). Healthy and MS donors showed much lower circulating frequencies of CD8+ 
T-cells specific for wild type LCL as shown by levels of IFNg production; levels of IL-2 and 
GM-CSF were also unchanged between the two groups (Figure 5.1.6B and 5.1.6C). BZLF1 
KO LCL stimulation showed responding CD8+ T-cells to be at much lower frequencies than 
for wild type LCL, and this reflects the high numbers of circulating CD8+ T-cells that are 
specific for EBV lytic proteins (Figure 5.1.6B and 5.1.6C). There were no significant 
differences between groups in cytokine production following autologous BZLF1 KO LCL 
stimulation (Figure 5.1.6C).  
Interestingly, IL-17 production in response to both LCLs was significantly different across 
groups, with HC showing the highest cytokine production (B95.8 LCL: p=0.0343, BZLF1 KO 
LCL: p=0.0212, Kruskal-Wallis test) (Figure 5.1.6B and 5.1.6C). Cytokine production by 
CD8+ T-cells in response to EBNA1 peptide mix did not differ significantly between patient 
groups (Figure 5.1.6D). 
CD4+ T-cells are key orchestrators of the immune response and many CD8+ T-cell responses 
are dependent on CD4+ T-cells for immunological help. We therefore investigated whether 
HLA-DR15 status of patients made a difference to the frequency or phenotype of CD8+ T-cell 
responses to EBV in HC or MS patients by comparing only data from patients who possessed 
the allele (Figure 5.1.7).  
IL-17 production in HLA-DR15+ donors’ CD8+ T-cells in response to wild type LCL 
remained very low but significantly higher in HC than MS donors (HC:MS p=0.0323, Mann-
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Whitney test; all groups p=0.0475, Kruskal-Wallis test), but production in response to BZLF1 
KO LCL lost significance (p=0.1006, Kruskal-Wallis test) (Figure 5.1.7C). 
Production of GM-CSF in response to wild type LCL became significant between the three 
groups, however this may be skewed due to the high levels produced by the two HLA-DR15+ 
post-IM donors included in the analysis; levels between HC and MS donors were not different 
when statistically compared (p=0.0363, Kruskal-Wallis test) (Figure 5.1.7B).
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Figure 5.1.6 Ex vivo EBV-specific CD8+ T-cell responses. Whole PBMC were stimulated ex vivo and subjected 
to ICS. CD8+ T-cells are presented as a percentage of the whole CD8+ T-cell population responding to: A. SEB 
B. wild type LCL C. BZLF1 KO LCL and D. EBNA1 peptide mix. Colour of dots define patient group: 
blue=healthy control donors, red=RRMS patients and green=post-IM patients. Horizontal black line represents 
median of data set (SEB stimulation: HC n=20, MS n=19, all other stimulations: HC n=29, MS n=29, post-IM 
n=7). All statistics performed using the Kruskal-Wallis test for comparisons of three groups and the Mann-Whitney 








Figure 5.1.7 Ex vivo EBV-specific CD8+ T-cell responses in HLA-DR15+ donors. Whole PBMC from HLA-
DR15+ donors were analysed separately for their reactivity to EBV antigens and their cytokine production. 
Responding CD8+ T-cells were presented as a percentage of the whole CD8+ population producing cytokine in 
response to: A. SEB B. wild type LCL C. BZLF1 KO LCL and D. EBNA1 peptide mix. Colour of dots define 
patient group: blue=healthy control donors, red=RRMS patients and green=post-IM patients. Horizontal black 
line represents median of data set (SEB stimulation: HC n=8, MS n=9, all other stimulations: HC n=14, MS 
n=14, post-IM n=2). All statistics performed using the Kruskal-Wallis test for comparisons of three groups and 
the Mann-Whitney test for comparison of two patient groups (ns p>0.05, * p≤0.05). 
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5.2 Cytokine production of circulating EBV-specific T-cells 
 
We observed no obvious difference in frequency of circulating EBV-specific CD4+ or CD8+ 
T-cells, however there were small phenotypic differences observed in cells responding to LCL 
in MS patients, and we characterised these in detail.  
Ex vivo analysis of cytokine production in only responding T-cells was performed and 
compared between groups to gain a more detailed picture of function and phenotype of EBV-
specific responses.  
Responding cells were defined as CD4+ or CD8+ T-cells producing at least one cytokine in 
response to stimulation. Analysing only responding cells following EBV stimulation allows us 
to investigate the proportion of responding T-cells producing each cytokine in response to 
different stimuli, and through this interpret effector function or subset of T-cell responses to 
EBV antigens. It has been suggested that MS patients may have altered proportions of TH1 or 
TH17 CD4+ T-cells in their blood (Frisullo et al., 2008, Tzartos et al., 2008), and we sought to 
investigate whether EBV-responding T-cells showed different phenotype to those of HC or 
post-IM donors. 
 
5.2.1 EBV-specific CD4+ T-cell responses 
 
Figure 5.2.1 shows the overall percentage of responding CD4+ T-cells that produce each of the 
four cytokines. There were no significant differences in cytokine level produced following 
stimulation with SEB, autologous wild type LCL or EBNA1 peptide mix. However, there was 
a significant difference in IL-17 production between BZLF1 KO LCL-responding CD4+ T-
cells from all three groups, with a higher proportion of CD4+ T-cells from HC producing IL-
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17 than those from MS patients (HC:MS p=0.0414, Mann-Whitney test; HC:MS:IM p=0.0355, 
Kruskal-Wallis test) (Figure 5.2.1C). 
This increased IL-17 production by CD4+ T-cells in response to LCL is in concordance with 
data shown earlier in the chapter (Figures 5.1.1 and 5.1.2), and indicates that fewer responding 
cells from MS patients produce IL-17 in response to LCL stimuli compared with those from 
HC.  
A trend towards GM-CSF production in wild type LCL-specific CD4+ T-cells from 
HLADR15+ MS patients was observed compared to HC but did not reach significance. 
However, analysis of the whole cohort revealed the difference to be significant, and suggests 
that analysis of fewer subjects causes the data to lose power (Figure 5.1.1 and 5.2.1). 
HLA-DR15+ donors were analysed separately to elucidate if the allele has any influence on 
cytokine production in responding cells, and results are shown in Figure 5.2.2. A higher 
proportion of CD4+ T-cells from DR15+ MS patients produced IL-17 compared to healthy 
donors following SEB stimulation (HC:MS p=0.0315, Mann-Whitney test), a contrast with 
BZLF1 KO LCL stimulation where healthy donors produced more IL-17 than MS patients 
(HC:MS p=0.0100, Mann Whitney test; HC:MS:IM p=0.0058, Kruskal-Wallis test) (Figure 
2.2C). In the same analysis, MS patients were also shown to produce more GM-CSF than 
healthy controls in response to wild type LCL, a trend that did not reach significance when all 
donors were compared (Figure 5.2.2B; HC:MS p=0.0036, Mann-Whitney test) (Figure 5.2.1). 
Variation in GM-CSF production between groups in response to BZLF1 KO LCL stimulation 
was significant when only HLA-DR15+ donors were considered (Figure 5.2.2C; p=0.0356, 
Kruskall-Wallis test) (Figure 5.2.2B and C).  
A difference in cytokine production when only analysing HLA-DR15+ donors may suggest 
that the allele affects phenotype of CD4+ T-cell responding to both SEB and EBV antigens, 
and this is interesting given that HLA-DR15 positivity is the strongest genetic link with MS. 
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Analysis of only HLA-DR15+ donors showed higher production of GM-CSF in response to 
wild type and BZLF1 KO LCLs (Kruskall-Wallis test), indicating that these donors produce 




   
Figure 5.2.1 Function of EBV-specific CD4+ T-cells. Whole PBMC were stimulated and subjected to ICS. 
Responding CD4+ T-cells were defined as producing any combination of four cytokines in the staining panel. The 
proportion of responding CD4+ T-cells producing each of the cytokines are presented as a percentage of the total 
responding CD4+ T-cell population after stimulation with: A. SEB B. wild type LCL C. BZLF1 KO LCL and D. 
EBNA1 peptide mix. Colour of dots define patient group: blue=healthy control donors, red=RRMS patients and 
green=IM patients. Horizontal black line represents median of data set (SEB stimulation: HC n=20, MS n=19, all 
other stimulations: HC n=29, MS n=29, post-IM n=7). The Kruskal-Wallis test was used for direct comparison of 
variance between the three groups (long bar above data)and the Mann-Whitney test was used separately to analyse 
two patient groups (short bar above data) (ns p>0.05, * p≤0.05). 
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Figure 5.2.2 Function of EBV-specific CD4+ T-cells from HLA-DR15+ donors. Whole PBMC from HLA-
DR15+ donors only were stimulated and subjected to ICS. Results from HLA-DR15+ donors only were compared. 
Responding CD4+ T-cells were defined as producing any combination of four cytokines in the staining panel. The 
proportion of responding CD4+ T-cells producing each of the cytokines are presented as a percentage of the total 
responding CD4+ T-cell population after stimulation with: A. SEB B. wild type LCL C. BZLF1 KO LCL and D. 
EBNA1 peptide mix. Colour of dots define patient group: blue=healthy control donors, red=RRMS patients and 
green=IM patients. Horizontal black lines represent median of data set (SEB stimulation: HC n=8, MS n=9, all 
other stimulations: HC n=14, MS n=14, post-IM n=2). The Kruskal-Wallis test was used for direct comparison of 
variance between the three groups and the Mann-Whitney test was used separately to analyse two patient groups 
(ns p>0.05, * p≤0.05, ** p≤0.01). 
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5.2.2 Boolean gate analysis of EBV-specific CD4+ T-cells 
 
Further analysis of cytokine production from ex vivo T-cell stimulations was performed using  
Boolean combination gate analysis of Funky Cells transformed data using SPICE software. 
This data mining allowed further investigation of responding cells by calculating proportions 
of cells producing each of the sixteen possible combinations of cytokines in our staining panel 
and plotting them graphically. Annotation describing cytokine profile of T-cells is shown in 
table 5.1 and will be used throughout this thesis to refer to each of the sixteen Boolean gates 
(Table 5.1). 
 
Table 5.1 Annotation for Boolean gating 
IFNγ- IL2- IL17- GMCSF- - - - - 
IFNγ- IL2- IL17- GMCSF+ - - - + 
IFNγ- IL2- IL17+ GMCSF- - - + - 
IFNγ- IL2- IL17+ GMCSF+ - - + + 
IFNγ- IL2+ IL17- GMCSF- - + - - 
IFNγ- IL2+ IL17- GMCSF+ - + - + 
IFNγ- IL2+ IL17+ GMCSF- - + + - 
IFNγ- IL2+ IL17+ GMCSF+ - + + + 
IFNγ+ IL2- IL17- GMCSF- + - - - 
IFNγ+ IL2- IL17- GMCSF+ + - - + 
IFNγ+ IL2- IL17+ GMCSF- + - + - 
IFNγ+ IL2- IL17+ GMCSF+ + - + + 
IFNγ+ IL2+ IL17- GMCSF- + + - - 
IFNγ+ IL2+ IL17- GMCSF+ + + - + 
IFNγ+ IL2+ IL17+ GMCSF- + + + - 
IFNγ+ IL2+ IL17+ GMCSF+ + + + + 
 
 
Cytokine profile was first analysed in CD4+ T-cells responding to SEB stimulation with results 
shown in Figure 5.2.3. Cytokine profile of responding CD4+ cells was similar between groups, 
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with HC and MS donors both showing a response in which cells mostly produced IL-2 (Figure 
5.2.3).  
Following stimulation with autologous wild type LCL, post-IM patients showed a significant 
increase compared to HC in the proportion of responding cells that produce IFNg only (HC:IM 
+--- p=0.030) and co-express IFNg and GM-CSF (HC:IM +--+ p=0.009), and a reduced 
proportion of responding CD4+ T-cells in the IFNg+IL-2+ subset (HC:IM ++-- p=0.009) 
(Figure 5.2.4).  
MS patients’ responding CD4+ T-cells showed a slightly different pattern of cytokine 
production after wild type LCL stimulation, with increased proportion of cells in the 
IFNg+GM-CSF+ and IFNg+IL-2+GM-CSF+ subsets compared to healthy controls (HC:MS +-
-+ p=0.016) (HC:MS ++-+ p=0.034) (Figure 5.2.4).  
The proportion of responding CD4+ T-cells producing IFNg only and co-expressing IFNg and 
IL-2 were unchanged between all three groups, but a higher proportion of cells from post-IM 
donors produced IL-2 only compared to healthy controls (HC:IM -+-- p=0.048) (Figure 5.2.5).  
Healthy donors had a higher proportion of CD4+ T-cells producing IL-17 only but this did not 
reach significance when compared with other groups (Figure 5.2.5).  
CD4+ T-cell responses to EBNA1 were more varied in their cytokine responses, with many 
subsets making up the overall response for each group and potentially skewed by the small 
numbers of responding cells in the populations. There were no significant differences in 
phenotype between groups’ CD4+ T-cells responding to EBNA1 antigen (Figure 5.2.6). 
Permutation tests were also used to compare contribution of cells in each combination gate to 
the responding populations as a whole, and the data for CD4+ T-cells are presented in pie chart 
format using SPICE software in Figure 5.2.7. SEB responding CD4+ T-cells did not show any 
difference in proportion of cells in each combination gate between healthy or MS donors. 
However, a difference was observed between MS and post-IM patients’ CD4+ T-cells 
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responding to wild type LCL, with a higher proportion of cells from MS donors in the IFNg+IL-
2+ and IL-2+ subsets (MS:IM p=0.0498) (Figure 5.2.7B). No significant differences were seen 
in subset usage of CD4+ T-cells responding to BZLF1 KO LCL or EBNA1, however EBNA1 
responses showed a very different subset usage compared to other stimuli indicating a strong 
phenotypic difference in cells responding to the antigen (Figure 5.2.7D).
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Figure 5.2.3 Cytokine profile of ex vivo SEB-specific CD4+ T-cells. Whole PBMC were stimulated 
ex vivo with SEB and ICS was performed (HC n=21, MS n=19). Responding CD4+ T-cells were defined 
as T-cells positive for any combination of cytokines. A. Graphical representation of responding cells in 
each combination gate with bars representing the mean of data set. Statistics were calculated using the 
Wilcoxon Signed Rank test. B. Scatter plot showing percentage of responding cells for each donor in 
combination gates. Black bars represent median of data set. C. Table shows results from the Wilcoxon 
rank test. D. Percentage of responding CD4+ T-cells shown in heatmap form. Combination gate data 














































Figure 5.2.4 Cytokine profile of ex vivo wild type LCL-specific CD4+ T-cells. Whole PBMC were 
stimulated ex vivo with wild type LCL and ICS was performed (HC n=28, MS n=27, IM n=7). 
Responding CD4+ T-cells were defined as T-cells positive for any combination of cytokines. A. 
Graphical representation of responding cells in each combination gate with bars representing the mean 
of data set. Statistics were calculated using the Wilcoxon Signed Rank test. B. Scatter plot showing 
percentage of responding cells for each donor in combination gates. Black bars represent median of data 
set C. Table shows results from Wilcoxon Rank test. D. Percentage of responding CD4+ T-cells shown 
in heatmap form. Combination gate data was processed using Funky Cells software and graphically 














































Figure 5.2.5 Cytokine profile of ex vivo BZLF1 KO LCL-specific CD4+ T-cells. Whole PBMC were 
stimulated ex vivo with BZLF1 KO LCL and ICS was performed (HC n=28, MS n=27, IM n=7). 
Responding CD4+ T-cells were defined as T-cells positive for any combination of cytokines. A. 
Graphical representation of responding cells in each combination gate with bars representing the mean 
of data set. Statistics were calculated using the Wilcoxon Signed Rank test. B. Scatter plot showing 
percentage of responding cells for each donor in combination gates. Black bars represent median of data 
set C. Table shows results from Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown 
in heatmap form. Combination gate data was processed using Funky Cells software and graphically 














































Figure 5.2.6 Cytokine profile of ex vivo EBNA1-specific CD4+ T-cells. Whole PBMC were 
stimulated ex vivo with EBNA1 peptide mix and ICS was performed (HC n=28, MS n=27, IM n=7). 
Responding CD4+ T-cells were defined as T-cells positive for any combination of cytokines. A. 
Graphical representation of responding cells in each combination gate with bars representing the mean 
of data set. Statistics were calculated using the Wilcoxon Signed Rank test. B. Scatter plot showing 
percentage of responding cells for each donor in combination gates. Black bars represent median of data 
set. C. Table showing results from Wilcoxon rank test. D. Percentage of responding CD4+ T-cells 
shown in heatmap form. Combination gate data was processed using Funky Cells software and 















































Figure 5.2.7 Cytokine profile of ex vivo EBV-specific CD4+ T-cells. Whole PBMC from each donor 
were stimulated before ICS the following day. CD4+ T-cells were categorised into 16 combination gates 
for cytokine production. Pie charts show the mean percentage of responding CD4+ T-cells belonging to 
each gate after stimulation with: A. SEB (HC n=21) (MS n=19) B. wild type LCL (HC n=28) (MS n=27) 
(IM n=7) C. BZLF1 KO LCL (HC n=28) (MS n=27) (IM n=7) and D. EBNA1 (HC n=28) (MS n=27) 
(IM n=7). Combination gate data was processed using Funky Cells software and graphically displayed 
using the program SPICE, statistics were calculated using a permutation test (ns p>0.05, * p<0.05). 
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5.2.3 EBV-specific CD8+ T-cell responses 
 
Cytokine production in CD8+ T-cells responding to ex vivo stimuli showed a different pattern 
to that of CD4+ T-cells. Example staining for SEB, wild type LCL, BZLF1 KO LCL and 
EBNA1 protein is shown in Figure 5.1.5. We characterised the cytokine production of ex vivo 
CD8+ T-cells responding to stimuli to elucidate if they are phenotypically different between 
patient groups or different from those secreted by CD4+ T-cells. This was performed by sorting 
responding CD8+ T-cells in to Boolean combination gates which allows production of multiple 
cytokines to be measured and compared between groups.  
IFNg production by responding CD8+ T-cells was found to be significantly higher in HC in 
response to SEB (HC:MS p=0.0051, Mann-Whitney test), with GM-CSF production 
significantly lower in healthy controls compared to MS patients (p=0.0259, Mann-Whitney 
test) (Figure 5.2.8A). IL-2 production was also higher in MS patient CD8+ T-cells but this did 
not reach significance (Figure 5.2.8A). 
CD8+ T-cells responding to LCLs were similar between groups for IFNg, IL-17 and GM-CSF, 
however for both wild type LCL and BZLF1 KO LCL a higher proportion of responding cells 
from healthy donors produced IL-2 (Figure 5.2.8B and C). The variation in levels of IL-2 
production in response to wild type LCL across three groups reached significance (p=0.0026, 
Kruskal-Wallis test), but did not for the BZLF1 KO LCL response (Figure 5.2.8B and C). There 
were no differences observed in cytokine responses towards EBNA1 peptide mix (Figure 
5.2.8D). 
HLA-DR15+ donors were analysed for their cytokine production in responding CD8+ T-cells 
(Figure 5.2.9). The increased IFNg production of HC in response to SEB remained elevated 
when only HLA-DR15+ donors were analysed. Elevated GM-CSF no longer reached 
significance when only HLA-DR15+ donors were analysed (Figure 5.2.9A).  
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There was no significant difference between the three groups in IL-2 production following wild 
type LCL stimulation when only HLA-DR15+ donors were analysed, and variation in 
production of GM-CSF between cohorts was seen when comparing all three groups directly 
(p=0.0138, Kruskal-Wallis test) (Figure 5.2.9B).  
GM-CSF production in wild type LCL-specific CD8+ T-cells from HLA-DR15+ MS patients 
was higher than that of HC (HC:MS p=0.0318, Mann-Whitney test) (Figure 5.2.9B), an effect 
that was not apparent when all donors were analysed. Significant variation was also seen across 
all three donor groups when the Wilcoxon rank test was applied (HC:MS:post-IM p=0.0138).  
Interestingly, CD8+ T-cells from HLA-DR15+ MS donors had a significantly higher 
production of IL-2 in response to EBNA1 peptide mix than healthy donors (HC:MS p=0.0245, 
Mann-Whitney test) (Figure 5.2.9D). This increase was seen with all donors were analysed but 
did not reach significance, suggesting that CD8+ T-cells from HLA-DR15+ MS donors 




Figure 5.2.8 Cytokine production of EBV-specific CD8+ T-cells. Whole PBMC were stimulated and subjected 
to ICS. Responding T-cells were defined as producing any combination of four cytokines. Percentage of 
responding cells positive for each cytokine were analysed between patient groups in response to: A. SEB B. wild 
type LCL C. BZLF1 KO LCL and D. EBNA1 peptide mix. Colour of dots define patient group: blue=healthy 
control donors, red=RRMS patients and green=IM patients. Horizontal black line represents median of data set 
(SEB stimulation: HC n=20, MS n=19, all other stimulations: HC n=29, MS n=29, post-IM n=7). The Kruskal-
Wallis test was used for direct comparisons of the three groups and the Mann-Whitney test was used to analyse 
two patient groups at a time (ns p>0.05, * p≤0.05, ** p≤0.01). 
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Figure 5.2.9 Cytokine production of EBV-specific CD8+ T-cells from HLA-DR15+ donors. Whole 
PBMC were stimulated and subjected to ICS. Results from HLA-DR15+ donors only were compared. 
Responding CD8+ T-cells were defined as T-cells producing any combination of four cytokines in response 
to four stimuli: A. SEB B. wild type LCL C. BZLF1 KO LCL and D. EBNA1 peptide mix. Colour of dots 
define patient group: blue=healthy control donors, red=RRMS patients and green=IM patients. Horizontal 
black line represents median of data set (SEB stimulation: HC n=8, MS n=9, all other stimulations: HC 
n=14. MS n=14, post-IM n=2). The Kruskal-Wallis test was used for direct comparisons of the three groups 
and the Mann-Whitney test was used to analyse two patient groups at a time (ns p>0.05, * p≤0.05). 
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5.2.4 Boolean gate analysis of EBV-specific CD8+ T-cells  
 
As previously described for ex vivo CD4+ T-cell data, SPICE software was used to analyse 
Boolean combination gate data for responding CD8+ T-cells and allows analysis of cells 
producing multiple cytokines. The notation for cytokine production shown in Table 5.1 was 
also applied to CD8+ T-cell Boolean gates. 
Cytokine production seen in SEB stimulated CD8+ T-cells reflects that seen in Figure 5.2.8, 
and an increased proportion of cells from MS patients were IL-2+ and IL-2+GM-CSF+ 
compared to healthy donors (HC:MS -+-- p=0.048, HC:MS -+-+ p=0.009) (Figure 5.2.10). 
Healthy donors showed an increased proportion of responding CD8+ T-cells expressing IFNg 
only (HC:MS +--- p=0.037) (Figure 5.2.10).   
No significant differences were seen in cytokine production between responding CD8+ T-cell 
from HC and MS patients following wild type LCL stimulation (Figure 5.2.11). However, post-
IM donors showed increased proportion of cells belonging to the IFNg+ and IFNg+GM-CSF+ 
subsets (HC:IM +--- p=0.001I, HC:IM, +--+ p=0.005), with a decreased number of IFNg+IL-
2+ CD8+ T-cells (HC:IM ++-- p=0.004) (Figure 5.2.11). These findings might reflect the 
disruption of the CD8+ T-cell compartment that occurs during IM, indicating that EBV-
specific CD8+ cells are still altered in phenotype as well as frequency 4-6 months following 
symptomatic primary infection.  
Cytokine production in response to BZLF1 KO LCL stimulation follows the same pattern as 
that for wild type LCL stimulation, with post-IM donors showing increased proportion of 
IFNg+ and IFNg+GM-CSF+ subsets with decreased number co-expressing IFNg and IL-2 
(HC:IM +--- p=0.013, HC:IM +--+ p=0.001, HC:IM ++-- p=0.032) (Figure 5.2.12).  Cytokine 
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production following BZLF1 KO LCL stimulation in MS patient CD8+ T-cells was not 
different from that of healthy donors (Figure 5.2.12).  
High variation in CD4+ T-cell responses to EBNA1 were observed across all groups (Figure 
5.2.6D) and this was also shown in EBNA1-specific CD8+ T-cells (Figure 5.2.13D). Despite 
this variability in responses no significant differences were seen in cytokine profile of 
responding CD8+ cells between donor groups.  
As previously shown for responding CD4+ T-cells, permutation tests were performed on 
cytokine combination gate data from CD8+ T-cells, and the proportion of cells in each gate are 
displayed in pie chart format in Figure 5.2.14. MS patient and HC CD8+ T-cells responding to 
SEB stimulation showed significantly different subset usage, with differences mainly with the 
proportion of donor responses producing IFNg only and IL-2 only (HC:MS p=0.0268) (Figure 
5.2.14A).  
The phenotype of CD8+ T-cells responding to wild type LCL also differed significantly 
between groups, with post-IM donors showing the biggest change. The vast majority of 
responding CD8+ T-cells in post-IM donors produced IFNg only after wild type LCL 
stimulation, with this subset making up ~70% of the response (Figure 5.2.14B). However, HC 
and MS patients showed a decreased proportion of cells producing IFNg alone compared to 
post-IM donors. A larger proportion of the wild type LCL response in HC and MS donors co-
produced IFNg and IL-2, indicating a more mature and polyfunctional response in donors who 
have carried the virus for longer (HC:IM p=0.0017, MS:IM p=0.0016) (Figure 5.2.14B), and 
showing responses in HC and MS were similar in phenotype.  
CD8+ T-cell responses to the BZLF1 KO LCL again showed similar cytokine production 
between all three cohort groups, however a difference was observed between HC and post-IM 
donors, who exhibited a higher proportion of CD8+ T-cells producing IFNg only following 
stimulus (HC:IM p=0.0134) (Figure 5.2.14C). 
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More varied production of cytokines was present in CD8+ T-cells responding to EBNA1 
peptide mix but responses between patient groups did not show any significant differences 
between groups (Figure 5.2.14D). 
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Figure 5.2.10 Cytokine profile of ex vivo SEB-specific CD8+ T-cells. Whole PBMC were stimulated 
ex vivo with SEB before ICS was performed. (HC n=21, MS n=19). Responding CD8+ T-cells were 
defined as T-cells positive for any combination of cytokines. A. Graphical representation of responding 
cells in each combination gate with bars representing the mean of data set. Statistics were calculated 
using the Wilcoxon Signed Rank test B. Scatter plot showing percentage of responding cells for each 
donor in combination gates. Black bars represent median of data set. C. Table showing results from 
Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in heatmap form. Combination 
gate data was processed using Funky Cells software and graphically displayed using the program SPICE 














































Figure 5.2.11 Cytokine profile of ex vivo wild type LCL-specific CD8+ T-cells. Whole PBMC were 
stimulated ex vivo with wild type LCL before ICS was performed (HC n=28, MS n=27, IM n=7). 
Responding CD8+ T-cells were defined as T-cells positive for any combination of cytokines. A. 
Graphical representation of responding cells in each combination gate with bars representing the mean 
of data set. Statistics were calculated using the Wilcoxon Signed Rank test. B. Scatter plot showing 
percentage of responding cells for each donor in combination gates. Black bars represent median of data 
set. C. Table of results from Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically 














































Figure 5.2.12 Cytokine profile of ex vivo BZLF1 KO LCL-specific CD8+ T-cells. Whole PBMC 
were stimulated ex vivo with BZLF1 KO LCL subjected to ICS (HC n=28, MS n=27, IM n=7). 
Responding CD8+ T-cells were defined as T-cells positive for any combination of cytokines. A. 
Graphical representation of responding cells in each combination gate with bars representing the mean 
of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot showing 
percentage of responding cells for each donor in combination gates. Black bars represent median of data 
set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically 














































Figure 5.2.13 Cytokine profile of ex vivo EBNA1-specific CD8+ T-cells. Whole PBMC were 
stimulated ex vivo with EBNA1 peptide mix subjected to ICS (HC n=28, MS n=27, IM n=7). 
Responding CD8+ T-cells were defined as T-cells positive for any combination of cytokines. A. 
Graphical representation of responding cells in each combination gate with bars representing the mean 
of data set. Statistics were calculated using the Wilcoxon Signed Rank test B. Scatter plot showing 
percentage of responding cells for each donor in combination gates. Black bars represent median of data 
set. C. Table showing results from Wilcoxon rank test. D. Percentage of responding CD8+ T-cells 
shown in heatmap form. Combination gate data was processed using Funky Cells software and 















































Figure 5.2.14 Cytokine profile of ex vivo EBV-specific CD8+ T-cells. Whole PBMC were stimulated 
overnight and subjected to ICS. Responding CD8+ T-cells were defined as cells producing any combination 
of cytokines and were categorised into 16 combination gates. Pie charts show the mean percentage of 
responding CD8+ T-cells belonging to each gate after stimulation with: A. SEB (HC n=21, MS n=19) B. wild 
type LCL (HC n=28, MS n=27, IM n=7). C. BZLF1 KO LCL (HC n=28, MS n=27, IM n=7) and D. EBNA1 
peptide mix (HC n=28, MS n=27, IM n=7). Combination gate data was processed using Funky Cells software 
and graphically displayed using the program SPICE, statistics were calculated using a permutation test (ns 
p>0.05, * p<0.05, ** p<0.005).  
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5.3 Polyfunctionality of EBV-specific T-cell responses 
 
Multidimentional analysis of T-cell cytokine production is a growing area of interest which, 
due to advances in flow cytometry, has significantly changed the way we view T-cells in the 
past 10 years. Using the Boolean data mining software Funky Cells, we investigated multiple 
cytokine production by EBV-specific T-cells in our cohorts. 
 
5.3.1 Polyfunctionality Index 
 
Polyfunctionality index (PI) is a value calculated by an algorithm developed and patented as 
part of the Funky Cells software, and provides a numerical value which takes into account the 
degree and variation in the data from all the combinatorial cell phenotypes (Larsen et al., 
2012b). Using this measure, we were able to compare directly the level of co-secretion of 
cytokines in response to different stimuli and compare values between patient groups. 
No difference was seen in PI of CD4+ T-cells between groups in response to SEB, wild type 
LCL, BZLF1 KO LCL or EBNA1 peptide mix stimulation, indicating that there is no difference 
in the co-secretion of cytokines in this T-cell subset and no difference was revealed when only 
the DR15+ donors were considered (Figures 5.3.1A and C). 
CD8+ T-cells showed variation across groups in the polyfunctionality of cells responding to 
wild type LCL, with HC and MS donors having significantly higher scores than IM donors 
(p=0.0069, Kruskal-Wallis test) (Figure 5.3.1B). No difference was seen between PI values of 




Figure 5.3.1 Polyfunctionality index of EBV-specific T-cells. T-cells were stimulated ex vivo and subjected to 
ICS. Responding T-cells were defined as CD4+ or CD8+ producing any combination of cytokines after 
stimulations. Polyfunctionality index (PI) was calculated using Funky Cells software for A. CD4+ T-cells and B. 
CD8+ T-cells. Responses in HLA-DR15+ donors only are shown in C. for CD4+ and D. for CD8+ subsets. Colour 
of dots define patient group: blue=healthy control donors, red=RRMS patients and green=IM patients. Horizontal 
black line represents median of data set. The Kruskal-Wallis test was used for direct comparisons of the three groups 
and the Mann-Whitney test was used to analyse two patient groups at a time (ns p>0.05, * p≤0.05, ** p≤0.01). 
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5.3.2 Number of functions 
 
As a different measure of polyfunctionality we compared the percentage of responding cells 
producing 1, 2, 3 or 4 cytokines after stimulation. This provides a different measure of 
polyfunctionality and shows the number of functions T-cells responding to EBV stimuli have. 
A higher number of functions could have both implications for the speed in which pathogens 
are cleared in vivo and for other immune functions such as T-cell subset skewing, innate cell 
recruitment and promoting inflammation.  
Data for CD4+ T cells is presented in Figure 5.3.2 and agrees with polyfunctionality index – 
no significant differences are seen in the number of cells producing multiple cytokines in 
response to SEB or EBV antigen stimulus. IM donor CD4+ T-cells appear to produce fewer 
cytokines in response to wild type LCL compared to the other groups (p=0.0224, Kruskal-
Wallis test) (Figure 5.3.2).  
Number of functions in responding CD8+ T-cells were similarly analysed with variation seen 
in the proportion of responding cells producing one or two cytokines. IM donors had a lower 
proportion of CD8+ T-cells with two functions and a higher proportion of cells with a single 
function compared to HC and MS donors (two functions p=0.0076, Kruskal-Wallis test; one 
function p=0.0079, Kruskall-Wallis test) (Figure 5.3.3B). Responses to BZLF1 KO LCL 
showed a similar pattern for IM donors with data for production of one cytokine not reaching 
significance (two functions p=0.0395, Kruskal-Wallis test; one function p=0.0508, Kruskal-
Wallis test) (Figure 5.3.3C).  
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Figure 5.3.2 Number of functions of ex vivo EBV-specific CD4+ T-cells. T-cells were stimulated ex vivo 
and subjected to ICS. Number of functions of CD4+ T-cells were compared between patient groups in 
response to A. SEB B. wild type LCL C. BZLF1 KO LCL and D. EBNA1 peptide mix. Horizontal black line 
represents median of data set. Colour of dots define patient group: blue=healthy control donors, red=RRMS 
patients and green=IM patients. The Kruskal-Wallis test was used for direct comparisons of three groups and 
the Mann-Whitney test was used to analyse two patient groups at a time (ns p>0.05, * p≤0.05). 
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Figure 5.3.3 Number of functions of EBV-specific CD8+ T-cells. T-cells were stimulated ex vivo and subjected to 
ICS. Number of functions of responding CD8+ T-cells were compared between patient groups in response to A. SEB 
B. wild type LCL C. BZLF1 KO LCL and D. EBNA1 peptide mix. Horizontal black line represents median of data 
set. Colour of dots define patient group: blue=healthy control donors, red=RRMS patients and green=IM patients. 
The Kruskal-Wallis test was used for direct comparisons of three groups and the Mann-Whitney test was used to 
analyse two patient groups at a time (ns p>0.05, * p≤0.05, ** p≤0.01). 
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HLA-DR15+ donors, analysed separately for number of functions of their responding CD4+ 
T-cells, did not show any significant differences between patient groups (Figure 5.3.4).    
Analysis of HLA-DR15 donors only showed the pattern of increased number of functions in 
CD8+ T-cells from healthy donors compared to MS patients however these differences did not 
reach significance (Figure 5.3.5).  
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Figure 5.3.4 Number of functions of ex vivo EBV-specific CD4+ T-cells from HLA-DR15+ donors. T-cells 
were stimulated ex vivo and subjected to ICS. Number of functions of CD4+ T-cells in HLA-DR15+ donors only 
were compared in response to different stimuli: A. SEB B. wild type LCL C. BZLF1 KO LCL and D. EBNA1 
peptide mix. Colour of dots define patient group: blue=healthy control donors, red=RRMS patients and green=IM 
patients. Horizontal black line represents median of data set (SEB stimulation: HC n=8, MS n=9, all other 
stimulations: HC n=14, MS n=14, post-IM n=2). The Kruskal-Wallis test was used for direct comparisons of 





Figure 5.3.5 Number of functions of ex vivo EBV-specific CD8+ T-cells from HLA-DR15+ donors. T-
cells were stimulated ex vivo and subjected to ICS. Number of functions in CD8+ T-cells from HLA-
DR15+ donors were compared after stimulation with: A. SEB B. wild type LCL C. BZLF1 KO LCL and 
D. EBNA1 peptide mix. Colour of dots define patient group: blue=healthy control donors, red=RRMS 
patients and green=IM patients. Horizontal black lines represent median of data set. The Kruskal-Wallis 
test was used for direct comparisons of three groups and the Mann-Whitney test was used to analyse two 
patient groups at a time (ns p>0.05, * p≤0.05). 
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5.4 Correlation of EBNA1 T-cell responses with antibody production 
 
It is known that CD4+ T-cells provide immunological help to B-cells, and therefore it may be 
expected that CD4+ T-cell responses correlate with antibody titres to the same antigen. Despite 
previous, separate analysis of EBNA1-specific antibody and T-cell responses in MS patients 
by other research groups there has been no investigation of whether these two aspects of the 
adaptive immune response to EBV correlate.  
We correlated plasma EBNA1 IgG with CD4+ and CD8+ T-cell responses from each donor to 
examine whether there was a trend from experimental data previously described for EBNA1 
antibody responses in Chapter 4.2 and for EBNA1-specific T-cell responses in Chapter 5.1. 
CD4+ T-cell responses to EBNA1 peptide mix were measured by production of each cytokine 
in the ICS panel: IFNg, IL-2, IL-17 and GM-CSF. CD4+ T-cell cytokine production was 
correlated with plasma EBNA1 IgG production in each individual donor and the correlation 
calculated using Spearman’s rank correlation coefficient (r).  IFNg production in CD4+ T-cells 
after EBNA1 stimulation was found to correlate positively with level of EBNA1 IgG when all 
donors were analysed (r=0.2620, p=0.0450), however this effect was not significant when other 
cohort groups were analysed individually (Figure 5.4.1).  Positive correlations were observed 
for HC and MS donor IFNg CD4+ T-cell responses with antibody responses to EBNA1 
however these did not reach significance, possibly due to the reduced number of data points 
for individual groups reducing power of statistical analysis (Figure 5.4.1). 
IL-2 production by EBNA1-specific CD4+ T-cells did not correlate with antibody titre when 
all donors were analysed, however a slight positive correlation was observed for HC donors 
(Figure 5.4.1).  No correlation was seen when MS donor IL-2 responses were plotted against 
EBNA1-specific IgG (Figure 5.4.1).  
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No correlations were observed between IL-17 or GM-CSF production from EBNA1-specific 
CD4+ T-cells and EBNA1 IgG in any cohort groups (Figure 5.4.1). 
Due to restrictions in cell numbers only 7 post-IM donors were screened for EBNA1 responses 
in ex vivo T-cell stimulations, and therefore fewer data points were available to analysed in this 
group. Low patient numbers make it difficult to draw conclusions from data regarding a 
correlation between T-cell and antibody responses, and we found no correlation between 
numbers of EBNA1-specific CD4+ T-cells and antibody levels in post-IM donors. 
CD4+ T-cells provide immunological “help” to CD8+ T-cells as well as B-cells, and as such 
we sought to investigate a possible correlation between EBNA1-specific antibodies and 
cytotoxic CD8+ T-cell responses. 
As previously described, CD8+ T-cell cytokine production from ex vivo EBNA1 stimulations 
were correlated with plasma EBNA1-specific IgG. IFNg production by EBNA1-specific CD8+ 
T-cells was found to have a significant positive correlation with antibody levels when all 
donors were analysed (r=0.3437, p=0.0072) (Figure 5.4.2); positive correlation was maintained 
when HC and MS cohort groups were analysed separately but were no longer significant (HC 
donors r=0.3824 p=0.0538, MS donors p=0.0790) (Figure 5.4.2).  
IL-2 production from CD8+ T-cells in response to EBNA1 stimulation also correlated 
significantly with antibody responses, both when all donors were analysed and when HC 
donors were analysed on their own (all donors r=0.2901 p=0.0245, HC donors r=0.4551 
p=0.0195) (Figure 5.4.2). No correlation was observed between IL-2 production from CD8+ 
T-cells and antibody production from MS and post-IM donors when analysed in their groups, 
indicating that the significant positive correlation seen in IL-2 production from all donors was 
mostly due to HC donors (Figure 5.4.2).  
No correlations were observed between IL-17 or GM-CSF production from EBNA1-specific 
CD8+ T-cells and antibody production in any donor groups (Figure 5.4.2).  As previously 
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mentioned for CD4+ T-cells, only 7 data points were available for post-IM donors correlating 
EBNA1-specific CD8+ T-cell responses with IgG in plasma. This again made it difficult to 
draw any conclusions for adaptive immune responses to EBNA1 in post-IM donors, and this 
would need to be carried out with more samples to establish if any correlation was present. 
Despite correlations showing significance when statistical tests were applied, low positive 
correlations – such as those for IFNg producing EBNA1-specific CD4+ T-cells versus anti-
EBNA1 IgG – may not be high enough in this context to indicate a positive relationship 
between T-cell and B-cell responses to the viral antigen.  Visual interpretation of the correlation 
would suggest that there is little relationship between these two aspects of immunity in our 
cohort, and therefore we should be cautious in assuming that these two aspects of adaptive 
immunity are highly linked in individual donors from our cohort.   A larger cohort with a fully 
quantitative EBNA1-specific IgG assay would enable these two parameters to be investigated 
further and reliable conclusions to be drawn. 
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Figure 5.4.1 Correlation of EBNA1 IgG responses with EBNA1-specific CD4+ T-cell responses.  Plasma EBNA1 IgG responses from donors were correlated with cytokine 
production by CD4+ T-cells in response to ex vivo EBNA1 peptide mix stimulation. Plasma EBNA1 IgG was analysed by ELISA and values represent the median of at least 
3 separate experiments. Cytokine production by ex vivo CD4+ T-cells was analysed using ICS. Colour of dots represents cohort group: black = all donors, blue = HC, red = 
MS, green = post-IM. Spearman’s rank correlation coefficient was used to calculate correlation (HC n=26, MS n=27, IM n=7) (ns p>0.05, * p<0.05). 
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Figure 5.4.2 Correlation of EBNA1 IgG responses with EBNA1-specific CD8+ T-cell responses.  Plasma EBNA1 IgG responses from donors were correlated 
with cytokine production by CD8+ T-cells in response to ex vivo EBNA1 peptide mix stimulation. Plasma EBNA1 IgG was analysed by ELISA and values represent 
the median of at least 3 separate experiments. Cytokine production by ex vivo CD8+ T-cells was analysed using ICS. Colour of dots represents cohort group: black = 
all donors, blue = HC, red = MS, green = post-IM. Spearman’s rank correlation coefficient was used to calculate correlation (HC n=26, MS n=27, IM n=7) (ns p>0.05, 




Studies of ex vivo analysis EBV-specific T-cell responses in MS patients have produced varied 
results, and such mixed conclusions from published data makes it extremely difficult to 
decipher exactly what role T-cell responses to the virus are playing in disease development. 
We analysed CD4+ and CD8+ T-cell responses ex vivo from RRMS patients, HC and patients 
with a recently history of IM (4-6 months post-infection) to elucidate if there were any clear 
differences in cytokine production between groups in response to EBV antigens, using SEB as 
a positive control of T-cell activation and cytokine production.  
IFNg was selected for its key role in cytotoxic responses and is rapidly produced by TH1 CD4+ 
and CD8+ T-cells upon exposure to their cognate antigen (Schoenborn and Wilson, 2007). 
CD4+ T-cells with TH1 phenotype are part of the cell-mediated immune response and rapidly 
produce IFNg in response to viral and other intracellular pathogens (Schoenborn and Wilson, 
2007). Other cytokines in our staining panel consisted of IL-2, IL-17 and GM-CSF, all selected 
for their potential role in immune responses directed against the CNS in MS pathogenesis.  
IL-2 is a key cytokine regulating T-cell maturation and tolerance mechanisms, and 
polymorphisms in the IL-2 receptor a-chain (IL2Ra, also called CD25) have been associated 
with multiple sclerosis development and relapse rates (International Multiple Sclerosis 
Genetics et al., 2007, Wang et al., 2011b, Ainiding et al., 2014). Daclizumab, an anti-IL2Ra 
monoclonal antibody, has been shown in trials to reduce disease activity and slow down 
progression in patients currently not responding to other treatments (Rose et al., 2004, Wiendl 
and Gross, 2013), indicating a role for IL-2 signalling in MS disease mechanisms. These 
findings are interesting given the therapeutic potential for CD25 blockade in the treatment of 
cancer. In a clinical trial of patients with metastatic breast cancer, daclizumab was administered 
alongside a cancer vaccine and was shown to selectively downregulate FoxP3 in Treg cells, 
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deplete these cells long-term and also to mediate reprogramming of Treg cells to an IFNg-
producing phenotype. Results also showed that patient CD4+ and CD8+ T cell responses to 
vaccine antigens were boosted by daclizumab without autoimmune side effects (Rech et al., 
2012). Daclizumab’s impact on Treg-cells in this study suggests that its therapeutic potential in 
MS is not due to effects on this subset, and it is possible that effects on activated T-cells 
expressing CD25 are responsible for the amelioration of disease exacerbations (Fazekas de St 
Groth et al., 2004).  
IL-17 was selected for our cytokine staining panel as its production has been linked to disease 
processes in autoimmunity and inflammation, and with relation to MS its role is mainly thought 
to be involved in early disease (Kostic et al., 2014, Wing et al., 2016). Additional studies of 
MS and neuromyelitis optica (NMO) – a T-cell-mediated autoimmune disease – have also 
shown levels of circulating CD4+ T-cells with a TH17 phenotype to be more frequent in patients 
compared to controls during disease exacerbation, with serum IL-17 also found to be elevated 
(Wang et al., 2011a). Extensive research using the EAE mouse models of MS have also shown 
IL-17 to have a role in disease (Waisman et al., 2015).  
GM-CSF pathways have been identified to be antagonistically controlled to those of IL-17, 
with a role identified for GM-CSF only producing CD4+ T-cells in the inflamed brain in MS 
(Noster et al., 2014). Expression of GM-CSF has also been found to be increased in T- and B-
cells from MS patients and it is linked to inflammatory pathways of pathogenic T-cells (Rasouli 
et al., 2015, Sheng et al., 2014, Li et al., 2015). Analysis of these cytokines produced by EBV-
specific T-cells ex vivo enabled us to get a clear picture of any phenotypic differences that may 
be present in these responses between HC, MS patients and post-IM donors.  
Overall, levels of IFNg-producing CD4+ and CD8+ cells were not changed between MS 
patients or HC, indicating that there is no altered frequency of these cells in the blood. 
However, we observed small differences in production of other cytokines in response to both 
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wild type and BZLF1 KO LCL, indicating that there may be a slight phenotypic difference in 
cells responding to EBV antigens between groups. 
Multiple cytokine production of T-cells responding to EBV antigens has not been analysed in 
depth in the context of MS, with previous studies mainly investigating IFNg secretion with 
some also investigating IL-2 (Pender et al., 2017, Lunemann et al., 2008b, Gronen et al., 2006, 
Jilek et al., 2008). We sought to characterise expression of multiple cytokines by T-cells 
responding to EBV for the first time in RRMS patients and healthy controls. 
We did not find any significant differences in the overall frequency of IFNg-secreting wild type 
or BZLF1 KO LCL-specific CD4+ or CD8+ T-cells in MS patients compared to healthy 
controls. The wild type LCL-specific CD8+ T-cell response in post-IM donors was a little 
higher than for other groups and this was probably due to incomplete resolution of expansion 
of lytic antigen-specific T-cells seen in primary infection (Figures 5.1.6 and 5.1.7). 
IL-2 production was mostly unchanged between groups in response to LCL or EBNA1 stimuli, 
and CD4+ T-cell responses from HLA-DR15+ donors showed a slight trend towards increased 
IL-2 production in response to wild type LCL but this did not reach significance (Figure 5.1.4).  
Also notable was a modest increase in LCL-specific CD4+ and CD8+ T-cells producing IL-17 
in healthy donors compared to levels from MS patients, and this was surprising given that 
increased IL-17 production and signalling is generally associated with autoimmunity and has 
been shown to have a role in pathogenesis of EAE (Volpe et al., 2015, Reboldi et al., 2009, 
Kostic et al., 2015). A higher proportion of responding CD4+ T-cells after BZLF1 KO LCL 
simulation were IL-17+ in HC compared to MS patients, suggesting that healthy donors have 
increased IL-17 production in response to latent proteins, as this effect was not seen in response 
to wild type LCL (Figures 5.1.3 and 5.2.1). This difference in IL-17 production was not 
observed between HC and MS donors following wild type LCL stimulation, suggesting that 
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either IL-17 production was higher in MS patients in response to lytic cycle proteins not 
expressed by BZLF1 KO LCL.   
It is unclear what this may mean for the involvement of EBV-specific T-cell responses in MS 
pathogenesis, however these differences in IL-17 production are in very small populations of 
responding cells and therefore results may be slightly skewed by the low numbers of cells 
stained positive for IL-17; a larger number of donors would be needed to see if this effect is 
real.  
GM-CSF production in MS patients was significantly increased in CD4+ T-cells responding to 
wild type LCL, a trend that was also maintained when only looking at HLA-DR15+ donors 
(Figure 5.1.3 and 5.1.4). GM-CSF is a cytokine promotes proliferation of lymphocytes and 
differentiation of TH1 CD4+ and cytotoxic CD8+ T-cell responses (Francisco-Cruz et al., 
2014). Increased GM-CSF production by EBV-specific T-cells may indicate a greater capacity 
to drive immune cell proliferation and local activation of innate cells. Increased GM-CSF 
production may also be a consequence of increased frequency of IL-2Ra polymorphisms in 
MS, and mutations in IL-2Ra have been shown to increase production of IL-2 and other 
cytokines in patient immune cells (Hartmann et al., 2014).  
GM-CSF is produced mainly by TH1 CD4+ T-cells in humans and increased production of 
GM-CSF by MS patient CD4+ T-cells in response to EBV antigens suggest that these cells 
might be skewed towards a TH1 phenotype (Codarri et al., 2011). Findings of an increased 
proportion of LCL-specific CD4+ T-cells expressing GM-CSF in response to EBV antigens 
indicates a phenotypic alteration of these responses in MS patients, and this may affect the 
inflammation and recruitment of other immune cells to the CNS, causing further demyelination 
and axonal damage. 
GM-CSF-positive microglia and macrophages have also been shown to be present in brain 
lesions of MS patients with the GM-CSF receptor shown to be expressed on neurones, 
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suggesting a role for this cytokine in lesion pathology (Vogel et al., 2015). GM-CSF is also 
known to be involved in recruitment of microglia and other immune cells to sites of 
inflammation (Mayo et al., 2014).  
EBV antigen-specific CD4+ T-cells from MS patients produce significantly higher levels of 
GM-CSF when activated, and if these cells were to gain access to the CNS they may propagate 
inflammation and lesion formation. Molecular mimicry suggests that CD4+ T-cells with 
receptors able to recognise both EBV and CNS antigens are responsible for attack on neuronal 
tissue. Increased cytokine production by EBV-specific CD4+ T-cells may lead to inflammatory 
events in vivo and permeabilisation of the BBB, permitting influx of T-cells and other immune 
cells into the CNS promoting further tissue damage. Increased GM-CSF production by wild 
type LCL-specific CD4+ T cells in MS patients from our study suggests a qualitative difference 
in T-cell responses between groups and may account for why some individuals develop MS 
and others do not. 
Analysis of CD8+ T-cells responding to EBNA1 peptide mix revealed a higher proportion of 
cells that produce IL-2 in MS patients compared to HC and post-IM donors, an effect which 
became significant when analysing the HLA-DR15+ donors only (Figure 5.2.8D and 5.2.9D). 
This finding is interesting given that previous literature describes an increased frequency and 
broadened specificity of EBNA1-specific CD4+ T-cell responses in MS patients (Lunemann 
et al., 2006). Our study did not replicate these results as we saw no elevated frequency of 
EBNA1-specific CD4+ T-cells in MS patient blood. Other publications show EBNA-1 specific 
T-cell responses to be decreased in MS following administration of clinically effective IFNb 
therapy, suggestive of a pathogenic role for these T-cells in disease relapses (Comabella et al., 
2012).  
Increased IL-2 expression by SEB-stimulated CD8+ T-cells indicates that some predisposition 
may occur to high IL-2 production in MS patient T-cells (Figure 5.1.6), however this was not 
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mirrored in responses to wild type or BZLF1 KO LCL. Increased IL-2 production by CD8+ T-
cells in response to EBNA1 may be due to some other effect, potentially CD4+ T-cell “help” 
perpetuating responses or other immune mechanisms not yet known.  
In-depth analysis of multiple cytokine production by EBV-specific T-cell responses in MS 
patients has not been performed before, and our study sought to address this to not only 
investigate frequency of these cells but also function. Funky cells software enabled the 
subtraction of background staining and avoided skewing of results by this effect. This analysis, 
combined with presentation of combination gate data in SPICE software, allowed us to gain an 
extremely detailed picture of CD4+ and CD8+ T-cell function in response to both LCL 
stimulations and to EBNA1. Despite this in-depth characterisation, we were not able to detect 
any major variation in responses between HC and MS patients in polyfunctionality or 
differential cytokine expression. This suggests that circulating responses to EBV latent and 
lytic antigens are largely unchanged in MS patients, and there were no clear indications of how 
immune responses to EBV may be contributing towards MS disease development. However, 
as our blood samples were from patients who were currently in the remission phase of disease 
we may have missed some differences that only become apparent during clinical exacerbations, 
and future work would need to investigate relapse samples before any definitive conclusions 
can be made. 
Rapid cytokine production in response to stimulation ex vivo is indicative of T-cells that have 
a memory phenotype, as naïve T-cells do not produce cytokine in response to pathogens as 
readily.  EBV-specific T-cells producing multiple cytokines after stimulation with autologous 
LCL by indicates a memory compartment with previous EBV antigenic experience, and a 
larger proportion of these cells with increased effector function may suggest a larger memory 
T-cell pool responding to the virus.  It may be that, whilst there were no major differences in 
cytokine production by EBV-specific T-cells between MS and healthy controls, differences in 
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ratio of naïve and effector memory T-cell compartments may exist. Future investigation of ex 
vivo T-cell responses to EBV antigens in MS patients should include T-cell memory subset 
markers to investigate this further. 
Publications investigating relapses in MS have shown disease activity to be positively 
correlated with EBV-specific T-cell responses. Angelini et al. showed frequency of lytic 
antigen-specific CD8+ T-cells to be positively correlated with disease activity as measured by 
MRI (Angelini et al., 2013). However, other groups have failed to find a correlation between 
T-cell or antibody responses to EBV and MS disease exacerbations, leading some to argue that 
immune responses to EBV are not stable enough markers to use in diagnosis or prognostic 
analysis (Ingram et al., 2010). 
Obtaining reliable samples of clinical relapses from MS patients is difficult due to the insidious 
onset of symptoms, causing patients to delay seeking medical attention until their condition 
gets worse. This, combined with time delays between hospital referrals and sample collections, 
means that it is often several weeks before blood is collected by which time symptoms may 
have started to resolve. Analysis of EBV-specific T-cell responses during relapses may reveal 
a difference in frequency or phenotype that might give crucial insight into disease processes, 
analysis of CSF responses in addition to the blood will give a more detailed picture of responses 
during clinical exacerbations. CSF samples are also difficult to gather due to delays in lumber 
puncture from onset of symptoms and also due to the frequent contamination of CSF with blood 
during the procedure, rendering the sample useless for immunological investigation in this 
context. Despite problems faced in gathering CSF samples, some studies have shown 
intrathecal enrichment of EBV-specific CD8+ T-cell responses during early disease (Jaquiery 
et al., 2010).  
Differences in disease status or lack of clinical data regarding time of sample collection may 
account for the tremendous amount of variation in reports of EBV-specific T-cell responses 
 168 
being increased, unchanged or decreased in MS (van Nierop et al., 2016a, Pender et al., 2009, 
Cepok et al., 2005); careful patient recruitment with detailed and strict criteria for blood and 
CSF donation are needed in order to perform reliable studies of MS relapse pathogenesis. 
Due to no obvious differences between the frequency of EBV-specific CD4+ or CD8+ T-cells 
in MS patient blood compared to that of HC or post-IM donors in our cohort, we analysed the 
production of different cytokines by T-cells to see if differences occurred in the phenotype of 
EBV-specific responses that were not apparent from our initial analysis. 
Analysis of production of other cytokines by MS patient T-cells responding to EBV antigens 
may reveal differences that were not apparent in this study, and additional ex vivo analysis of 
cytokines such as IL-22 and IL-23 might give a broader picture of CD4+ T-cells with a TH17 
phenotype in MS (Wing et al., 2016, Wang et al., 2011a).  
Staining of T-cells for homing markers might also give an idea of which cells are capable of 
migrating to the CNS causing disease: CCR7 is a key protein used in identifying populations 
of mature T-cells and its function allows T-cells to home to lymphoid tissues (Forster et al., 
2008).  Studies of leukaemic mouse models have shown CCR7 to be essential in mediating 
migration of T-cells into the CNS (Buonamici et al., 2009), and investigation of CSF-resident 
T-cells from MS patients found up to 90% of them to express the chemokine CCR7 (Kivisakk 
et al., 2004). CCR7+ TFH cells have also been linked with clinical relapses of MS in one cohort 
(Fan et al., 2015), and it would therefore be a marker of interest when investigating EBV-
specific T-cells in MS patients during relapse and their potential to home to the CNS. 
Antibody responses and T-cell responses to EBV have been extensively investigated separately 
for many years, however few studies have attempted to correlate both of these parameters in 
individuals. Little is known about the kinetics of asymptomatic infection, but EBNA1-specific 
CD4+ T-cell and antibody responses have been shown to be delayed after IM with responses 
only appearing 4-6 months post-infection (Long et al., 2013). However, EBNA1 responses 
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have so far not been correlated in individual donors to show that these antigen responses are 
directly linked in vivo. Research from other systems studying parasites and cancer/testis 
antigens have shown there to be limited correlation between antibody and T-cell responses to 
the same antigen (Walker et al., 2015, Gnjatic et al., 2003), and lack of publications describing 
a link potentially reflects the difficulty or lack of correlation between these two aspects of 
adaptive immunity.   
We correlated EBNA1-specific IgG responses with cytokine production from both CD4+ and 
CD8+ T-cells following stimulation with EBNA1 peptide mix and found there to be a modest 
correlation with IFNg production in both T-cell subsets (Figure 5.4.1 and 5.4.2). The positive 
correlation of antibody responses with EBNA1-specific IFNg+ CD4+ T-cells was significant 
when all donors were analysed, and this effect was maintained but no longer significant when 
HC and MS patient data were correlated independently (Figure 5.4.1). These findings suggest 
that IFNg+CD4+ T-cell responses to EBNA1 in MS patients match elevations seen in EBNA1-
specific IgG titres but higher numbers in cohorts are needed to determine if this effect is 
significant (Lunemann et al., 2010, Lunemann et al., 2008a). However, previous publications 
have reported an increased frequency of peripheral EBNA1-specific CD4+ T-cells in MS 
patients (Lunemann et al., 2006) which was not found in our cohort, and this is reflected in the 
absence of strong positive correlation seen in our cohort between EBNA1-specific antibody 
and CD4+ T-cell responses in Figure 5.4.1.  
EBNA1-specific CD4+ T-cells that produced other cytokines – IL-2, IL-17 or GM-CSF – were 
not found to be correlated with anti-EBNA1 IgG in plasma in all cohort groups, indicating that 
it is specifically IFNg-producing CD4+ T-cells that positively correlate with antibody 
responses to the antigen in the blood (Figure 5.4.1). Lack of correlation between CD4+ T-cells 
producing other cytokines and antibody responses suggests that it is mainly the IFNg-producing 
subset that is linked to EBNA1 IgG synthesis, and implicates TH subsets that are able to secrete 
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IFNg in generation of antibody responses. CD4+ TH subsets that are characterised by IFNg 
production include TH1 cells, however it has also been shown that TFH cells are able to produce 
small amounts of the cytokine (Vinuesa et al., 2005) and that IFNg production promotes class-
switching in B-cells to IgG2 antibody production during antiviral responses (MacLennan et al., 
2003). It is therefore perhaps not surprising that EBNA1-specific IFNg+CD4+ T-cells are 
shown to be correlated with IgG responses to the same antigen but T-cells producing other 
cytokines in our study are not.  
EBNA1-specific CD8+ T-cell responses producing IFNg and IL-2 were also found to be 
positively correlated with anti-EBNA1 IgG production when all donors were analysed (Figure 
5.4.2). This finding is interesting, and perhaps to be expected, given that naïve CD8+ T-cells 
(as well as B-cells) require immunological help from CD4+ T-cells to mature and elicit their 
full cytotoxic potential (Bevan, 2004). Absence of positive correlation between IL-2-producing 
EBNA1-specific CD8+ T-cells and IgG in MS donors potentially reflects the elevated antibody 
titres not reflected by T-cell responses in these patients (Figure 5.4.2). Data from our cohort 
suggest that elevations of EBNA1-specific IgG occur independently of CD8+ T-cell responses 
and support evidence for unchanged CD8+ T-cell responses to the antigen in MS patients (van 
Nierop et al., 2016a), and contradict publications reporting an increase in EBNA1-specific 
CD8+ T-cells in the blood of MS (Cepok et al., 2005). However, the commercially available 
kit used for analysis of plasma EBNA1-specific IgG responses in our cohort is only semi-
quantitative, and conclusions from our data need to consider this. Further studies should use a 
fully quantitative method of measuring EBNA1-specific antibody responses to determine if 
this effect is real.  
Currently there is no conclusive mechanism for how EBV infection might contribute towards 
the development of MS, and analysis of ex vivo T-cell responses to the virus in our cohort have 
not shown any clear difference in frequency of circulating virus-specific CD4+ or CD8+ T-
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cells. Subtle changes in the cytokines produced following latent and lytic LCL stimulation 
between HC and MS patients indicate that there might be differences, but these do not shed 
any light on why some individuals develop disease. Analysis of T-cell responses in patients 
with a recent history of IM were analysed due to their increased subsequent risk of developing 
CNS-directed autoimmunity, however no significant correlations were seen in frequency or 
function of CD4+ or CD8+ T-cells between the two groups which might shed light on this 
association. Analysis of EBV-specific T-cell responses in clinical relapse of MS might shed 
light on the immunology of disease exacerbations and the contribution of the virus-specific 
immune response during relapse. 
Positive correlation of CD4+ and CD8+ T-cell responses to EBNA1 with antibody levels has 
not previously been investigated in individual donors and data from HC in our cohort suggest 
that these are intrinsically linked. This is likely to be due to the immunological help provided 
by CD4+ T-cells to other cells of the adaptive immune response with specificity for the same 
antigen. Absence of significant positive correlation between these two parameters in MS 
patients reflects the increased plasma EBNA1 IgG levels without elevated T-cell responses, 
suggesting that this increase in antibody titres is independent of the T-cell compartment. 
However, analysis of more donors would provide more statistical weight to this finding and 
further research in this area is warranted to understand immunological kinetics of EBV 
immunity in MS. 
Small differences observed between ex vivo T-cell responses to EBV antigens between MS 
patients and healthy controls do not shed light on how these responses may drive disease in 
MS patients, leading us to investigate further characteristics of the EBV-specific T-cell 
repertoire in donors.  The ability of T-cells to become activated relies on specificity of the T-
cell receptor, and we investigated whether functional differences existed between donor groups 
by exploring whether EBV-specific T-cells could also become activated by neuronal antigens. 
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6 Generation of LCL-specific polyclonal T-cell lines and their reactivity with 
the CNS 
 
CD4+ T-cells with reactivity to both EBV and CNS antigens in MS patients have been 
previously reported (Lunemann et al., 2008b, Lang et al., 2002), and the cross-reactive 
hypothesis remains one of the mechanisms best supported by the currently available data to 
explain how EBV contributes towards disease pathogenesis (discussed Chapter 1.5.5). 
Following on from ex vivo analysis of circulating EBV-specific CD4+ and CD8+ T-cells, we 
sought to investigate whether EBV-reactive T-cells would become activated by CNS proteins. 
To perform these experiments, we developed a panel of recombinant MVA viruses containing 
EBV and CNS antigens which enabled the expression of EBV and CNS proteins in autologous, 
EBV-negative B-cell lines. Optimisation and employment of this system is described in this 
chapter, and has allowed us to thoroughly examine the cross-reactive potential of EBV-specific 
T-cells in vitro.  
 
6.1 Generation of recombinant MVA viruses expressing CNS antigens 
 
In order to study T-cell responses to CNS antigens, an expression system was developed based 
on a genetically engineered poxvirus, modified vaccinia Ankara (MVA) virus (Chapter 2.2).   
Nine potential autoantigenic targets were selected for cloning into MVA viruses and these 
included CNP, MAG, MOG, PLP, MBP, MBP-V8, MOBP, TAL-H and CRYAB. MVA virus 
was previously attenuated by serial passage through chicken embryo fibroblasts resulting in 
genomic deletions and subsequent loss of the ability to replicate in multiple cell types. MVA 
viruses were selected as vectors for CNS protein expression for our project as they are a safe 
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vector to work with and can be used to stably overexpress large, recombinant proteins. Despite 
its diminished replication capacity, MVA virus has retained the ability to infect most cell types 
and produce recombinant protein, making MVA an efficient vector with which to express 
desired proteins safely in a wide variety of cell types. 
Alongside the CNS proteins, two other recombinant MVAs were made containing EBNA1 and 
an empty vector negative control (pYWK). EBNA1ΔGA is the truncated EBNA1 protein from 
EBV with its GA repeat sequence deleted. The GA repeat sequence of EBNA1 acts to inhibit 
its own translational processing, preventing presentation of epitopes via MHC class I molecules 
on the cell surface (Levitskaya et al., 1995). By deleting this sequence EBNA1 epitope 
presentation efficiency is greatly improved and immune responses to the unrepeated region can 
be properly studied. In addition to this, an empty vector control MVA virus was made to serve 
as a negative control and contains no recombinant protein insert downstream of the T7 
promoter (pYWK). This enabled background immune responses to the recombinant MVAs to 
be accurately measured in the same system.  
A schematic of recombinant proteins expressed in this system under the control of the T7 
promoter can be found in Figure 6.1.1. This system was selected for two main reasons; first, to 
prevent theoretical induction of autoimmunity in the event of accidental human infection with 
the recombinant CNS protein MVAs. Second, to prevent over-expression of the proteins during 
amplification of the viruses, as their high hydrophobicity can be cytotoxic to cells. Placing 
CNS proteins under control of the T7 promoter ensures that the gene locus should only be 
transcribed and translated when the T7 polymerase is expressed in the same cell. As the enzyme 
is not expressed in eukaryotic cells, T7 polymerase was supplied in this system by co-infection 
with a second MVA virus expressing the bacteriophage T7 polymerase in trans. 
MVA viruses were engineered to express GFP constitutively which allows recombinant virus 
quantification by fluorescent microscopy, and further modifications were made to aid the 
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proteins’ detection in vitro. A FLAG-tag is a short, hydrophilic polypeptide tag which can be 
added on to proteins without affecting their biological function or cellular processing (Lichty 
et al., 2005), and its addition to recombinant CNS proteins allowed detection of the 
recombinant CNS protein expression in Western blots by a FLAG tag-specific monoclonal 
antibody (Figure 6.1.2). The FLAG tag was also added as a means of purifying protein were 
this needed for future experiments. 
Construction of vaccinia shuttle plasmids containing the CNS genes or T7 polymerase were 
completed by two previous students; Yolanda van Wijck (van Wijck, Y. (2011) Construction 
of recombinant MVAs encoding CNS proteins and testing the MVA-T7 system with EBNA1-
specific T-cells. MSc internship unpublished thesis. Vrije Universiteit, Amsterdam, the 
Netherlands and the University of Birmingham, UK) and Marye Hogenboom (Hogenboom, M. 
Figure 6.1.1 Schematic of CNS protein expression by recombinant MVA viruses. MVA T7 virus was 
engineered to express T7 polymerase in trans in host ccells and does not express GFP or FLAG protein. MVA 
CNS viruses were engineered to only express CNS proteins in the presence of bacterial T7 polymerase. MVA 
CNS viruses were GFP positive, FLAG and invariant chain tagged, ensuring expression of CNS epitopes in 
both MHC class I and II presentation pathways.  
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(2012) Cloning of CNS proteins as cross-reactive targets for EBNA1-specific T-cells of MS 
patients. MSc internship unpublished thesis. Vrije Universiteit, Amsterdam, the Netherlands 
and the University of Birmingham, UK).  
Development of a system using recombinant MVA viruses expressing CNS proteins is a key 
tool in the investigation of autoreactive T-cell responses in MS, and we used this system to 
screen EBV-specific T-cell responses for cross-reactivity with neuronal antigens in vitro.  
 
Figure 6.1.2 Confirmation of CNS protein expression in MVA viruses. 293 cells were infected individually 
with MVA CNS or alongside MVA T7 virus. Membranes were probed with anti-FLAG monoclonal antibody 
and correct band size was used to confirm presence of CNS protein insert. A. Bands of correct sizes were 
detected in MVAs containing CNP (46kDa), MAG (67kDa), MOG (27kDa), PLP (25kDa), MBP (33kDa), 
MBP V8 (38kDa), CRYAB (28kDa), Claudin-11 (24kDa). MVA Contactin-2 was subsequently dropped from 
analysis due to difficulties in protein expression. B. MVA MOBP blot contained a band (24kDa) indicating 
MOBP protein expression. C. Bands of correct sizes were detected in MVAs pYWK (no band), EBNA1 
(63kDa) and TAL-H (38kDa). Cells without co-infection of MVA T7 did not produce bands. 
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6.2 Optimisation of MVA T-cell stimulation assay 
 
Optimisation of conditions in which best to screen for reactivity to proteins expressed in MVA-
infected cells is crucial in order to reliably investigate T-cell recognition of autoantigenic 
targets. Therefore, assay sensitivity is key to detecting any low-level cytokine production that 
may occur. In addition to this requirement, assay optimisation will both preserve target cell (B-
cell blast) and MVA stocks, allowing their use for all experiments throughout the project to 
maintain consistency. 
IFNg ELISA was performed using lab donor-derived CD4+ and CD8+ T-cell clones which 
recognise different epitopes from EBNA1. Autologous B-cell blasts were infected at differing 
multiplicity of infection (MOI) to determine the amount of virus needed to get good recognition 
of target cells by T-cells. Different effector to target ratios were used to determine the optimal 
number of targets needed to ensure that antigen recognition can occur in both CD4+ and CD8+ 
T-cells. 
As our assay will be used for screening polyclonal T-cell lines containing both CD4+ and CD8+ 
T-cells, we selected the conditions at which both T-cell subsets were able to recognise targets 
efficiently. The CD8+ T-cell clone preferentially recognised targets that were infected at a MOI 
of 1.0, with a target cell:T-cell ratio of 20:1 respectively. The CD4+ T-cell clone also 
recognised MVA EBNA1-infected B-cell blasts that were infected at a MOI of 1.0, but the 
most effective target cell:T-cell ratio was 50:1. It was therefore concluded that the optimal MOI 
for B-cell blast infection was 1.0 and that T-cells should be incubated with target cells at a ratio 
of  30:1, as this would provide the best conditions for both responding CD4+ and CD8+ T-cells 
in future assays (Figure 6.2.1).
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Figure 6.2.1 Optimisation of MOI and effector to target ratio for recognition of recombinant MVA-infected B-cell blasts by T-cells. Two EBNA1-
specific T-cell clones isolated from healthy lab donors were used to investigate optimal conditions for T-cell recognition assays using MVA EBNA1-
infected B-cell blasts. Clone 34 was CD8+ T-cell clone recognized the HLA-B35-restriced HPV epitope and the CD4+ T-cell clone 7 recognised the HLA-
DR51-restricted epitope SNP.  T-cell clones were screened by IFNg ELISA against autologous B-cell blasts infected with MVA EBNA1 at various A. MOIs 
and B. effector to target ratios. Points represent mean of data with error bars indicating standard deviation of results from triplicate wells. 
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6.3 Investigation of CNS antigen reactivity in EBV-stimulated T-cell lines 
 
We investigated whether T-cells specific for EBV antigens are able to cross-react with myelin 
proteins in our cohort using the MVA CNS system previously described in Chapter 6.1. 
EBV-specific polyclonal T-cell lines were generated from HC and MS donors by stimulating 
with irradiated, autologous LCL on days 0 and 7 and allowing T-cells to expand in culture. 
After 4 weeks, the polyclonal T-cell lines were screened for both reactivity with EBV antigens 
and to CNS proteins expressed via our MVA panel. Autologous B-cell blasts served as an EBV-
negative B-cell background in which to express CNS proteins and measure responses. B-cell 
blasts were infected separately with MVAs for 4 hours in low serum media, washed to remove 
unattached virus and added to polyclonal T-cell lines before incubating overnight. The 
following day cells were analysed by ICS. Example staining for CD4+ and CD8+ T-cell 
responses to CNS MVAs and LCL are shown in Figures 6.3.1 and 6.3.2 respectively.  
T-cell responses to the majority of proteins expressed in our MVA panel induced IFNg 
production, however there was also production of IL-2, IL-17 and GM-CSF in response to 
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6.4 EBV-specific T-cell lines display reactivity with CNS proteins  
 
6.4.1 CD4+ T-cell responses 
 
Stimulation of whole PBMC with wild type LCL induced both CD4+ and CD8+ T-cell 
responses expanded over several weeks in culture into polyclonal lines that were enriched for 
specificity to EBV antigens, allowing us to screen lines simultaneously for reactivity in both 
of these subsets. Overall frequency of CD4+ T-cells compared to CD8+ T-cells in the LCL-
stimulated polyclonal lines varied and this is probably a result of natural variation in responses 
between donors, attributed to factors including HLA type, age, gender and differences between 
the autologous LCLs established between individuals. Polyclonal T-cell lines expanded after 
stimulation with autologous wild type LCL were subsequently screened for reactivity to the 
original stimulus to investigate frequency of EBV-specific cells in cultures. 
Responding T-cells were defined as any cells positive for any combination of the four cytokines 
in our staining panel – IFNg, IL-2, IL-17 and GM-CSF – and percentages of CD4+ T-cells 
responding to each target in our stimulation panel are shown in Figure 6.4.1. MS patient CD4+ 
T-cell responses to CNS and EBV antigens from LCL-stimulated polyclonal lines (with 
background subtracted by Funky Cells) are shown in Figure 6.4.1B. Variation in size and 
frequency of responses to CNS antigens was observed in MS patient CD4+T-cells, with a 
pattern emerging showing particular proteins in the panel as frequent targets. Antigens eliciting 
the highest responses were MOG, PLP, MBP, TAL-H and MOBP, with ~4% of one MS 
patient’s CD4 T-cells in the EBV-specific polyclonal exhibiting cytokine production in 
response to MBP (Figure 6.4.1A).   
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Surprising results were obtained from HC when their EBV-stimulated polyclonal lines were 
subjected to the same experiment.  CD4+ T-cells from healthy donors showed a very similar 
pattern to that seen in MS patients, with MOG, PLP, MBP, TAL-H and MOBP shown as 
targets. However less variation between donors was seen between responses of HC than was 
observed in MS patients, suggesting that there is more heterogeneity in the patient group 
(Figure 6.4.1B).  
In addition to investigating CNS responses, we also screened LCL-stimulated polyclonal T-
cell lines for responses to the EBV proteins EBNA1 and EBNA3A. EBNA1 and EBNA3A 
peptides are naturally processed and presented on MHC molecules in LCLs, and as such 
responses to the proteins may have been generated in polyclonal lines. T-cell responses to 
EBNA1 have been described as cross-reactive in MS patients (Lunemann et al., 2008b), and 
we sought to correlate EBNA1 responses in polyclonal lines with those to CNS proteins 
expressed by our MVA panel. Reports of increased circulating EBNA1-specific CD4+ T-cells 
in MS patients also indicate that EBNA1 is a key target in MS patient responses to EBV 
(Lunemann et al., 2006, Lunemann et al., 2010). EBNA3A was selected due to interesting 
antibody response data from our project suggesting increased antibody responses towards 
EBNA3A. EBNA3A is also a common target of CD4+ and CD8+ T-cell responses in healthy 
people but one that has so far not been studied in the context of MS (Taylor et al., 2015).  
From these experiments, it is evident that stimulating whole PBMC with autologous LCL not 
only allows EBV antigen-specific T-cells to grow out, but also stimulates those with reactivity 
to CNS antigens. This suggests that EBV epitopes displayed by autologous MHC molecules 
share some structural homology with peptides processed and presented from CNS proteins, and 
may shed light on the mechanism by which the risk allele HLA-DR15 contributes towards 
disease development. Presence of circulating T-cells that are able to target both EBV and CNS 
antigens has strong implications for EBV’s role in the development of MS, however similar 
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responses in polyclonal lines from healthy donors suggests that presence of cross-reactive cells 
alone is not enough to cause disease, and these cells must be investigated further in order to 
understand their contribution towards MS pathogenesis. 
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Figure 6.4.1 CD4+ T-cell responses to CNS proteins in wild type LCL-stimulated polyclonal T-
cell lines. Whole PBMC from separate donors were stimulated with wild type LCL twice (day 0 and 
day 7) and responding T-cells were expanded over 4 weeks. Polyclonal lines generated were then 
stimulated with autologous, MVA-infected B-cell blasts expressing CNS and EBV proteins 
individually and subjected to ICS. Responding CD4+ T-cells were defined as producing any 
combination cytokines. Background staining from MVA empty vector stimulations was subtracted 
from CNS and EBV protein stimulations, background staining in unstimulated T-cell samples was 
subtracted from LCL stimulations. A. HC polyclonal T-cell lines (n=6) B. MS patient polyclonal T-
cell lines (n=7). 
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6.4.2 CD8+ T-cell responses 
 
From the same polyclonal T-cell lines generated by stimulating with autologous wild type LCL, 
we were also able to investigate frequency and cytokine production of CD8+ T-cells in 
response to CNS and EBV proteins with results shown in Figure 6.4.2.  
CD8+ T-cell responses to CNS proteins from wild type LCL-stimulated polyclonal T-cell lines 
showed a similar pattern to those of CD4+ T-cells. After subtraction of background responses, 
MS patient CD8+ T-cell responses to CNS proteins were overall higher than those observed in 
CD4+ T-cells, with the same antigens as major targets of responses: MOG, PLP, MBP, TAL-
H and MOBP (Figure 6.4.2). Some of the highest responses observed were to MOBP, with 
~8% of one MS donor’s CD8+ T-cells in the polyclonal T-cell line showing reactivity to 
MOBP.  
A similar picture was seen again in the CD8+ T-cells from healthy donors, and responses to 
CNS antigens were at comparable levels with those from MS patients (Figure 6.4.2). CD8+ T-
cell responses to CNS proteins in both HC and MS patients were proportionally higher than 
those observed to CD4+ T-cells, and this pattern of responses was consistent between the 
groups (Figure 6.4.1 and 6.4.2). These data suggest that LCL stimulation not only activates 
CD4+ T-cell responses but also CD8+ T-cells to potentially higher levels, indicating that there 
may also be cross-reactivity in the CD8+ T-cell compartment between EBV and CNS antigens.  
This comparison between groups was carried out looking at total responding cells, taking into 
account all cells producing any one of the four cytokines in our flow cytometry staining panel: 
IFNg, IL-2, IL-17 and GM-CSF. It is clear from these graphs that there is no overall difference 
in frequency of “cross-reactive” T-cells between HC and MS patients, and we therefore sought 
to investigate function and phenotype of responses, investigating if there is a difference in 
cytokine profile of responding CD4+ and CD8+ T-cells between groups.  
 186 
Figure 6.4.2 CD8+ T-cell responses to CNS proteins in wild type LCL-stimulated polyclonal T-
cell lines. Whole PBMC from separate donors were stimulated with wild type LCL twice (day 0 and 
day 7) and responding T-cells were expanded over 4 weeks. Polyclonal lines generated were then 
stimulated with autologous, MVA-infected B-cell blasts expressing CNS and EBV proteins individually 
and subjected to ICS. Responding CD8+ T-cells were defined as producing any combination cytokines. 
Background staining from MVA empty vector stimulations was subtracted from CNS and EBV protein 
stimulations, background staining in unstimulated T-cell samples was subtracted from LCL 
stimulations. A. HC polyclonal T-cell lines (n=6) B. MS patient polyclonal T-cell lines (n=7). 
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6.5 Polyfunctionality and cytokine profile of cross-reactive cells 
 
6.5.1 Polyfunctionality index 
 
Similar frequencies of CNS protein responses in wild type LCL-stimulated polyclonal T-cell 
lines from HC and MS patients led us to further investigate function of responding CD4+ and 
CD8+ T-cells. This was achieved using Boolean combination gating as previously described 
in Chapter 5 for analysis of ex vivo T-cell responses.  
As previously described in Chapter 5.3.1, polyfunctionality can be measured in Funky Cells 
software to give an arbitrary score calculated by an algorithm, termed polyfunctionality index 
(PI). Comparing these values enables direct comparison of the number of functions responding 
cells have to different targets, and these can also be used to compare CD4+ and CD8+ T-cells 
to each other.  
Figure 6.5.1A shows the PI of CD4+ T-cells in wild type LCL-stimulated polyclonal T-cell 
lines after stimulation with autologous B-cell blasts infected with the MVA CNS panel. The 
majority of CNS protein CD4+ T-cell responses were similar in polyfunctionality between HC 
and MS patients, with much variation in degree of function between CNS targets (Figure 
6.5.1A). CD4+ responses from healthy donor T-cell lines to claudin had significantly higher PI 
values than those of MS patients (HC:MS p=0.0082, Mann-Whitney test), an interesting 
finding as claudin was not a major CNS target for CD4+ T-cell responses described in Figure 
6.4.1, indicating a qualitative difference in cells responding to this antigen. 
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Figure 6.5.1 Polyfunctionality of CD4+ and CD8+ T-cells responding to CNS antigens from wild 
type LCL-stimulated polyclonal T-cell lines. CNS responses observed in wild type LCL-stimulated 
polyclonal T-cell lines were analysed for multiple cytokine production (IFNγ, IL-2, IL-17 and GM-CSF) 
using Funky Cells software which was used to calculate polyfunctionality index (PI) of responding 
CD4+ (A.) and CD8+ (B.) T-cells. Black lines represent median of data set. Colour of dots represent 
cohort group: blue=HC, red=MS. Statistics analysis performed using the Mann-Whitney test (ns p>0.05, 
* p>0.05, ** p>0.005). 
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CD8+ T-cell responses from wild type LCL-stimulated polyclonal lines showed a similar 
pattern of limited variation between groups, however PI value for CD8+ responses to claudin 
were also significantly higher in HC than MS patients (HC:MS p=0.0023, Mann-Whitney test) 
(Figure 6.5.1B).  PI values of CD8+ T-cells responding to CNP were also significantly higher 
than in MS patients (HC:MS p=0.0452, Mann-Whitney test) (Figure 6.5.1B), a trend that was 
also seen in healthy control CNP-specific CD4+ T-cell responses but did not reach significance 
(Figure 6.5.1A).  
The target MAG showed great variation between donors, however due to difficulties with virus 
production only 5 donors were tested (two MS and three HC), meaning that the Mann-Whitney 
test could not be applied as a minimum of three data points per group are needed to apply this 
particular statistical test. Further studies of responses to this target may reveal significant 
differences between groups but this was not possible for our project. 
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6.5.2 Cytokine profile of cross-reactive CD4+ T-cells 
 
ICS of wild type LCL-stimulated polyclonal T-cell lines allowed in-depth analysis of the 
cytokine profile of cells responding to CNS antigens, and their exact combination of IFNg, IL-
2, IL-17 and GM-CSF production was analysed as previously described in Chapter 5.3 using 
both Funky Cells and SPICE analysis software.  
MVA empty vector control stimulations were used for each donor to remove background 
staining from MVA CNS stimulations, giving a clear picture of effector molecules produced 
by CD4+ and CD8+ T-cells in response to each CNS protein without background staining.  
Levels of staining from unstimulated T-cell controls were applied in the same way to wild type 
and BZLF1 KO LCL stimulations to remove background. 
Patterns of cytokine production for responding CD4+ T-cells in each of sixteen combination 
gates are shown for all targets in our stimulation panel in Figures 6.5.2 to 6.5.17, with all figures 
showing the same format: the mean values of combination gates are shown in A, with 
individual data points and median values shown by black bars in B. The non-parametric 
Wilcoxon Signed Rank Test was applied to statistically analyse cytokine production between 
groups with statistics shown in table format in C. A heat map of responses in each combination 
gate is shown in D of figures. Cytokine notation from table 5.1 is used to denote production of 
IFNg, IL-2, IL-17 and GM-CSF (ie. ++-- would mean IFNg+ IL-2+ IL-17- GM-CSF-). 
Figure 6.5.2 shows the cytokines produced by polyclonal CD4+ T-cells after overnight 
stimulation with the same autologous wild type LCL used initially when setting up the lines. 
Cytokine production between responding cells from HC and MS patients was similar and did 
not show any significant differences between groups (Figure 6.5.2). Polyclonal line stimulation 
with autologous BZLF1 KO LCL showed an increased proportion of cells in healthy donors 
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producing IFNg, but levels did not reach significance after applying the Wilcoxon Signed Rank 
Test (Figure 6.5.3).  
LCL-stimulated polyclonal T-cell lines were also screened for reactivity to EBNA1 and 
EBNA3A to investigate whether any qualitative differences in cytokine production could be 
seen in responding cells between groups. MVA EBNA1 and EBNA3A-infected autologous B-
cell blasts were used to stimulate wild type LCL-specific polyclonal T-cell lines separately and 
cytokine profile of responding cells analysed. CD4+ T-cell responses to EBNA1 were similar 
between groups but a higher proportion of responding cells from MS patients produced either 
GM-CSF only or IFNg only. Responding cells from HC showed an increase in the subset 
producing IL-17 only, and this mirrors findings from ex vivo T-cell responses in Chapter 5.3 
showing an increased production of IL-17 in response to EBV antigens (Figure 6.5.4). 
However, these differences did not reach significance and more data points may be needed to 
see if this effect is real.  
CD4+ T-cell responses to EBNA3A were distinct between groups, with MS patients showing 
a high proportion of cells producing IFNg only in response to the antigen compared with none 
observed in those from HC, an effect that did not quite reach significance (HC:MS +--- 
p=0.066) (Figure 6.5.5). Also notable was the increased proportion of cells from HC producing 
GM-CSF only in response to the antigen, but this also did not reach significance. 
Figure 6.5.6 shows cytokine profile of CD4+ T-cells responding to stimulation with MVA 
empty vector-infected autologous B-cell blasts with no significant differences observed 
between groups.   
Overall response data did not show CNP to be an important, cross-reactive CD4+ target in our 
experiments, with only a few donors showing a small response to the protein after stimulation 
with wild type LCL (Figure 6.4.1).  However, upon looking at the mean percentage of CD4+ 
T-cell responses to CNP in each combination gate, we found them to be significantly different 
 192 
between groups. Healthy controls showed a response that was predominantly producing IL-17 
only, with other responding cells co-expressing IFNg, IL-2 and GM-CSF in various 
combinations (Figure 6.5.7). In contrast MS patients showed a CD4+ T-cell response that was 
mostly producing one cytokine only, with most cells singularly expressing IL-2, IFNg or GM-
CSF (Figure 6.5.7). Using the median percentage of responding CD4+ T-cells in each cytokine 
group skews data less and removes this effect, and more donors need to be analysed to 
determine if this effect is true; results did not reach significance between groups after statistical 
analysis using the Wilcoxon Signed Rank test (Figure 6.5.7C).  
Cytokine production of responding CD4+ T-cells between groups in response to MOG was 
very similar, with the majority of cells fitting into the IFNg only category (Figure 6.5.8). MOG 
was one of the antigens which induced the highest overall responses after wild type LCL 
stimulation, and interestingly the quality of response was very similar in level and function 
between HC and MS.  
PLP is an antigen that induced modest responses from LCL-stimulated polyclonal T-cell lines 
with quite a lot of variation (7.2.3). The cytokine production between groups did vary, with 
more CD4+ T-cells producing IFNg only in MS patients compared to HC, a level that did not 
reach significance (Figure 7.3.9). Healthy donors showed an increase in a subset of responding 
CD4+ T-cells co-producing IL-2, IL-17 and GM-CSF, an increase that reached statistical 
significance (Figure 7.3.9C). 
MBP CD4+ T-cell responses been investigated extensively in the context of MS, and this 
protein was a frequent response in our cultured LCL-specific polyclonal T-cell lines (Figure 
6.5.3). Cytokine production in responding cells showed a marked decrease in variation 
compared to other CNS responses, with the majority of MBP-reactive CD4+ T-cells from HC 
and MS patients producing IFNg only (Figure 6.5.10).   
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MBP’s splice variant MBP V8 is a shorter molecule and CD4+ T-cell responses were overall 
lower to this protein than to MBP, with analysis of cytokine production also showing a different 
pattern.  MS patients showed an increase in CD4+ T-cells producing IFNg only after 
stimulation with MBP V8 compared to HC, but this effect did not quite reach significance when 
analysed using the Wilcoxon Signed Rank test (HC:MS +--- p=0.086) (Figure 6.5.11C).  HC 
showed a significant increase in cells producing IL-17 only in response to MBP V8 compared 
to MS patients (HC:MS --+- p=0.045) (Figure 6.5.11C). 
CD4+ T-cell responses from polyclonal lines showed a great variation in cytokine production 
in response to claudin, a result reflected in analysis of polyfunctionality index between groups 
(Figure 6.5.1A).  Most notable is the increase in proportion of CD4+ T-cells from MS patients 
producing IFNg only, with no cells in this gate from healthy controls (HC:MS +--- p=0.032) 
(Figure 6.5.12). 
CRYAB induced CD4+ T-cell responses with great variation in quality of response, with 
subsets producing IL-2 or GM-CSF only showing an increase in MS patients compared to 
healthy controls. (Figure 6.5.13).  MS donors also showed an increase in proportion of 
responding cells co-producing IL-2 and GM-CSF, but this did not reach significance (HC:MS 
-+-+ p=0.074) (Figure 6.5.13).  
TAL-H CD4+ T-cell responses in polyclonal T-cell lines were again a modest target for overall 
responses in healthy and MS donors, however less variation was seen in cytokine production 
by CD4+ T-cell responses to the protein than to other proteins.  An increase in cells singularly 
producing IFNg amongst HC did not reach significance (HC:MS +--- p=0.116) (Figure 6.5.14).  
CD4+ T-cells from polyclonal lines responding to the major CNS target in our study MOBP 
showed similar cytokine production patterns between groups, with the majority producing IFNg 
only in response to the antigen (Figure 6.5.15). 
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Fewer wild type LCL-stimulated polyclonal T-cell lines were screened against MVA MAG 
due to difficulties halfway through the project in virus stock production, meaning that only 
three healthy controls and two MS donors were screened against the protein. An increased 
proportion of cells producing IFNg only in response to MAG was observed in HC, but this did 
not reach significance (HC:MS +--- p=0.083) (Figure 6.5.16). MS patient responding cells 
showed a broader range of cytokines produced in response to MAG proteins, but reduced 
number of data points makes drawing conclusions from data difficult, and more donors need 
to be screened to determine if this effect is real (Figure 6.5.16).  
Pie charts showing the proportion of CD4+ T-cells in each combination gate can be viewed for 
all targets in Figure 6.5.17, allowing visual comparison of the contribution of each cellular 
phenotype to responses between groups. Using this visual analysis allows CNS and EBV 
antigens to be divided into roughly two groups: those which induce a response that 
predominantly produces IFNg only (turquoise segments) and another that induces a response 
which is much more polymorphic (Figure 6.5.17). This observation is interesting as the targets 
which make up the first group – MOG, MBP, MOBP and TAL-H – are the antigens that were 
able to stimulate the highest proportion of cells from wild type LCL-stimulated polyclonal cell 
lines. 
A permutation test is used to determine the amount of variation between groups by random 
sampling and this analysis was applied to our data set using SPICE software, allowing us to 
determine if there were significant differences between HC and MS donor groups in 
distribution of cytokine responses. No differences were seen in CD4+ T-cell responses to wild 
type and BZLF1 KO LCLs between groups, and in addition to this EBNA1 responses were not 
significantly different between groups in their cytokine expression (Figure 6.5.17).   
EBNA3A was added to our screening panel after early observations from our cohort indicated 
that MS donors more frequently had an antibody response to the protein than HC (Figure 4.2.3). 
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Analysis of EBNA3A-specific CD4+ T-cell responses in wild type LCL-stimulated polyclonal 
lines indicate that cytokine production between healthy controls and MS patients is very 
different. In HC ~50% of the EBNA3A-specific cells are in the subset producing GM-CSF 
only, however MS patient responses are predominantly made up from cells producing IFNg, 
with permutation tests indicating that the two groups’ responses are significantly different 
(HC:MS p=0.0296) (Figure 6.5.17).  
CD4+ T-cell cytokine responses to CNS proteins in our panel varied greatly between targets, 
with the majority not showing any significant differences between HC and MS patients (Figure 
6.5.17).  However, several antigens induced a CD4+ T-cell response that was markedly 
different between groups, one of these being MBP V8. Responses to MBP V8 were highly 
polymorphic in their production of cytokines with MS patients producing a response that was 
mainly IFNg positive, in contrast with HC CD4+ T-cells which mainly generated an IL-17 
response; this difference did not reach statistical significance (HC:MS p=0.0587) (Figure 
6.5.17).  
Differences in the production of cytokines between HC and MS groups were statistically 
significant for the CNS protein CNP, with MS patients displaying a CD4+ T-cell repertoire 
skewed towards single cytokine production of IFNg, IL-2 and GM-CSF; HC donor responses 
were more polymorphic and predominantly produced IL-17 alongside other cytokines (HC:MS 
p=0.474) (Figure 6.5.17).  
From these experiments, cytokine production by “cross-reactive” CD4+ T-cells in response to 
EBV and CNS antigens has been found to be very different from that of antigens which did not 
elicit a high response in LCL-stimulated polyclonal lines. Cytokines produced by CD4+ T-
cells reflect the effector function which has implications for their pathogenic potential in vivo. 
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Figure 6.5.2 Cytokine profile of CD4+ T-cells responding to wild type LCL from wild type LCL-specific 
polyclonal lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with autologous wild type LCL and 
subjected to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.3 Cytokine profile of CD4+ T-cells responding to BZLF1 KO LCL from wild type LCL-specific 
polyclonal lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with autologous BZLF1 KO LCL 
and subjected to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of 
four cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.4 Cytokine profile of CD4+ T-cells responding to EBNA1 from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA EBNA1-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 















































Figure 6.5.5 Cytokine profile of CD4+ T-cells responding to EBNA3A from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA EBNA3A-infected B cell blasts and 
subjected to ICS (HC n=5, MS n=4). Responding CD4+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.6 Cytokine profile of CD4+ T-cells responding to empty vector from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA empty vector-infected B cell blasts 
and subjected to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of 
four cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 
















































Figure 6.5.7 Cytokine profile of CD4+ T-cells responding to CNP from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA CNP-infected B cell blasts and subjected 
to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four cytokines in 
our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each combination gate 
with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot 
showing percentage of responding cells for each donor in combination gates. Black bars represent median of data set. 
C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in heatmap form. 
Combination gate data was processed using Funky Cells software and graphically displayed using the program SPICE 















































Figure 6.5.8 Cytokine profile of CD4+ T-cells responding to MOG from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA MOG-infected B cell blasts and subjected 
to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four cytokines in 
our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each combination gate 
with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot 
showing percentage of responding cells for each donor in combination gates. Black bars represent median of data set. 
C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in heatmap form. 
Combination gate data was processed using Funky Cells software and graphically displayed using the program SPICE 















































Figure 6.5.9 Cytokine profile of CD4+ T-cells responding to PLP from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA PLP-infected B cell blasts and subjected 
to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four cytokines in 
our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each combination gate 
with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot 
showing percentage of responding cells for each donor in combination gates. Black bars represent median of data set. 
C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in heatmap form. 
Combination gate data was processed using Funky Cells software and graphically displayed using the program SPICE 
















































Figure 6.5.10 Cytokine profile of CD4+ T-cells responding to MBP from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA MBP-infected B cell blasts and subjected 
to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four cytokines 
in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each combination gate 
with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot 
showing percentage of responding cells for each donor in combination gates. Black bars represent median of data set. 
C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in heatmap form. 
Combination gate data was processed using Funky Cells software and graphically displayed using the program SPICE 















































Figure 6.5.11 Cytokine profile of CD4+ T-cells responding to MBP V8 from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA MBP V8-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 















































Figure 6.5.12 Cytokine profile of CD4+ T-cells responding to claudin from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA claudin-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 















































Figure 6.5.13 Cytokine profile of CD4+ T-cells responding to CRYAB from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA CRYAB-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 















































Figure 6.5.14 Cytokine profile of CD4+ T-cells responding to TAL-H from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA TAL-H-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 















































Figure 6.5.15 Cytokine profile of CD4+ T-cells responding to MOBP from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA MOBP-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD4+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 















































Figure 6.5.16 Cytokine profile of CD4+ T-cells responding to MAG from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA MAG-infected B cell blasts and subjected 
to ICS (HC n=3, MS n=2). Responding CD4+ T-cells were defined as positive for any combination of four cytokines in 
our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each combination gate 
with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot 
showing percentage of responding cells for each donor in combination gates. Black bars represent median of data set. 
C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD4+ T-cells shown in heatmap form. 
Combination gate data was processed using Funky Cells software and graphically displayed using the program SPICE 














































Figure 6.5.17 Different cytokine profiles of CNS-stimulated CD4+ T cells from wild type LCL-specific polyclonal 
T cell lines. Wild type LCL-specific polyclonal T-cell lines were stimulated with autologous B-cell blasts infected with 
MVA viruses containing the CNS and EBV proteins individually. Responding CD4+ T-cells were defined as positive 
for any combination of cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. Pie charts show median values of all 
donors in each group. Groups were compared using the permutation test (ns p>0.05, * p<0.05).  
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6.5.3 Cytokine profile of cross-reactive CD8+ T-cells 
 
CD8+ T-cell responses to EBV and CNS antigens in wild type LCL-stimulated polyclonal T-
cell lines were also investigated alongside those of CD4+ T-cells to determine if any there was 
any difference in cytokine production between groups. As for CD4+ T-cell analysis, Funky 
Cells and SPICE software was used to remove background and perform statistical analysis of 
CD8+ T-cells respectively, and results are shown in Figures 6.5.18-6.5.32.  
Wild type LCL-stimulated polyclonal T-cell lines were first analysed for their cytokine 
production in response to the original stimulus – wild type LCL – and BZLF1 KO LCL.     Both 
cell lines induced responses that predominantly produced IFNg only, and no differences were 
seen in the CD8+ T-cell cytokine production in response to wild type or BZLF1 KO LCL 
between donor groups (Figures 6.5.18 and 6.5.19). No differences in cytokine production from 
CD8+ T-cells to the empty vector control were observed between groups (Figure 6.5.22). 
CD8+ T-cell responses to EBNA1 from wild type LCL-stimulated polyclonal lines showed 
similar cytokine production between HC and MS donors with a slightly higher proportion of 
MS donor cells producing IL-2 only, however this did not reach significance using the 
Wilcoxon Signed Rank Test (HC:MS -+-- p=0.109) (Figure 6.5.20).  
EBNA3A, as previously mentioned, was introduced to the screening panel after interesting 
preliminary data from our project suggested that EBNA3A-specific antibody responses were 
more frequent in MS patients than healthy controls (Figure 4.2.3). Analysis of CD4+ T-cell 
responses from wild type LCL-stimulated polyclonal T-cell lines showed that cytokine 
production was very different between HC and MS patients (Figure 6.5.5), and investigation 
of CD8+ responses to the protein were also different between groups. EBNA3A induced a 
heterogeneous CD8+ T-cell response in MS patients characterised by IFNg production 
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alongside IL-2 and GM-CSF, a contrast to HC who showed a broader and marginally less 
polyfunctional CD8+ T-cell response (Figure 6.5.21). 
CD8+ T-cell responses to CNP in LCL-stimulated polyclonal T-cell lines showed variation 
between MS patients and HC, with MS patient responses being dominated by cells which 
singularly produced IFNg, IL-2 or GM-CSF (Figure 6.5.23). HC generated a response to CNP 
which was characterised by IL-17 production with a significantly higher proportion of cells co-
expressing IL-2 and IL-17 making up the responding repertoire in HC compared to MS subjects 
(HC:MS -++- p=0.045) (Figure 6.5.23). However as previously mentioned CNP responses 
were very small and therefore fewer events may have skewed cytokine production in each 
group. 
MOG induces CD8+ T-cell responses in healthy and MS donors with comparatively little 
variation in cytokine production, with the majority of cells from both groups producing IFNg 
(Figure 6.5.24). A small proportion of CD8+ T-cells from MS donors also express IL-17 in 
response to MOG antigen but this did not reach significance (Figure 6.5.24). 
Cytokine production in PLP-specific CD8+ T-cells showed little variation between groups, 
with most cells singularly expressing IFNg after stimulation (Figure 6.5.25). Responses to MBP 
were also similar between groups with CD8+ T-cells mostly producing IFNg in response to the 
antigen (Figure 6.5.26). 
The isoform MBP-V8 showed a different cytokine profile in responding CD8+ T-cells than 
MBP, with a broader range of cytokine combinations produced. HC showed a higher proportion 
of cells that produced IL-17 only in response to MBP-V8 but did not quite reach significance 
(HC:MS --+- p=0.074) (Figure 6.5.27). HC also had higher proportions of MBP-V8-specific 
CD8+ T-cells co-expressing IFNg and IL-17 (HC:MS +-+- p=0.012) (Figure 6.5.27).  
CD8+ T-cell responses to claudin from LCL-stimulated polyclonal T-cell lines were 
heterogeneous between donor groups, MS patients showing a higher proportion of responding 
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cells producing IFNg only, and healthy donors showing higher proportions of cells co-
producing IFNg and IL-2 in response to the antigen (Figure 7.3.28). Despite these differences 
the results did not reach statistical significance and more donors would need to be screened to 
determine if the effect is true. 
CD8+ T-cell responses to CRYAB protein did not overall show significant differences in 
cytokine production after stimulation with this target, however a broad range of phenotypes is 
displayed by responding cells, with MS patients having higher proportions overall of cells 
singularly producing IL-2 and GM-CSF (Figure 7.3.29).  
TAL-H, as previously described, was one of the proteins which induced the highest overall 
response in LCL-stimulated polyclonal T-cell lines, and further analysis of cytokine production 
shows that CD8+ T-cell responses to the antigen from HC mainly produce IFNg. However, for 
MS patients TAL-H specific cells fit into two main groups of those producing IFNg only or IL-
2 only (Figure 7.3.30), but these differences in cytokine secretion did not reach significance.  
MOBP was also one of the antigens with the highest overall response in polyclonal T-cell lines, 
with up to ~5% of certain polyclonal T-cell lines responding to the antigen. As with TAL-H, 
the majority of responding CD8+ T-cells from both patient groups produced IFNg. However, 
a small subset of IFNg+IL-17+ cells were significantly higher in HC than MS patients who had 
no responding cells that fit into this subset (HC:MS +-+- p=0.022) (Figure 7.3.31).  
Due to previously mentioned problems with the MVA MAG virus stock, only a few donors 
were screened against the protein allowing very few conclusions to be drawn from the data. 
Over 80% MAG-specific CD8+ T-cells from HC produced IFNg only. MS patient responses 
were much more spread, with CD8+ T-cells mostly producing a mix of IFNg and IL-2 
following MAG stimulation (Figure 7.3.32).  
 215 
 
Figure 6.5.18 Cytokine profile of CD8+ T-cells responding to wild type LCL from wild type LCL-specific 
polyclonal lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with autologous wild type LCL and 
subjected to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.19 Cytokine profile of CD8+ T-cells responding to BZLF1 KO LCL from wild type LCL-specific 
polyclonal lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with autologous BZLF1 KO LCL 
and subjected to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of 
four cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.20 Cytokine profile of CD8+ T-cells responding to EBNA1 from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA EBNA1-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.21 Cytokine profile of CD8+ T-cells responding to EBNA3A from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA EBNA3A-infected B cell blasts and 
subjected to ICS (HC n=5, MS n=4). Responding CD8+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.22 Cytokine profile of CD8+ T-cells responding to empty vector from wild type LCL-specific 
polyclonal lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA empty vector-infected 
B cell blasts and subjected to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any 
combination of four cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding 
cells in each combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon 
Signed Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars 
represent median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells 
shown in heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed 














































Figure 6.5.23 Cytokine profile of CD8+ T-cells responding to CNP from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA CNP-infected B cell blasts and subjected 
to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four cytokines in 
our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each combination gate 
with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot 
showing percentage of responding cells for each donor in combination gates. Black bars represent median of data set. 
C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in heatmap form. 
Combination gate data was processed using Funky Cells software and graphically displayed using the program SPICE 














































Figure 6.5.24 Cytokine profile of CD8+ T-cells responding to MOG from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA MOG-infected B cell blasts and subjected 
to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four cytokines in 
our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each combination gate 
with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot 
showing percentage of responding cells for each donor in combination gates. Black bars represent median of data set. 
C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in heatmap form. 
Combination gate data was processed using Funky Cells software and graphically displayed using the program SPICE 














































Figure 6.5.25 Cytokine profile of CD8+ T-cells responding to PLP from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA PLP-infected B cell blasts and subjected 
to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four cytokines in 
our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each combination gate 
with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot 
showing percentage of responding cells for each donor in combination gates. Black bars represent median of data set. 
C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in heatmap form. 
Combination gate data was processed using Funky Cells software and graphically displayed using the program SPICE 














































Figure 6.5.26 Cytokine profile of CD8+ T-cells responding to MBP from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA MBP-infected B cell blasts and subjected 
to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four cytokines in 
our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each combination gate 
with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot 
showing percentage of responding cells for each donor in combination gates. Black bars represent median of data set. 
C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in heatmap form. 
Combination gate data was processed using Funky Cells software and graphically displayed using the program SPICE 














































Figure 6.5.27 Cytokine profile of CD8+ T-cells responding to MBP V8 from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA MBP V8-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.28 Cytokine profile of CD8+ T-cells responding to claudin from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA claudin-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.29 Cytokine profile of CD8+ T-cells responding to CRYAB from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA CRYAB-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.30 Cytokine profile of CD8+ T-cells responding to TAL-H from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA TAL-H-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.31 Cytokine profile of CD8+ T-cells responding to MOBP from wild type LCL-specific polyclonal 
lines. Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA MOBP-infected B cell blasts and 
subjected to ICS (HC n=6, MS n=7). Responding CD8+ T-cells were defined as positive for any combination of four 
cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each 
combination gate with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed 
Rank. B. Scatter plot showing percentage of responding cells for each donor in combination gates. Black bars represent 
median of data set. C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in 
heatmap form. Combination gate data was processed using Funky Cells software and graphically displayed using the 














































Figure 6.5.32 Cytokine profile of CD8+ T-cells responding to MAG from wild type LCL-specific polyclonal lines. 
Wild type LCL-stimulated polyclonal T-cell lines were stimulated with MVA MAG-infected B cell blasts and subjected 
to ICS (HC n=3, MS n=2). Responding CD8+ T-cells were defined as positive for any combination of four cytokines in 
our panel: IFNγ, IL-2, IL-17 and GM-CSF. A. Graphical representation of responding cells in each combination gate 
with bars representing the mean of data set. Statistics were calculated using the Wilcoxon Signed Rank. B. Scatter plot 
showing percentage of responding cells for each donor in combination gates. Black bars represent median of data set. 
C. Table shows results of Wilcoxon rank test. D. Percentage of responding CD8+ T-cells shown in heatmap form. 
Combination gate data was processed using Funky Cells software and graphically displayed using the program SPICE 














































As previously described for CD4+ T-cell response analysis, pie charts were used to visualise 
the contribution of each cytokine production combination gate to overall CD8+ T-cell 
responses to antigens. Pie charts for all CD8+ targets are shown in Figure 6.5.33. Permutation 
tests were performed to analyse differences between distribution of cytokine production 
between groups, an advantage of this is that it allows analysis of whole cytokine profile of 
responding cells between groups and not just individual subsets. 
Cytokine production in response to stimulation with wild type LCL and BZLF1 KO LCL was 
similar between HC and MS patient groups, with no significant differences apparent after 
permutation tests were performed (Figure 6.5.33). 
EBNA1 CD8+ T-cell responses from LCL-stimulated polyclonal T-cell lines were similar 
between groups with no major differences in cytokine production after permutation tests were 
applied, however EBNA3A responses were very different in subset usage with most of the 
responding cells from both groups producing multiple cytokines (Figure 6.5.33).  
CNS antigens that induced the highest responses in wild type LCL-stimulated polyclonal T-
cell lines (Figure 6.4.2) tended to produce a predominantly IFNg positive response: MBP, 
MOBP and MOG, with TAL-H mainly inducing an IFNg-mediated response in HC but a 
broader response in MS patients (Figure 6.5.33). A larger proportion of TAL-H CD8+ 
responses in MS patients produced IL-2 only but permutation tests showed overall cytokine 
profiles to not be significantly different to those of HC (HC:MS p=0.0742) (Figure 6.5.33).  
MAG antigen in HC also produced a mainly IFNg-driven response, and MS patients produced 
a more polymorphic response with almost 25% of the response positive for all four cytokines 
(Figure 6.5.33). However, as previously mentioned, no conclusions can be drawn from this 
observation due to the low patient numbers studied in this response; more donors would need 
to be tested to see if this effect is real. 
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CNS antigens that produce more diverse cytokine responses were MBP V8, CRYAB, PLP, 
claudin and CNP and are generally small responses, however no significant variations were 
seen in the overall cytokine profile of responding CD8+ T-cells between patient groups. CD8+ 
T-cell responses to CNP differed the most between HC and MS patients with a trend towards 
higher polyfunctionality in those from HC, however difference in combination gate usage did 
not reach significance between groups (HC:MS p=0.0666) (Figure 6.5.33).  
No permutation tests performed on pie charts representing CD8+ T-cell responses from wild 
type LCL-stimulated polyclonal lines revealed significant differences between healthy and MS 
donors, unlike for CD4+ T-cell responses which exhibited a few key differences in the 
repertoire of cytokine production following CNS and EBV antigen stimulation (Figure 6.5.18 
and 6.5.33).  No differences were observed in cytokine profile of unstimulated T-cells between 
groups prior to analysis in Funky Cells (data not shown). 
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Figure 6.5.33 Different cytokine profiles of CNS-stimulated CD8+ T-cells from wild type LCL-specific polyclonal 
T cell lines. Wild type LCL-specific polyclonal T-cell lines were stimulated with autologous B-cell blasts infected with 
MVA viruses containing the CNS and EBV proteins individually. Responding CD8+ T-cells were defined as positive 
for any combination of cytokines in our panel: IFNγ, IL-2, IL-17 and GM-CSF. Pie charts show median values of all 
donors in each group. Groups were compared using the permutation test (ns p>0.05, * p<0.05).  
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6.6 Single cell isolation of cross-reactive T-cells 
 
High levels of CNS-reactive T-cells in EBV-stimulated polyclonal lines suggests that there is 
structural mimicry between neuronal and viral antigens, however to formally show this we 
sought to isolate single cells with dual specificity. 
To isolate single T-cells with specificity for both EBV and CNS antigens we explored several 
methods, the first of which was limiting dilution. T-cells which had been expanded in culture 
for 2 weeks following autologous wild type LCL stimulation were stimulated again on the day 
of T-cell cloning with LCL and then diluted in T-cell medium with feeder cells before being 
seeded out. Plates were incubated for two weeks to enable expansion of activated clones, which 
were subsequently screened for specificity using IFNg ELISA against LCL, or individual EBV 
and CNS antigens. The aim was to isolate many T-cell clones with specificity for EBV antigens 
and which could then be screened against CNS antigens using our MVA panel, and this 
experiment was performed five times using different donors. 
We found that, whilst many of the LCL-stimulated clones reacted to EBV antigens, none of 
the T-cell clones screened exhibited reactivity to neuronal proteins in our MVA panel. An 
overview of limiting dilution cloning experiments is summarised in Table 6.1. Due to the large 
number of non-specific and only EBV-specific T-cell clones this method produced, we 
subsequently used a different approach, utilising CNS antigen stimulation on the day of cloning 
to selectively stimulate T-cell clones with dual reactivity.  
We selectively expanded T-cells with reactivity to neuronal proteins and enriched populations 
using IFNg capture. We selected four proteins in our CNS panel with the highest frequency of 
responding cells in our previous stimulation assays as a focus of efforts to isolate cross-reactive 
T-cells: MOG, PLP, MBP and MOBP.  
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IFNg capture uses magnetic beads to isolate cells producing the cytokine, and was used to 
selectively enrich responding cells following CNS antigen stimulation and increase the yield 
of clones that show specificity for EBV and CNS antigens. However, this method requires 
several steps in which cells are subjected to low temperatures and removal of culture medium 
over a period of six hours, meaning that many of them die during the process or shortly 
afterwards. Two experiments were performed using this technique and the results are shown in 
table 6.1. Despite the large number of microcultures that were established, very few clones 
expanded after incubation. This result led us to employ a third technique that did not expose T-
cells to harsh conditions for such long periods of time.  
In this third approach, we employed an assay which prevented cleavage of an activation marker 
from the cell surface using an inhibitor. The TNFa processing inhibitor-0 (TAPI-0) acts on a 
Table 6.1 Table of yields from T-cell cloning using different methods. Three methods were used for 
cloning of cross-reactive T-cells from polyclonal T-cell lines: limiting dilution, IFNγ capture and TNFα 
capture. Number of expanded clones varied between donors and cloning method used to isolate cells. EBV 
reactivity was defined as cytokine production in response to any EBV antigen, but most responded either to 
the wild type or to the BZLF1 KO LCL. Stimulus with wild type LCL refers to the autologous LCL made 
from each individual donor. CNS antigen stimulation was performed using autologous B-cell blasts from each 
donor infected with the respective recombinant MVA viruses.  
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metalloproteinase on the surface of T-cells called TNFa converting enzyme (TACE, also called 
ADAM17) thereby preventing extracellular release of TNFa from the outer surface of T-cells. 
This removes the need to fix and permeabilise T-cells for TNFa staining and detection, and 
viable antigen-specific T-cells can therefore be easily detected and isolated by FACS. 
Several experimental approaches using the TNFa capture technique were used to investigate 
cross-reactive T-cells from MS donors and HC. A schematic of the cloning strategies is show 
in Figure 6.6.1. The first method was similar to previously described strategies (limiting 
dilution and IFNg capture) and aimed to isolate single T-cell clones with dual specificity for 
EBV and CNS antigens from MS patients to map their restrictions and epitope specificity on 
the single cell level (Figure 6.6.1A). Four proteins were selected from the CNS panel that had 
the highest frequency of responding cells in previous stimulation assays: MOG, PLP, MBP and 
MOBP. All polyclonal lines generated for sorting were screened for LCL specificity prior to 
single cell sorting by TNFa capture and staining to ensure that experiments would yield 
positive T-cell clones. 
As previously described, polyclonal T-cell lines from each donor were expanded by stimulating 
with autologous wild type LCL for three weeks. Cells were then stimulated with autologous B-
cell blasts infected with selected CNS MVAs on the day of sorting and T-cells were surface 
stained in the presence of TAPI-0 and single, LiveCD19-CD3+TNFa+ sorted clones were 
incubated in 96-well plates in the presence of feeder cells and anti-CD3 antibody (OKT3). A 
schematic of experimental strategy is shown in Figure 6.6.1A, with gating strategy and example 
staining from two MS donors shown in Figure 6.6.2. After incubation for two weeks, all 
expanded clones were screened by IFNg ELISA against autologous wild type and BZLF1 KO 
LCL and CNS antigens and a summary of the results of these assays are shown in Table 6.1.  
T-cell cloning was carried out after stimulating wild type LCL-specific T-cell lines with CNS 
antigens on the day of sorting; approximately a third of sorted T-cells expanded after sorting 
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into 96-well plates. Further functional studies performed on growing clones revealed a 
proportion of them to have reactivity against autologous LCL, but almost none with reactivity 
to CNS antigens in our panel, and this method yielded only T-cell clones with reactivity to 
EBV antigens (summary of experiments and results using these stimulations is shown in Table 
6.1).   
However, T-cell cloning from one donor – MS34 – did produce four T-cell clones which 
exhibited reactivity to both EBNA1 and MOG antigens, and their cytokine production in 
response to stimuli is shown in Figure 6.6.3. All four clones, despite producing different 
amounts of IFNg in response to antigen, displayed good recognition of MVA EBNA1-infected 
B-cell blasts and lower recognition MVA MOG-infected cells. Due to these similarities 
between the four T-cell clones from patient MS34 is possible that they are descended the same 
T-cell clone. After initial analysis for function, all four clones appeared to lose specificity (or 
to have become anergic) in vitro as they no longer responded to stimulation with the cognate 
antigen. This unfortunately prevented further characterisation of HLA and epitope restriction 
of T-cell clones and further investigation of these cells could not continue. 
However, evidence of a cross-reactive T-cell receptor recognising EBNA1 and MOG at a lower 
level is consistent with observations from polyclonal T-cell lines in the patient and previous 
studies findings of cross-reactivity in MS donors’ EBNA1-specific T-cell pool (Lunemann et 
al., 2008b, Lang et al., 2002, Holmoy et al., 2004). Further characterisation is needed to confirm 
these observations, and mapping epitope and HLA restriction is of prime importance when 
considering potential contribution of these cross-reactive T-cell clones to MS pathogenesis. 
It is possible that single, cross-reactive T-cells do not expand in vitro post-single cell sorting, 
or that these cells do not maintain functionality or specificity. Failure to grow or characterise  
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Figure 6.6.1 Schematic of experimental approach using TNFa capture to isolate cross-reactive T-cells. A. Whole PBMC from donors were stimulated with autologous wild 
type LCL and cultured for 7 days, after which a second LCL stimulus was given to cells. On day 21 polyclonal T-cell lines had grown out and cells were stimulated with CNS antigens 
in the presence of TAPI-0. Polyclonal lines were surface stained and the LiveCD19-CD3+TNFα+ sorted into 96-well plates. 2 weeks later expanded T-cell clones were screened by 
IFNγ ELISA for reactivity to EBV and CNS antigens. This approach yielded many EBV-reactive clones with varying specificity; four clones with reactivity to both EBV and CNS 
antigen were isolated from one MS donor using this method. B. B-cell blasts infected with CNS MVAs were used to stimulate whole PBMC from donors on day 0, and 7 days later 
PBMCs were stimulated a second time. The resulting polyclonal lines that grew out did not expand very efficiently and cell numbers dropped dramatically. 3 weeks after initial 
stimulation the expanded polyclonal T-cell culture was stimulated with CNS antigens in the presence of TAPI-0 before surface staining and single cell sorting of LiveCD19-
CD3+TNFα+ T-cells. Plates were incubated for 2 weeks and expanded clones were screened for reactivity to CNS an EBV antigens by ELISA: no clones were found to be specific. 
C. Whole PBMC from donors were stimulated with autologous wild type LCL on day 0 and day 7 and cultures for 3 weeks. Expanded LCL-specific T-cell lines were then stimulated 
with LCL a third time in the presence of TAPI-0 and surface stained to identify the responding population. The positive (LiveCD19-CD3+TNFα+) and negative (LiveCD19-
CD3+TNFα-) fractions were bulk sorted separately and both lines cultured for two weeks to expand populations. Positive and negative fractions were then screened for reactivity 
against CNS and EBV antigens: reactivity to CNS proteins was identified in the positive, LCL-specific T-cell population.  
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in detail single, cross-reactive T-cell clones in culture prompted a change in experimental 
direction, analysing bulk populations of cells which survive and are better maintained in vitro.  
The reverse approach using initial stimulation with CNS antigens to expand a population of T-
cells with neuronal specificity yielded similar results. We stimulated whole PBMC with 
autologous B-cell blasts infected with selected CNS MVAs in our panel (MOG, PLP, MBP, 
MOBP) on day 0 and day 7, allowing responding cells to grow out over 3 weeks before single 
cell sorting of CNS-specific T-cells using TNFa capture (Figure 6.6.1B). CNS-specific T-cell 
lines expanded in this way showed different growth kinetics to those stimulated with viral 
antigens, and expanded more slowly with end cell numbers being lower than those of initial 
PBMCs in the starting population (data not shown). Despite these low cell numbers, we 
stimulated with MVA CNS-infected autologous B-cell blasts on the day of sorting, performing 
TNFa capture and single cell sorting into 96-well plates containing feeder cells and anti-CD3 
antibody as previously described. The TNFa+ population from CNS-stimulated T-cell lines 
was small and fewer single cells were sorted than previously for EBV-stimulated lines. A 
summary of T-cell clone yield using this stimulation technique can be found in Table 6.6.1. 
The aim was to screen by ELISA sorted clones from CNS-stimulated polyclonal T-cell lines 
against EBV antigens, as the CNS antigens have fewer epitopes than in LCLs carrying all EBV 
latency proteins and we hypothesised that this would enable us to narrow down the pool of 
responses and thus increase the chances of isolating T-cell clones with dual specificity. 
However, few T-cell clones sorted following CNS antigen stimulation grew in culture, and we 
observed only 2 expanded microcultures in plates from these experiments (Table 6.6.1). 
These findings supported previous experimental outcomes that suggested an inability to grow 
autoreactive T-cells in vitro, and it is possible that these cells require different conditions to 
live in culture or that they do not receive such strong signals upon exposure to their cognate 
antigen due to lower avidity of their TCR for peptide:MHC complexes.  It is also possible that 
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autoreactive T-cells do not grow well in single cell suspension or not as part of a heterogeneous 
population. T-cells in a state of replicative senescence are able to produce high levels of 
cytokine in response to stimulus but are not able to proliferate, and T-cells which belong to 
effector memory subsets often have limited replicative capacity. Multiple rounds of stimulation 
during cloning experiments may have sorted T-cells that were subsequently unable to expand 
in culture, limiting our ability to study these cells in further experiments. 
We therefore explored bulk sorting of wild type LCL-specific polyclonal T-cell lines as a 
means of investigating whether CNS reactivity could still be found in expansions that only 
contained cells with EBV-specificity.
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Figure 6.6.2 Gating strategy for single cell sorting of T-cells with potential dual-specificity for EBV and CNS antigens using TNFα capture. Whole PBMC were 
stimulated with autologous wild type LCL for 3 weeks, and on the day of sorting expanded, LCL-specific T-cell lines were stimulated with autologous B-cell blasts infected 
with selected MVAs containing CNS antigens in the presence of TAPI-0. Following stimulation T-cells were surface stained and single, LiveCD19-CD3+TNFa+ cells 
sorted into 96-well plates. Gating strategy is shown for two representative donors (MS13 and MS14); sorted populations from MOG-stimulated wild type LCL-specific 




Figure 6.6.3 T-cell clones isolated from MS patient exhibit cross-reactive recognition of EBNA1 and 
MOG. Single T-cells were expanded for two weeks in culture following TNFa capture and single cell sorting. 
Expanded clones were screened for reactivity to autologous wild type and BZLF1 KO LCLs, EBNA1 and MOG 
by IFNγ ELISA. Four clones exhibited reactivity to both EBNA1 and MOG stimulation. Bars represent mean 
IFNγ concentration from three triplicate data points with error bars displaying the standard error of the mean 
(SEM).   
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6.7 Analysis of bulk sorted wild type LCL-specific polyclonal T-cell lines 
 
Despite high levels of CNS antigen reactivity in wild type LCL-stimulated polyclonal T-cell 
lines it could not be confirmed that the cells responding to EBV – or cellular antigens up-
regulated by EBV – are the same cell that respond to neuronal antigens. Our inability to expand 
autoreactive T-cells in culture long term also prevented functional studies, epitope mapping 
and HLA-restriction being performed on the T-cell clones which appeared to have reactivity 
with EBNA1 and MOG. We therefore sought to address these questions by bulk sorting wild 
type LCL-specific T-cells to produce a population of T-cells with 100% specificity, and in turn 
screen this against the MVA CNS panel to determine if CNS antigen reactivity is retained in 
the positively sorted population.  
TNFa capture was again used to sort wild type LCL-specific T-cells (LiveCD19-CD3+TNFa+ 
cells) but this time as one bulk population. Following bulk-sorting, T-cells were added to 24-
well plates with feeder cells (without anti-CD3 antibody). T-cell lines sorted into positive and 
negative fractions were cultured for two weeks post-sorting, enabling cell numbers to increase 
for subsequent experiments and to allow cytokine production to recover to normal levels ahead 
of screening against CNS antigens. T-cells from the non-specific (LiveCD19-CD3+TNFa- 
cells) population were bulk sorted as a negative control and screened against the recombinant 
MVA panel to investigate if CNS antigen specificity also existed in this fraction (experimental 
approach described in Figure 6.6.1C). 
Representative staining from one donor’s positive and negative sorted LCL-specific T-cell 
lines is shown for CD4+ T-cells in Figure 6.7.1 and for CD8+ T-cells in Figure 6.7.2. CD4+ 
T-cells in the positive fractions sorted following autologous wild type LCL stimulation showed 
~82% specificity for the LCL after screening as measured by TNFa production (top line Figure 
6.7.1). The negative fraction sorted from T-cells that were not responding to wild type LCL on 
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the day of sorting also showed some reactivity to LCL when screened two weeks later, with 
~41% of CD4+ T-cells responding with TNFa production (bottom line Figure 6.7.1). This 
might be due to the fact that sorted cells were rested in culture for two weeks following 
antigenic stimulation and sorting, which might mean that any wild type LCL-specific T-cells 
that did not produce TNFa on the day of the sorting experiment will have been included in the 
negative fraction and subsequently expanded in vitro. 
Background TNFa staining was observed in both positive and negative fractions of CD4+ T-
cells from sorted wild type LCL-stimulated polyclonal lines, with more in the negatively sorted 
population (Figure 6.7.1).  TNFa production in response to autologous B-cell blasts infected 
with MVAs expressing CNS antigens was not much above background levels in the negatively 
sorted fraction. However, CNS antigen reactivity was higher in CD4+ T-cells from the 
positively sorted population, indicating that the reactivity to neuronal proteins might occur in 
CD4+ cells that also respond to autologous wild type LCL. This experiment was performed for 
a further 3 MS donors with very similar results, suggesting that CNS reactivity lies with the 
wild type LCL-specific CD4+ T-cells in polyclonal lines. Sorted fractions were screened 
against all other neuronal antigens in the CNS MVA panel but TNFa production was shown 
to be not above background levels, showing no specific recognition of these antigens (data not 
shown). 
CD8+ T-cells from the same experiment, sorting T-cells based on their TNFa production in 
response to autologous wild type LCL, also showed high levels of background cytokine 
staining in the negative fraction, and staining is shown from one representative MS donor’s 
CD8+ T-cells in Figure 6.7.2. Similar to CD4+ T-cells, CD8+ responses from the negative 
sorted fraction showed similar proportions of cells that were specific for wild type LCL after 
culturing for two weeks; ~52% CD8+ T-cells were shown to be wild type LCL-specific in the 
negative fraction and ~82% were specific in the positive fraction (Figure 6.7.2). 
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Figure 6.7.1 CNS reactivity of CD4+ T-cells from MS patient sorted, wild type LCL-stimulated polyclonal T-cell lines. Whole PBMC from one representative MS donor 
(MS14) were stimulated with autologous wild type LCL on day 0 and day 7, and cultured for a further two weeks. On day 21 expanded T-cell lines were stimulated again with 
wild type LCL in the presence of TAPI-0, surface stained and populations of LiveCD19-CD3+TNFα+ and LiveCD19-CD3+TNFα- were bulk sorted separately. These TNFα+ 
and – populations were cultured separately for 2 weeks to increase cell number, before screening against MVA CNS panel-infected autologous B-cell blasts, using TNFα capture 
and surface staining for the CD4+ T-cell subpopulation. This method was repeated for a further 3 MS donors with similar results. Value in the top, right corner of plots shows 
the percentage of CD4+ T-cells producing TNFα in response to each stimulus; top plots show LiveCD19-CD3+TNFα+ sorted CD4+ T-cells responding to LCL and bottom 




Figure 6.7.2 CNS reactivity of CD8+ T-cells from MS patient sorted, wild type LCL-stimulated polyclonal T-cell lines. Whole PBMC from one representative MS donor 
(MS14) were stimulated with autologous wild type LCL on day 0 and day 7, and cultured for a further two weeks. On day 21 expanded T-cell lines were stimulated again with 
wild type LCL in the presence of TAPI-0, surface stained and populations of LiveCD19-CD3+TNFα+ and LiveCD19-CD3+TNFα- were bulk sorted separately. These TNFα+ and 
– populations were cultured separately for 2 weeks to increase cell number, before screening against MVA CNS panel-infected autologous B-cell blasts, using TNFα capture and 
surface staining for the CD8+ T-cell subpopulation. This method was repeated for a further 3 MS donors with similar results. Value in the top, right corner of plots shows the 
percentage of CD8+ T-cells producing TNFα in response to each stimulus; top plots show LiveCD19-CD3+TNFα+ sorted CD8+ T-cells responding to LCL and bottom plots show 
LiveCD19-CD3+TNFα- cells which did not respond to the LCL at the time of sorting. 
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This is probably due to the LCL-specific T-cells outgrowing the non-specific cells in the period 
following sorting (Figure 6.7.2).  
Unlike CD4+ T-cells, reactivity to neuronal proteins in CD8+ T-cells from sorted wild-type 
LCL-specific polyclonal lines was higher than background for CD8+ T-cells in the negative 
fraction. Low levels of cytokine production following neuronal antigen stimulation in the 
positive fraction suggests that the CD8+ T-cells sorted for their response to wild type LCL do 
not highly recognise CNS epitopes in the MVA panel.  
EBNA1 has been shown previously to contain several cross-reactive epitopes (Lang et al., 
2002, Holmoy et al., 2004, Lunemann et al., 2008b) and, due to difficulties in cloning single 
T-cells with dual specificity for EBV and neuronal antigens, we used the same bulk sorting 
approach as for wild type LCL stimulated polyclonal lines to investigate this further. 
 MVA EBNA1-infected B-cell blasts were used to stimulate whole PBMC from three MS 
donors on day 0 and day 7. On day 21 the expanded T-cell lines were stimulated again with 
EBNA1 in the presence of TAPI-0 and stained to identify the T-cell population producing 
TNFa; LiveCD19-CD3+TNFa+ and LiveCD19-CD3+TNFa- fractions were bulk sorted 
separately.
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Figure 6.7.3 CNS-specific CD4+ T-cell responses in sorted EBNA1-stimulated polyclonal T-cell line. Whole PBMC were stimulated with autologous B-cell blasts infected with 
MVA EBNA1 on day 0 and day 7. On day 21 the expanded T-cell cultures were stimulated with MVA EBNA1-infected B-cell blasts in the presence of TAPI-0, surface stained and 
subpopulations of LiveCD19-CD3+TNFα+ (top row) and LiveCD19-CD3+TNFα- (bottom row) cells bulk sorted. Sorted cells were then expanded in culture for 2 weeks to increase 
cell numbers and screened against MVA CNS-infected autologous B-cell blasts. Reactivity was measured by TNFα production. Top right corner values represent the percentage of 
CD4+ T-cells producing TNFα in response to individual antigens. 
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Figure 6.7.4 CNS-specific CD8+ T-cell responses in sorted EBNA1-stimulated polyclonal T-cell line. Whole PBMC were stimulated with autologous B-cell blasts infected with 
MVA EBNA1 on day 0 and day 7. On day 21 the expanded T-cell cultures were stimulated with MVA EBNA1-infected B-cell blasts in the presence of TAPI-0, surface stained and 
subpopulations of LiveCD19-CD3+TNFα+ (top row) and LiveCD19-CD3+TNFα- (bottom row) cells bulk sorted. Sorted cells were expanded in culture for 2 weeks to increase cell 
numbers and screened against MVA CNS-infected autologous B-cell blasts. Reactivity was measured by TNFα production. Top right corner values represent the percentage of CD8+ 
T-cells producing TNFα in response to individual antigens. 
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This experiment was performed in three MS donors with sizeable CD4+ and CD8+ responses 
as shown by ex vivo analysis of T-cell responses in Chapter 5.  
CD4+ T-cell responses to CNS antigens in the EBNA1-responding positive fraction are 
presented from one donor in Figure 6.7.3, and show this donor to have no TNFa production 
above background in response to the initial stimulus EBNA1. This is surprising given that cells 
were sorted based on their reactivity to the protein two weeks previously, and that pre-sorting 
screening of EBNA1-expanded lines two days prior to sorting showed ~2% CD4+ T-cells 
producing TNFa in response to the antigen. It is possible that these responding CD4+ T-cells 
have lost specificity in culture in the period between sorting and screening versus CNS 
antigens, but more analysis would be needed on this population to determine whether this is 
the case. 
Interestingly, despite this population showing no specificity for EBNA1, CD4+ T-cells in the 
positively sorted fraction showed higher TNFa production in response to MOG, MBP and 
MOBP than that of CD4+ T-cells in the negatively sorted fraction, indicating that sorting for 
EBNA1 specificity may also enrich for CD4+ T-cells that respond to neuronal proteins.  CD4+ 
T-cell responses in the positive fraction of two other MS patient EBNA1 sorted polyclonal 
lines showed reactivity to the CNS, but these experiments would need to be repeated in several 
more donors or polyclonal lines to corroborate results. 
In contrast, CD8+ T-cells from the positively sorted fraction of EBNA1 specific T-cell 
expansions showed a high reactivity to the protein, with example staining from one donor 
showing ~39% of CD8+ T-cells producing TNFa following EBNA1 stimulation (Figure 6.7.4).  
CD8+ reactivity to CNS antigens in TNFa positive and negative sorted EBNA1-specific T-cell 
expansions was seen at similar levels, with an increase in cytokine production seen in the 
negative fraction for MOG and MOBP (Figure 6.7.4). This is similar to what was observed for 
CD8+ T-cells in sorted wild type LCL polyclonal lines, and again indicates that selecting CD8+ 
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T-cells for their ability to produce TNFa in response to EBNA1 does not enrich cells for 
neuronal antigen specificity. Two further FACS sorted EBNA1-specific polyclonal lines 
established from MS patients were screened for CNS responses in their positive and negative 
fractions with very similar results, suggesting that neuronal antigen reactivity is enriched by 
sorting in the CD4+ T-cell subset but not CD8+ (data not shown). 
These experiments show that using the TNFa capture and staining system it is possible to 
enrich T-cell populations reacting to a specific stimulus. High percentage wild type LCL 
specificity in T-cell lines sorted for reactivity to this same stimulation shows that the bulk 
sorting of CD4+ T-cells did work and enrich populations successfully. However, the presence 
of T-cells in the negatively sorted fractions with reactivity to wild type LCL makes it difficult 
to interpret results with confidence. Discounting results from the negatively sorted fraction, the 
presence of CD4+ T-cells that are able to react with CNS antigens in a population that is 80-
90% specific for wild type LCL is consistent with presence of molecular mimicry between 
EBV and neuronal peptides displayed by self-MHC molecules. However, reactivity to CNS 
antigens could also be attributed to the ~10% of CD4+ T-cells that do not react with the wild 
type LCL after sorting with this stimulus. 
Despite low reactivity for EBNA1 in subsequent screening, CD4+ T-cells from the positive 
fraction of EBNA1-sorted polyclonal lines showed a percentage of cells producing cytokine in 
response to particular neuronal antigens in our MVA panel. This supports the idea that by 





Cross-reactivity between viral and CNS epitopes has been previously reported in MS literature 
(Holmoy et al., 2004, Lunemann et al., 2008b, Lang et al., 2002) and these dual-specific T-cell 
responses are thought to have a key role in disease development. However, the exact 
contribution of these cells remains to be determined and there is currently no consensus reached 
regarding a mechanism of how EBV-specific T-cells might influence early pathological 
processes in MS. 
Experiments performed in our study show that stimulation of ex vivo T-cells with wild type 
LCL – cells which express both EBV latent and lytic cycle antigens – also expands populations 
of T-cells able to react with certain CNS antigens to high frequency. This observation suggests 
that a degree of structural mimicry is likely to exist between viral and neuronal epitopes. This 
theory is consistent with other epidemiological observations previously discussed, such as the 
increased prevalence of MS in individuals who have had IM (Thacker et al., 2006).  These data 
imply a role for the EBV-specific T-cell repertoire in MS disease development, however their 
presence in people unaffected by MS suggests their contribution is more complex than a simple 
causal association. 
Previous papers have detected autoreactive T-cells specific for neuronal antigens in healthy 
donors (Mazzanti et al., 2000), and T-cells with specificity for self-antigens in other 
autoimmune diseases have also been studied in unaffected individuals (Zou et al., 2008, Danke 
et al., 2004, Cao et al., 2015). The presence of myelin antigen-reactive T-cells in the blood of 
healthy donors as well as patients raises many questions as to why some individuals develop 
disease and others do not, and several studies have investigated the function and phenotype of 
autoreactive T-cells in MS to try to explain their relevance in disease mechanisms. One study 
by Cao et al. found myelin epitope-specific T-cells from MS patients to have different 
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transcriptional profiles to those of healthy donors (Cao et al., 2015). T-cells in this study were 
also found to produce higher levels of IFNg, IL-17 and GM-CSF which might indicate a more 
pathogenic phenotype of these cells in patients, contributing to local inflammation and further 
immune cell recruitment to the CNS.  
Due to the nature of T-cell degeneracy it is possible that stimulation with other pathogens 
would also create responses with a degree of reactivity to neuronal proteins, as is demonstrated 
in our experiments after stimulation with EBV antigens. Due to limitations in patient cell 
numbers creating parallel stimulations with alternative pathogens were not possible in our 
study, however future investigations should include a control pathogen-stimulated polyclonal 
T-cell line or an extra MVA encoding an alternative self-antigen not derived from the CNS. 
Investigation of reactivity to a non-myelin-derived self-antigen in EBV-specific T-cell 
populations would determine if cross-reactivity was specifically targeting neuronal proteins. 
Using ICS, we analysed CNS antigen-specific CD4+ and CD8+ T-cells from wild type LCL-
stimulated polyclonal T-cell lines, defining responding cells as those which produce one or 
more of the cytokines in our panel: IFNg, IL-2, IL-17 and GM-CSF.  Our aim was to elucidate 
whether there was a difference in cytokine production from myelin antigen-specific CD4+ or 
CD8+ T-cells expanded ex vivo from wild type LCL-stimulated PBMC. We found there to be 
no significant difference in cytokine production between cells responding to most CNS targets 
between groups, however there were phenotypic distinctions between MS patients and HC in 
their CD4+ T-cells responding to EBNA3A and CNP. CD4+ T-cell responses to CNP were 
very low in most individuals but one HC displayed a high percentage of responding cells in 
LCL-stimulated polyclonal lines which may have skewed the mean value of T-cell cytokine 
production.  
More interesting is the difference in phenotype of EBNA3A responding cells in HC and MS 
patients. Findings of differential cytokine expression between EBNA3A-specific CD4+ T-cells 
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showed MS donor responses to predominantly produce IFNg only, with responses from HC 
showing a large proportion of cells to produce GM-CSF only (Figures 6.5.5 and 6.5.17). 
Phenotypic differences in cells responding to this particular antigen between HC and MS 
patients might indicate a pathogenic role for these cells in MS in vivo, and further analysis of 
EBNA3A-specific CD4+ T-cells in MS is warranted following our study. Analysis of CD8+ 
T-cell responses to EBNA3A revealed there to be no significant difference in cytokine 
production between healthy and MS donors (Figures 6.5.21 and 6.5.33), suggesting that this 
difference between groups is specific to CD4+ T-cells. 
No differences were seen in cytokine production or polyfunctionality of CD8+ T-cells to CNS 
or EBV antigens in wild type LCL-stimulated polyclonal T-cell lines, and this is in contrast 
with findings by Pender et al. who observed a decreased cytokine polyfunctionality in latent 
antigen-specific CD8+ T-cell responses which they attributed to cellular exhaustion (Pender et 
al., 2017).  However, differences between these results may be due to experimental approach: 
our screening was performed on T-cell expansions which had been cultured in vitro for several 
weeks, with Pender et al. analysing cytokine production in small number of CD8+ epitope 
responses detected by tetramer analysis of T-cells ex vivo.  
Cytokine production from CNS reactive T-cells has direct implications for their in vivo function 
as this can control how responses are maintained and affect surrounding tissues, influencing 
the inflammatory environment and perpetuating further immune cell infiltration of the CNS. 
Our findings of little difference between HC and MS patients in cytokine phenotype of 
neuronal antigen-specific T-cells is interesting, but might reflect the long-term culture 
conditions of cells or that T-cell lines were derived from PBMCs collected from MS patients 
during disease remission. Investigation of ex vivo CNS-specific T-cells from patients currently 
undergoing relapse might give further insight into the contribution these cells make to MS 
pathogenesis and would be a logical progressive step in our project. 
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Our attempts to isolate single, cross-reactive T-cells with specificity for viral and CNS antigens 
were extensive and employed several different approaches. The difficulty we experienced in 
growing these cells in culture could be reflected by a number of factors: low frequency of T-
cells with dual specificity reducing likelihood of isolation, or by unsuitable growth conditions 
for autoreactive T-cells. Specificity or function of four T-cell clones isolated from one MS 
patient with reactivity to both EBNA1 and MOG was lost in culture shortly after the first 
screening assays for IFNg production, preventing further characterisation studies of HLA 
restriction and epitope mapping. This could be attributed to T-cell exhaustion after multiple 
rounds of antigen stimulation or induction of anergy, and it is possible that stimulation during 
the TNFa capture protocol did not provide adequate stimulus for subsequent maintenance and 
growth of cross-reactive T-cells in culture. Our inability to generate clones despite extensive 
efforts supports this theory and suggests that alternative methods downstream of isolation in 
analysing functionality of T-cells should not use long-term culture.   
Experiments exploring sorted polyclonal T-cell lines specific for wild type LCL and EBNA1 
provided an alternative method of verifying reactivity to the CNS in populations of cells that 
were specific for EBV antigens. T-cells responding to EBV stimulation were sorted and 
analysed for their reactivity to neuronal proteins, and the same screening against CNS antigens 
was also carried out for cells that did not react to EBV antigens. Experiments with sorted wild 
type LCL-specific T-cell lines showed over 80% of the cells in the positive fraction to have 
direct specificity for LCL and the sorting to have worked. Therefore, maintenance of CNS 
responses in this fraction post-sorting supports a role for molecular mimicry between neuronal 
and EBV antigens. However, this cannot be assumed as a proportion of the population still did 
not react to LCL after sorting, and further investigation is needed to confirm these findings. 
CD4+ and CD8+ T-cells in the negative fraction of sorted wild type LCL-stimulated polyclonal 
T-cell lines were also found to produce cytokine upon subsequent screening against the LCL 
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after two weeks. It is not clear why such high percentages of LCL-specific T-cell contaminants 
were left in the negative fraction as the sorting process has been shown to be very stringent, 
and this is further supported by the high percentage of LCL reactive T-cells found in the 
positive fraction in our experiments. For this reason, it is unlikely that the sorting process itself 
was the reason for this contamination and these cells may either have had a different phenotype 
at the time of sorting (producing other cytokines) before switching to become TNFa producers 
in culture, or they may have delayed response to LCL longer than the 4-hour incubation allowed 
for stimulation before sorting.  
Despite this reactivity in the negative fraction of LCL and EBNA1-stimulated polyclonal lines, 
the maintained reactivity to CNS antigens in the T-cells sorted positively for their EBV 
specificity supports the view that EBV peptides may have structural homology that T-cell 
responses are able to cross-recognise.  
Structural homology between viral and CNS epitopes has previously been described, with 
detailed analysis of structural interaction of a MBP (85-99) epitope presented by HLA-DR15 
and a BALF5 (627-641) epitope presented by HLA-DR51 (Lang et al., 2002), alleles which 
are inherited together in linkage disequilibrium in the MHC locus. Other reports have identified 
CD4+ T-cells as having dual specificity for EBV and CNS antigens, adding to literature 
surrounding this phenomenon and highlighting the role these cells may play in MS disease 
initiation and progression (Lunemann et al., 2008b, Holmoy et al., 2004). Despite these 
promising findings few studies have been published since this prior research, and as such the 
exact contribution of molecular mimicry in MS remains to be elucidated. 
Our work supports previous groups’ findings of cross-reactive EBV-specific T-cells in MS 
patient blood. However, our study has gone further to show the extent of molecular mimicry in 
virus-specific T-cell responses of HC, showing LCL-stimulated polyclonal lines from both MS 
patients and healthy donors to have high reactivity to certain CNS proteins expressed in our 
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MVA virus panel. Presence of cross-reactive responses in disease-free individuals suggests that 
other genetic or environmental circumstances might cause some people to develop disease, and 
analysis of molecular mimicry in patients alongside detailed aetiological data might provide an 
insight into this process.  
 
 257 
7 Final discussion  
 
As mentioned throughout this thesis, there is increasing evidence of a role for EBV in the both 
development and progression of MS but no accepted theories on how the virus influences these 
processes. 
The present study had two aims seeking to understand the connection between EBV and MS. 
First, to analyse the broad immune responses to EBV antigens in RRMS patients, healthy 
seropositive controls and those with a recent history of symptomatic primary infection. Second, 
to investigate T-cell responses to EBV antigens and to EBV-transformed B-cells for their 




EBV viral load and antibody responses were assessed in our cohort and the results compared 
to previous findings in the literature. Viral load was found to be unchanged in MS patients 
compared to healthy controls. Antibody responses to EBNA1 and VCA were found to be 
elevated in MS patient blood and were consistent with other MS studies with larger donor 
cohorts, supporting a role for these markers in calculating risk of disease. In addition to these 
parameters, antibody responses to EBNA3 proteins were investigated semi-quantitavely with 
increased frequency found to EBNA3A and EBNA3B antigens observed amongst patients 
compared to HC.  
CD4+ and CD8+ T-cell responses to autologous wild type and BZLF1 KO LCL and EBNA1 
were analysed ex vivo for both frequency and phenotype of responses, and ICS of T-cells 
allowed expression of four cytokines to be assessed: IFNg, IL-2, IL-17 and GM-CSF. A trend 
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towards increased IL-17 production amongst LCL-specific T-cells from HC was observed, and 
in contrast MS patient cells showed elevated GM-CSF secretion after stimulation with 
autologous LCL. In depth analysis of ex vivo EBV-specific T-cell responses revealed no overall 
differences to exist in polyfunctionality or cytokine usage between MS patients and HC.  
EBNA1-specific antibody and T-cell responses were correlated in individual donors, revealing 
a modest correlation between these two arms of the adaptive immune response. To our 
knowledge this has not previously been carried out for EBV antigens, and provides an insight 
into the close interplay of CD4+ T-cells with those of CD8+ T-cells and B-cells in directing 
immune responses to the same cognate antigen. 
A panel of MVA viruses expressing neuronal antigens were used in an in vitro system to 
analyse T-cell responses to the CNS. EBV-specific T-cell responses were screened using ICS 
for their ability to recognise CNS antigens, and it was observed that stimulation of whole 
PBMC with wild type LCL caused the expansion of CD4+ and CD8+ T-cells with reactivity 
to certain neuronal antigens. This phenomenon was shown in both MS patients and HC, and 
in-depth analysis of cytokine production in response to these proteins was carried out, revealing 
a phenotypic difference in CD4+ T-cells between HC and MS patients responding to CNP and 
EBNA3A.  
Final experiments using multiple protocols sought to address whether cross-reactivity could be 
shown in EBV-specific T-cells on a single cell level, and employment of a method to stain for 
TNFa on viable T-cells enabled single cell isolation of T-cells with dual specificity for EBNA1 
and MOG antigens by FACS. However, these cells did not grow in culture preventing further 
characterisation. A separate method was subsequently used to bulk sort T-cells for TNFa 
production in response to autologous LCL, and it was found that reactivity to selected CNS 
proteins was maintained at low levels in sorted, wild type LCL-specific T-cell lines. These 
findings support the presence for molecular mimicry between EBV and CNS antigens, however 
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more research is needed in this area to fully understand this phenomenon and also to determine 
the immunological contribution of cross-reactive T-cells in MS. 
 
7.2 Conclusions and future work  
 
A number of important conclusions can be drawn from different sections in this body of work.  
Unchanged viral load in MS patients is indicative of a stable infection with EBV with no 
evidence of viral reactivation driving disease or gross loss of EBV control. This is an important 
clinical observation given that clinical trials are using adoptively-transferred EBV-specific 
CD8+ T-cells to treat MS patients (Pender et al., 2014b).  
Elevated antibody responses to EBNA1 and VCA have previously been reported, but our 
findings of increased frequency of anti-EBNA3 IgG responses are novel and indicate that more 
research is needed to investigate responses to these viral antigens in MS. Further 
characterisation of EBNA3 antibody responses and their correlation with ex vivo EBNA3-
specific T-cells would provide an insight into their contribution towards MS development. 
This is the first in-depth analysis of cytokines produced in MS patients with age, gender and 
HLA-matched healthy donors, also examining differences in donors with the HLA-DR15 
subtype. Extensive analysis of ex vivo CD4+ and CD8+ T-cell cytokine responses to autologous 
LCL and EBNA1 show there to be no overall differences between healthy seropositive controls 
and MS patients in frequency of these cells in the blood, however small differences in 
production of IL-17 and GM-CSF were observed in responding populations between groups. 
This analysis is the first time that polyfunctionality of EBV-specific T-cell responses has been 
analysed in depth in MS patients and healthy controls, and shows that there is no obvious 
functional difference between groups. However, analysis of alternative cytokines to those 
investigated in our study might yet identify differences in phenotype of EBV-specific T-cell 
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responses between HC and MS patients, and this should be a focus of further research. 
Investigation of EBV-specific T-cell responses from MS patient blood and CSF during relapse 
of disease is of prime importance, as this would provide a better insight into immunological 
mechanisms driving disease exacerbations.  
Further analysis of the cross-reactive potential of the EBV-specific T-cell repertoire is 
warranted to determine the contribution of these cells to MS disease pathology, and of most 
interest would be differences in the T-cell frequency, phenotype and antigen specificity 
between periods of relapse and remission.  
Inability to maintain T-cells displaying cross-reactivity in vitro prevented further 
characterisation of these cells’ function in our study. Future work on these responses should 
include methods which do not require culture of these cells long-term. Tracking of T-cell 
responses by sequencing of their receptors would allow detailed analysis of T-cell repertoires 
through disease, and enable identification of conserved sequences between donors and disease 
stages. Further information regarding TCR gene usage and dynamics of T-cell populations over 
time during remission and relapse would provide crucial insight into how these cells contribute 
to disease initiation and progression.  
Identification of cross-reactive epitopes between neuronal and viral proteins would allow these 
responses to be investigated by tetramer staining over time between relapse and remission of 
disease. Additional analysis of tissue homing marker expression and cytotoxic markers would 
allow pathogenicity of these cells to be characterised in detail. Longitudinal analysis of 
transcriptomes of EBV-specific T-cells from MS patients and healthy controls would also 
allow simultaneous investigation of many more phenotypic markers than permitted by ICS, 
and may reveal differences in gene expression between groups. Further sequencing of RNA 
transcripts from single, sorted cross-reactive cells could provide information on how these cells 
might be differentially regulated or their gene expression affecting development, 
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differentiation and function in vivo. Furthermore, in-depth investigation of EBV-specific T-
cells in MS will allow us to construct a model of how these cells contribute towards disease.  
Investigation of IM is also crucial in understanding how the immune response to EBV becomes 
dysregulated after symptomatic primary infection. Analysis of EBV-specific CD4+ T-cell and 
cross-reactive responses in acute disease and through convalescence may provide a crucial 
insight into disease processes that pre-dispose people who have had IM to develop MS.  
This work has contributed towards understanding of EBV-specific antibody and T-cell 
responses in MS, an area that is of crucial importance in determining what drives autoimmune 
attack on the CNS in patients. In the past 10 years, many more immunomodulatory therapies 
have become available to control inflammation in MS and associated relapses, but none of 
these are able to prevent progression. Better understanding of early disease is essential in the 
development of new drugs to target pathogenic processes and, with incidence of MS in Western 
countries increasing, there is a significant clinical demand for improved knowledge of the 
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